Salim Yusuf
Professor, Medicine

selected scholarly activity

• books

  • Evidence‐Based Cardiology 2009

• chapters

  • Hypertension in South Asians.  27-31. 2018
  • Statistical Approaches to Improving Trial Efficiency and Conduct.  71-84. 2014
  • The Role of the Polypill in Hypertension.  279-294. 2012
  • Clinical Applications of External Evidence.  1133-1137. 2009
  • Ethnicity and Cardiovascular Disease.  235-257. 2009
  • Evidence‐Based Decision Making: Patient–Physician Interface.  1-13. 2009
  • Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials: Avoiding Important Information Loss.  158-165. 2006
  • Data Monitoring in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study: When Reasonable People Disagree.  330-336. 2006
  • The secondary prevention of cardiovascular disease.  769-791. 2005
  • Aspirin and Thienopyridines.  33-44. 2004

• conferences

  • Contrasting patterns of symptoms compared to mortality in women and men with Congestive Heart Failure (the G-CHF registry).  European Heart Journal. 2023
  • ASSOCIATION OF MIGRAINE AND RISK OF ACUTE STROKE: INTERSTROKE CASE-CONTROL STUDY.  International Journal of Stroke. 48-48. 2023
  • Identification of PAM as a novel monogenic diabetes gene.  Diabetologia. S209-S209. 2023
  • IMPACT OF SEASONAL BLOOD PRESSURE CHANGES ON VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY.  Journal of Hypertension. E17-E17. 2023
  • Multi-Ancestry Proteo-Genomic Association Study of eGFR.  Journal of the American Society of Nephrology. 259-259. 2022
  • Body mass index from the RE-LY trial: further evidence of the obesity paradox.  European Heart Journal. 629-629. 2022
  • Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: results of the global congestive heart failure research program.  European Heart Journal. 879-879. 2022
  • BARIATRIC SURGERY AS SECONDARY PREVENTION FOR CARDIOVASCULAR DISEASE: A POPULATION-BASED MATCHED COHORT STUDY IN A UNIVERSAL HEALTHCARE SYSTEM Cardiovascular risk and bariatric surgery.  Obesity Surgery. 76-77. 2022
  • OP05 Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the prospective urban rural epidemiology (PURE) study: A prospective cohort study.  Journal of Crohn's and Colitis. S006-S006. 2021
  • CONTROL OF HYPERTENSION BY ETHNICS IN COLOMBIA, A SECONDARY ANALYSIS OF COLOMBIA PURE STUDY.  Journal of Hypertension. E234-E234. 2021
  • ETHNIC DIFFERENCES IN THE ASSOCIATION BETWEEN HANDGRIP STRENGTH AND THE PREVALENCE OF HYPERTENSION.  Journal of Hypertension. E238-E238. 2021
  • A Polypill for Primary Prevention of Cardiovascular Disease in Intermediate Risk People: Results of the International Polycap Study (TIPS)-3.  Circulation. E490-E490. 2020
  • Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post Trial Observation in the HOPE 3 (Heart Outcomes Prevention Evaluation) Study.  Circulation Research. E108-E108. 2019
  • No UHC without medicines: out-of-pocket payments for non-communicable diseases in 18 countries.  European Journal of Public Health. 2019
  • 240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study.  Diabetes. 2019
  • CLINICAL IMPACT OF DIRECT STENTING AND INTERACTION WITH THROMBUS ASPIRATION IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: THROMBECTOMY TRIALISTS COLLABORATION.  Journal of the American College of Cardiology. A1167-A1167. 2018
  • First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study.  Stroke. 2018
  • Costs Impact Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial.  Circulation. E456-E457. 2017
  • Socio-economic inequality in the use of secondary prevention of cardiovascular disease.  European Journal of Public Health. 96-+. 2017
  • Which characteristics of frontline health systems affect the control of hypertension?.  European Journal of Public Health. 2017
  • IGFBP-3 is a marker of impaired adipose tissue function and a novel causal mediator of type 2 diabetes risk: a report from the ORIGIN study.  Diabetologia. S99-S99. 2017
  • Gene Expression Profiles for the Identification of Prevalent Atrial Fibrillation.  Journal of the American Heart Association. e006057. 2017
  • Pilot and feasibility studies: a systematic review of studies conducted at the population health research institute.  Trials. 2017
  • IMPACT OF PREPROCEDURAL THROMBOCYTOPENIA ON SAFETY OF PERFORMING PERCUTANEOUS CORONARY INTERVENTION IN CANCER PATIENTS.  Journal of the American College of Cardiology. 1350-1350. 2017
  • Comparison of Contemporary Bleeding Risk Scores in Patients With Non-Valvular Atrial Fibrillation Treated With Dabigatran or Warfarin: Insights From the RE-LY Trial.  Circulation. 2016
  • The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis.  Circulation. 2016
  • The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis.  Circulation. 2016
  • The Impact of Smoking on Clinical Outcomes and the Role of Double-Dose versus Standard-Dose Clopidogrel Among Individuals With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention -Insights From the CURRENTOASIS 7 Trial.  Circulation. 2016
  • Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RELY trial.  Journal of the American Heart Association. 47-47. 2016
  • Evidence based medication use is highly predictive of survival in heart failure patients in Africa, Asia, the Middle East and South America: the INTERCHF Study.  European Heart Journal. 247-247. 2016
  • Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction.  Journal of Cardiac Failure. S65-S66. 2016
  • Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation: insights from the RE-LY trial.  European Heart Journal. 429-429. 2016
  • Identification of blood CSF1 and CXCL12 as new causal mediators of coronary artery disease using Mendelian randomization in the ORIGIN trial.  European Heart Journal. 458-458. 2016
  • Prognostic importance of precipitating factors leading to heart failure hospitalization in patients with preserved and reduced ejection fraction: Insights from CHARM.  European Heart Journal. 326-326. 2016
  • Global variations in heart failure outcomes: INTER-CHF.  European Journal of Heart Failure. 313-314. 2016
  • 794 What is the Clinical Profile of “Life-Threatening” Gastrointestinal Bleeding in Anticoagulated Patients? A Sub-Analysis of the RE-LY Trial.  Gastroenterology. S165-S166. 2016
  • CHA2DS2-VASC VERSUS HAS-BLED SCORE FOR PREDICTING RISK OF MAJOR BLEEDING AND ISCHEMIC STROKE IN ATRIAL FIBRILLATION: INSIGHTS FROM RE-LY TRIAL.  Journal of the American College of Cardiology. 1889-1889. 2016
  • CLINICAL OUTCOMES OF ATRIAL FIBRILLATION PATIENTS RECEIVING DIGOXIN IN THE RE-LY ® TRIAL.  Journal of the American College of Cardiology. 802-802. 2016
  • EFFECTS OF DABIGATRAN VERSUS WARFARIN IN RELATION TO LEFT VENTRICULAR HYPERTROPHY IN ATRIAL FIBRILLATION.  Journal of the American College of Cardiology. 884-884. 2016
  • EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-BLEEDING RISK SCORE FOR ATRIAL FIBRILLATION.  Journal of the American College of Cardiology. 893-893. 2016
  • EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-STROKE RISK SCORE FOR ATRIAL FIBRILLATION.  Journal of the American College of Cardiology. 879-879. 2016
  • LEFT ATRIAL DYSSYNCHRONY AS A PREDICTOR OF POSTOPERATIVE ATRIAL FIBRILLATION IN CANCER PATIENTS.  Cardiology. 131-131. 2016
  • Efficacy and Safety of Dabigatran Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function Over Time: Insights From the RE-LY Trial.  Circulation. 2015
  • Meta-analysis: Risk of congestive heart failure (CHF) in selected targeted agents..  Journal of Clinical Oncology. 64-64. 2015
  • Association of urinary sodium excretion with blood pressure and cardiovascular clinical events in South America: The PURE study.  European Heart Journal. 1186-1186. 2015
  • Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial.  European Heart Journal. 862-862. 2015
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for novel oral anticoagulant dose adjustment.  European Heart Journal. 340-340. 2015
  • Bleeding and thromboembolic outcomes in warfarin-and dabigatran-treated patients in the RE-LY trial who required an urgent surgery or procedure.  Journal of Thrombosis and Haemostasis. 393-394. 2015
  • Increasing incidence of cardiomyopathy among women between the last trimester and the first 6 months post delivery.  European Journal of Heart Failure. 403-403. 2015
  • How Often Does Major Gastrointestinal Bleeding in Patients Receiving Warfarin or Dabigatran Uncover Cancer? The US Experience From the RE-LY Trial.  Gastroenterology. S764-S764. 2015
  • CARDIAC CATHETERIZATION IN CANCER PATIENTS WITH THROMBOCYTOPENIA: 4-YEAR EXPERIENCE FROM A HIGH VOLUME CANCER CENTER CARDIAC CATHETERIZATION LABORATORY.  Journal of the American College of Cardiology. A1909-A1909. 2015
  • ENDOCARDITIS IN CANCER PATIENTS WITH AND WITHOUT THROMBOCYTOPENIA: PREVALENCE AND COMPLICATION RATES.  Journal of the American College of Cardiology. A1995-A1995. 2015
  • PATIENT AND SYSTEM-RELATED GAPS IN EMERGENCY MEDICAL SERVICES USE IN ST-ELEVATION MYOCARDIAL INFARCTION: RESULTS FROM THE THIRD GULF REGISTRY OF ACUTE CORONARY EVENTS.  Journal of the American College of Cardiology. A148-A148. 2015
  • TAKOTSUBO CARDIOMYOPATHY IN CANCER PATIENTS: TRIGGERS, RECOVERY, AND RESUMPTION OF THERAPY.  Journal of the American College of Cardiology. A927-A927. 2015
  • Sensitivity and Reliability of MRI SWI Compared With GRE Sequences for Detecting Microbleeds in a Community Population.  Stroke. 2015
  • Blood Pressure and Brain Atrophy in a Canadian Community-based Study.  Stroke. E260-E260. 2014
  • Can Biomarkers Improve Risk Stratification of Atrial Fibrillation Patients? Analysis of 3578 Aspirin-treated Patients in ACTIVE and AVERROES.  Circulation. 2014
  • Effects of Insulin Glargine on Left Ventricular Mass and Function in Patients With Dysglycemia.  Circulation. 2014
  • Transient Ischaemic Attack.  International Journal of Stroke. 28-28. 2014
  • Management of dyspepsia symptoms on dabigatran during RELY-ABLE: a long-term follow up of RE-LY patients..  Pharmacotherapy. E185-E186. 2014
  • The value of myocardial perfusion imaging in predicting cardiac events and hospital length of stay in abdominal aortic aneurysm repair.  Anaesthesia. 40-40. 2014
  • Value of Myocardial perfusion Scintigraphy in Predicting cardiac Risk in Abdominal Aortic Aneurysm (AAA) Repair.  European Journal of Nuclear Medicine and Molecular Imaging. S201-S201. 2014
  • A Prospective Analysis of Cardiac Biomarkers and Electrocardiogram Abnormalities in Patients Receiving Thoracic Radiation Therapy With High-Dose Heart Exposure.  International Journal of Radiation Oncology Biology Physics. S630-S631. 2014
  • Association between naps, snore, sleep duration and obesity in the population of INTER-HEART China Study.  European Heart Journal. 539-539. 2014
  • Dabigatran versus warfarin in patients with pacemaker or defibrillator wires in the RE-LY trial: the role of contact activation.  European Heart Journal. 1115-1115. 2014
  • Impact of lifestyle factors on fracture risk in older patients with cardiovascular disease: a prospective cohort study of 26,335 individuals from 40 countries.  Age and Ageing. 629-635. 2014
  • Outcome reduction with an initial glargine intervention and legacy effects (ORIGINALE).  Diabetologia. S516-S516. 2014
  • The use of dabigatran according to body mass index: the RE-LY experience.  European Heart Journal. 1111-1111. 2014
  • ONTARIO BARIATRIC SURGERY: COMPARISON OF MORTALITY AND MORBIDITY FOLLOWING THE IMPLEMENTATION OF A PROVINCE-WIDE BARIATRIC PROGRAM.  Obesity Surgery. 1141-1141. 2014
  • ACUTE CHANGE IN GFR WITH INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM (RASI) AS PREDICTOR OF FUTURE RENAL & CARDIOVASCULAR OUTCOMES.  Nephrology Dialysis Transplantation. 39-39. 2014
  • COMPARISON OF DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND VALVULAR HEART DISEASE: THE RE-LY® TRIAL.  Journal of the American College of Cardiology. A325-A325. 2014
  • RESTING HEART RATE AND CHANGES IN HEART RATE ARE ASSOCIATED WITH ADVERSE OUTCOME IN HEART FAILURE PATIENTS WITHOUT ATRIAL FIBRILLATION: AN ANALYSIS OF THE CHARM PROGRAM.  Journal of the American College of Cardiology. A947-A947. 2014
  • CT textural analysis of intraluminal thrombus in small abdominal aortic aneurysms as a biomarker for aneurysm growth.  British Journal of Surgery. 8-8. 2014
  • Hypertension prevalence, awareness, treatment and control between han and ethnic minorities in China.  Cardiology. 13-13. 2014
  • The Dose-Response Effect Of Cigarette Smoking On Chronic Airflow Limitation (cal) Prevalence Across The World: The Pure-Breath Study.  American Journal of Respiratory and Critical Care Medicine. 2014
  • The Global Prevalence Of Dyspnea And Its Contributing Factors: The Pure-Breath Study.  American Journal of Respiratory and Critical Care Medicine. 2014
  • Apixaban Versus Aspirin in Atrial Fibrillation Patients >= 75 Years Old: an Analysis From the AVERROES Trial.  Stroke. E187-E187. 2013
  • Incidental Small Acute Brain Infarcts Are Rare in Neurologically Asymptomatic Community-Dwelling Older Adults.  Stroke. E182-E182. 2013
  • Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial.  Circulation. 2013
  • Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation - a RE-LY Trial Analysis.  Circulation. 2013
  • RE-LY and RELY-ABLE: Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years.  Circulation. 2013
  • Community health worker based interventions in secondary prevention of CVD in India (SPREAD): methods and baseline results.  European Heart Journal. 799-799. 2013
  • Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction.  European Heart Journal. 352-352. 2013
  • Guidance adherent dabigatran etexilate treatment versus warfarin in the RE-LY population: an analysis on the basis of the European label recommendations for dabigatran etexilate.  European Heart Journal. 791-791. 2013
  • Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction.  European Heart Journal. 284-284. 2013
  • Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY.  European Heart Journal. 102-102. 2013
  • Physical activity levels, sport activities and risk of acute myocardial infarction: results of the INTERHEART study in China.  European Heart Journal. 1088-1088. 2013
  • Resting heart rate and decline in cognitive function: observations from the ONTARGET/TRANSCEND studies.  European Heart Journal. 499-500. 2013
  • Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial.  Diabetes. A98-A98. 2013
  • Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial.  Diabetes. A72-A72. 2013
  • Handgrip Strength Is Associated With Glomerular Filtration Rate in Patients With Diabetes Type 2.  Diabetes. A393-A393. 2013
  • Handgrip Strength Predicts Cardiovascular Mortality: A Subanalysis of the ORIGIN Trial.  Diabetes. A367-A367. 2013
  • Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme.  European Journal of Heart Failure. S110-S110. 2013
  • Recent prior heart failure hospitalization is associated with risk of clinical events in patients with reduced and preserved ejection fraction in the CHARM trials.  European Journal of Heart Failure. S268-S269. 2013
  • Resveratrol protects oxidative stress after ischemic injury by activating Nrf-2.  Journal of Neurochemistry. 144-144. 2013
  • EFFECT OF DABIGATRAN ON SERUM APOLIPOPROTEIN B AND APOLIPOPROTEIN A1 CONCENTRATIONS.  Journal of the American College of Cardiology. E300-E300. 2013
  • PHYSICAL ACTIVITY AND ITS RELATIONSHIP WITH OBESITY HYPERTENSION AND DIABETES IN URBAN AND RURAL CHINA: THE PURE CHINA STUDY.  Journal of the American College of Cardiology. E1610-E1610. 2013
  • PREVALENCE AND RISK FACTORS OF LEFT VENTRICULAR THROMBUS IN NONISCHEMIC CARDIOMYOPATHY PATIENTS WITH SEVERE LEFT VENTRICULAR SYSTOLIC DYSFUNCTION.  Journal of the American College of Cardiology. E593-E593. 2013
  • URBAN AND RURAL DIFFERENCES OF BLOOD PRESSURE AND HYPERTENSION CONTROL IN CHINESE COMMUNITIES: PURE CHINA STUDY.  Journal of the American College of Cardiology. E1350-E1350. 2013
  • Stroke-Related Specific Mortality and Influencing Factors in Patients with Atrial Fibrillation in the RE-LY Trial.  Stroke. 2013
  • Clinical Outcomes of Patients with Previous Transient Ischaemic Attack or Stroke - a Subgroup Analysis of the Long-Term Extension of Dabigatran in Patients with Atrial Fibrillation (RELY-ABLE) Study.  Cerebrovascular Diseases. 121-121. 2013
  • Physical activity levels, sport activities and risk of acute myocardial infarction in China population: Result of the interheart study.  Cardiology. 18-18. 2013
  • Recurrent Events and Mortality Among Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the RE-LY Trial.  Cerebrovascular Diseases. 165-165. 2013
  • Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-Able Double-Blind Randomized Trial.  Circulation. 2793-2793. 2012
  • Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial.  Circulation. 2012
  • Balancing the Benefits and Risks of Two Doses of Dabigatran Compared with Warfarin in Atrial Fibrillation.  Circulation. 2012
  • Cluster Randomized Controlled Trial to Test The Effect of a Multifaceted Comprehensive Cardiovascular Care Intervention on Clinical Outcomes in Atrial Fibrillation Patients Receiving Dabigatran.  Circulation. 2012
  • Current Status of Medication Usage for Cardiovascular Disease and Hypertension in China (PURE-China Study).  Circulation. 2012
  • Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial.  Circulation. 2012
  • Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation - A RELY Substudy.  Circulation. 2012
  • Management and Outcomes of Major Bleeding On Dabigatran or Warfarin.  Blood. 19-19. 2012
  • 023 Gender Differences in the Association Between Neighbourhood Environment Characteristics With Being Overweight.  Canadian Journal of Cardiology. S92-S92. 2012
  • 221 Elevated CETP Activity is Associated With Low Dysfunctional HDL in South Asians.  Canadian Journal of Cardiology. S172-S172. 2012
  • 422 Accelerated Adipose Tissue Dysfunction and Cardiovascular Risk in Individuals of South Asian Ethnicity.  Canadian Journal of Cardiology. S258-S258. 2012
  • 901 Importance of Risk Stratification to Explain International Variations in Results of the Coronary Trial (Off-Pump Vs. On-Pump Cabg Surgery) — the Canadian Results.  Canadian Journal of Cardiology. S416-S417. 2012
  • 902 Cluster Randomized Controlled Trial to Test the Effect of Computer-Generated Individualized Audit and Feedback to Patients and Physicians on Clinical Outcomes in Atrial Fibrillation Patients Participating in a Large Multi-Center Trial of Dabigatran.  Canadian Journal of Cardiology. S417-S417. 2012
  • Influence of socioeconomic status on Acute Myocardial Infarction (AMI) in China population: the Interheart China study.  European Heart Journal. 294-294. 2012
  • Prognostic Impact of an Ischemic Etiology of Chronic Heart Failure across the Spectrum of Ejection Fractions in the CHARM Program.  Journal of Cardiac Failure. S78-S78. 2012
  • Prognostic value of electrocardiographic left ventricular hypertrophy in patients with atrial fibrillation.  European Heart Journal. 376-376. 2012
  • Characteristics, treatments and outcomes in young as compared with elderly acute coronary syndrome patients in india (CREATE registry).  Circulation. E667-E667. 2012
  • Comparison of risk factor reduction and tolerability of a full dose versus low dose of a polypill (polycap) in individuals at high risk of cardiovascular diseases: a phase II, double blind randomized trial.  Circulation. E803-E803. 2012
  • Gender differences in presentation, treatments and outcomes of over 20,000 acute coronary syndromes patients in India: the CREATE registry.  Circulation. E780-E781. 2012
  • INSPIRE: methods and preliminary results of a large stroke registry from India.  Circulation. E673-E674. 2012
  • The Rheumatic Heart Disease Global Registry (REMEDY) study: preliminary report.  Circulation. E723-E723. 2012
  • BLEEDING WITH ASPIRIN AND APIXABAN IN PATIENTS UNSUITABLE FOR VITAMIN K ANTAGONIST THERAPY: THE AVERROES STUDY.  Journal of the American College of Cardiology. E572-E572. 2012
  • IMPACT OF CHRONIC THROMBOCYTOPENIA IN PATIENTS WITH CORONARY ARTERY DISEASE AND CANCER.  Journal of the American College of Cardiology. E1819-E1819. 2012
  • THE CHA2DS2-VASC SCORE IDENTIFIES AF PATIENTS WITH A CHADS2 SCORE OF 0 OR 1 TREATED WITH ANTIPLATELET THERAPY WHO ARE UNLIKELY TO BENEFIT FROM ORAL ANTICOAGULANT THERAPY.  Journal of the American College of Cardiology. E570-E570. 2012
  • Efficacy and Safety of Dabigatran Versus Warfarin in Patients with Atrial Fibrillation: Analysis in Asian Population in RE-LY Trial.  Cerebrovascular Diseases. 9-9. 2012
  • Investigating Abdominal Aortic Aneurysm (AAA) Texture Analysis, F-18-FDG Uptake on PET/CT and future growth rate.  British Journal of Surgery. 215-215. 2012
  • Alcohol Effect on Incident Atrial Fibrillation in Individuals with Cardiovascular Disease: Analysis of Data from the ONTARGET and TRANSCEND Studies.  Circulation. 2011
  • Global Variation in the Etiology and Management of Atrial Fibrillation: Results from a Global Atrial Fibrillation Registry.  Circulation. 2011
  • Impact of Treatment with Apixaban and Aspirin in Patients with Atrial Fibrillation in Relation to the CHADS2 and CHA2DS2-VASc Scores: the AVERROES Study.  Circulation. 2011
  • Rationale, design and preliminary findings of the prospective urban-rural epidemiologic mind (Pure-Mind) MRI Study.  Stroke. E587-E587. 2011
  • PREDICTIVE VALUE OF INCREASED BODY WEIGHT AND ABDOMINAL ADIPOSITY FOR CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS A SUB-STUDY OF THE ONTARGET/TRANSCEND TRIALS.  Canadian Journal of Cardiology. S311-S311. 2011
  • Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial.  European Heart Journal. 671-671. 2011
  • Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial.  European Heart Journal. 6-6. 2011
  • Dabigatran and warfarin affects the coagulation process at different levels during long-term treatment - a RELY substudy.  European Heart Journal. 467-467. 2011
  • Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: a secondary analysis of the AVERROES trial.  European Heart Journal. 465-465. 2011
  • Efficacy and safety of the novel oral factor Xa inhibitor apixaban in atrial fibrillation (AF) patients with chronic kidney disease (CKD): the AVERROES trial.  European Heart Journal. 6-6. 2011
  • First use in humans of the new Amigo remote catheter system in electrophysiology studies and catheter ablation for typical atrial flutter.  European Heart Journal. 1104-1105. 2011
  • Importance of algorithm-based warfarin dosing in the quality of anticoagulation control in atrial fibrillation - a multilevel analysis.  European Heart Journal. 461-461. 2011
  • No evidence of platelet activation in patients with atrial fibrillation who are treated with dabigatran: a substudy of the rely trial.  Journal of Thrombosis and Haemostasis. 346-346. 2011
  • 159 Pilot Study exploring the regional repolarisation instability index in relation to myocardial heterogeneity and prediction of ventricular arrhythmia and death.  Heart. A89-A89. 2011
  • Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial..  Journal of Clinical Oncology. 1504-1504. 2011
  • Pulmonary Function In Healthy Non-Smoking Adults From 17 Countries In Different Regions Of The World.  American Journal of Respiratory and Critical Care Medicine. 2011
  • ACUTE PERIPHERAL ARTERIAL ISCHEMIC EVENTS IN CANCER PATIENTS.  Journal of the American College of Cardiology. E1492-E1492. 2011
  • DABIGATRAN ETEXILATE VERSUS WARFARIN IN PATIENTS WITH DIFFERENT TYPES OF ATRIAL FIBRILLATION: A RE-LY® SUBGROUP ANALYSIS.  Journal of the American College of Cardiology. E62-E62. 2011
  • DABIGATRAN VERSUS WARFARIN AND IMPACT OF CHAD2-VASC SCORE ON OUTCOME IN ATRIAL FIBRILLATION PATIENTS: A RE-LY SUBGROUP ANALYSIS.  Journal of the American College of Cardiology. E7-E7. 2011
  • INTERLEUKIN-6 AND C-REACTIVE PROTEIN AND RISK FOR DEATH AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION.  Journal of the American College of Cardiology. E91-E91. 2011
  • AVERROES: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokes.  Stroke. E81-E81. 2011
  • Effect of Apixaban on Covert Stroke and Cognitive Function: AVERROES MRI-Brain Assessment Trial.  Stroke. E162-E162. 2011
  • Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial.  American Journal of Respiratory and Critical Care Medicine. 671-671. 2011
  • D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy.  Circulation. 2010
  • Heart Rate is associated with Increased Risk of Major Cardiovascular Events, Cardiovascular and All-Cause Death in Patients with Stable Chronic Cardiovascular Disease - An Analysis of ONTARGET/TRANSCEND.  Circulation. 2010
  • NT-proBNP is Prognostic for Stroke and Death in Atrial Fibrillation - a RELY Substudy.  Circulation. 2010
  • Randomized Trial of Fondaparinux versus Heparin to Prevent Graft Failure After Coronary Artery Bypass Grafting: The Fonda CABG Pilot Study.  Circulation. 2010
  • Genetic Variation in Hyaluronan Metabolism Genes (HYAL1, HABP2) Is Associated with Plasma Plasminogen Activator Inhibitor-1 Concentration.  Arteriosclerosis, Thrombosis and Vascular Biology. E220-E220. 2010
  • Genome-Wide Association Study of Patients with Severe Hypertriglyceridemia.  Arteriosclerosis, Thrombosis and Vascular Biology. E208-E208. 2010
  • EFFICACY AND SAFETY OF CLOPIDOGREL COMPARED WITH PLACEBO ACCORDING TO CYP2C19 GENOTYPE IN OVER 6000 PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES (CURE TRIAL) AND ATRIAL FIBRILLATION (ACTIVE TRIAL).  Canadian Journal of Cardiology. 146D-146D. 2010
  • FONDAPARINUX WITH UNFRACTIONATED HEPARIN DURING REVASCULARISATION IN ACUTE CORONARY SYNDROMES (FUTURA/OASIS 8): A RANDOMISED TRIAL EVALUATING THE SAFETY OF TWO REGIMENS OF ADJUNCTIVE INTRAVENOUS UNFRACTIONATED HEPARIN DURING PERCUTANEOUS CORONARY INTERVENTION IN HIGH-RISK PATIENTS WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROMES INITIALLY TREATED WITH SUBCUTANEOUS FONDAPARINUX.  Canadian Journal of Cardiology. 147D-147D. 2010
  • HEART RATE IS ASSOCIATED WITH INCREASED RISK OF MAJOR CARDIOVASCULAR EVENTS, CARDIOVASCULAR AND ALL-CAUSE DEATH IN PATIENTS WITH STABLE CHRONIC CARDIOVASCULAR DISEASE - ANALYSIS OF ONTARGET/TRANSCEND.  Canadian Journal of Cardiology. 76D-76D. 2010
  • INCIDENCE AND PREDICTORS OF STROKE FOLLOWING CARDIAC SURGERY: THE IMPACT OF ATRIAL FIBRILLATION.  Canadian Journal of Cardiology. 109D-109D. 2010
  • PLASMA RENIN ACTIVITY PREDICTS CARDIOVASCULAR EVENTS AND MORTALITY IN THE HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY.  Canadian Journal of Cardiology. 76D-76D. 2010
  • RANDOMIZED TRIAL OF FONDAPARINUX VERSUS HEPARIN TO PREVENT GRAFT FAILURE AFTER CORONARY ARTERY BYPASS GRAFTING: THE FONDA CABG PILOT STUDY.  Canadian Journal of Cardiology. 114D-114D. 2010
  • Catheter ablation for persistent atrial fibrillation ablation: randomised comparison of a new technique with conventional approach.  European Heart Journal. 550-550. 2010
  • Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation.  European Heart Journal. 886-886. 2010
  • Impact of Societal Influences on Chronic Noncommunicable Diseases in Low, Middle, and High Income Countries: The Prospective Urban Rural Epidemiology (PURE) Study.  Circulation. E177-E177. 2010
  • Potentially Modifiable Risk Factors Associated with Myocardial Infarction in China: The INTERHEART China Study.  Circulation. E86-E86. 2010
  • Predictors of Hypertension Awareness, Treatment, and Control in Rural and Urban Areas of 17 Countries (PURE Study).  Circulation. E78-E79. 2010
  • CHANGES IN ALBUMINURIA PREDICT MORTALITY AND MORBIDITY IN PATIENTS WITH VASCULAR DISEASE: PS.3.04.  Journal of Hypertension. e602-e602. 2010
  • Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: the RE-LY study.  Journal of Neurology. S31-S31. 2010
  • DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS.  Journal of the American College of Cardiology. 2010
  • DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION - AN ANALYSIS OF PATIENTS UNDERGOING CARDIOVERSION.  Journal of the American College of Cardiology. 2010
  • EFFECT OF AGE AND RENAL FUNCTION ON THE RISKS OF STROKE AND MAJOR BLEEDING WITH DABIGATRAN COMPARED TO WARFARIN: AN ANALYSIS FROM THE RE-LY STUDY.  Journal of the American College of Cardiology. 2010
  • Reduced Cerebral Bleeding Rates with Dabigatran Compared to Warfarin in Patients with Atrial Fibrillation: Results of RE-LY.  Neurology. A281-A281. 2010
  • Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE‐I, European CRT survey, German pre‐SCD II registry, and MADIT‐CRT.  European Journal of Heart Failure. 1214-1219. 2009
  • Erectile Dysfunction Predicts Cardiovascular Events in High Risk Patients Receiving Telmisartan, Ramipril or Both.  Circulation. S475-S475. 2009
  • Plasma Renin Activity is Associated With Increased Cardiovascular Events and Mortality in the HOPE Study.  Circulation. S453-S453. 2009
  • Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme.  European Heart Journal. 876-876. 2009
  • The trade off between device and patient longevity in cost-effective analyses of CRT-D.  European Heart Journal. 1010-1011. 2009
  • A 025 Prevalence of Cardiovascular Disease, Alcohol Consumption, Tobacco and Exhibition to the Tobacco. PURE Study.  Atherosclerosis Plus. 10-11. 2009
  • A 026 Healthy Food and Markers of Risk Cardiovascular between Urban and Rural Populations. PURE Study.  Atherosclerosis Plus. 11-11. 2009
  • A 027 Current Data to Demonstrate of Healthy Lifestyle and Cardiovascular Risk Markers Among Populations of Urban and Rural Areas. PURE Study.  Atherosclerosis Plus. 11-11. 2009
  • Replication of Loci Affecting Plasma Lipoproteins and Triglycerides Using a Targeted Cardiovascular SNP Microarray in a Multiethnic Sample.  Arteriosclerosis, Thrombosis and Vascular Biology. E59-E59. 2009
  • The Contribution of Genetic and Known Vascular Risk Factors to the Relationship Between Family History and Myocardial Infarction.  Arteriosclerosis, Thrombosis and Vascular Biology. E95-E96. 2009
  • A FUNCTIONAL VARIANT RS1048990 IN PSMA6 IS ASSOCIATED WITH SUSCEPTIBILITY TO MYOCARDIAL INFARCTION IN A CHINESE POPULATION.  Journal of Hypertension. S147-S147. 2009
  • EFFECT OF COMBINATIONS OF ANTIHYPERTENSIVE DRUGS IN A POLYPILL (POLYCAP) ON BLOOD PRESSURE LOWERING, IN INDIVIDUALS WITHOUT CARDIOVASCULAR DISEASE.  Journal of Hypertension. S17-S17. 2009
  • EFFECTS OF RAMIPRIL, TELMISARTAN AND THEIR COMBINATION ON AMBULATORY BLOOD PRESSURE IN AN ONTARGET SUBSTUDY.  Journal of Hypertension. S168-S168. 2009
  • EFFECTS OF TELMISARTAN, RAMIPRIL AND THEIR COMBINATION ON LEFT VENTRICULAR HYPERTROPHY IN INDIVIDUALS AT HIGH VASCULAR RISK.  Journal of Hypertension. S166-S166. 2009
  • Effect of Rosiglitazone and Ramipril on beta-Cell Function in Subjects with Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG): The DREAM Trial.  Diabetes. A255-A255. 2009
  • Impact of Ramipril on Body Fat Compartments and Hepatic Fat in the DREAM Trial.  Diabetes. A443-A443. 2009
  • Impact of Rosiglitazone on Body Fat Compartments and Hepatic Fat in the DREAM Trial.  Diabetes. A443-A443. 2009
  • RENAL OUTCOMES IN THE TRANSCEND STUDY COMPARING TELMISARTAN TO PLACEBO IN PEOPLE WITH ESTABLISHED CARDIOVASCULAR DISEASE OR COMPLICATED DIABETES.  Journal of Hypertension. S315-S315. 2009
  • SAFETY AND EFFICACY OF AGGRESSIVE BLOOD PRESSURE LOWERING AMONG PATIENTS WITH DIABETES: SUBGROUP ANALYSES FROM THE ONTARGET TRIAL.  Journal of Hypertension. S16-S16. 2009
  • TIPS (The Indian PolyCap Study).  P and T. 260. 2009
  • Effect Of Telmisartan On Functional Outcome, Recurrence And Blood Pressure In Patients With Acute Ischaemic Stroke: A PRoFESS Substudy.  Stroke. E128-E128. 2009
  • Effect of Telmisartan on Cognitive Decline following stroke: PRoFESS Cognitive Sub-study..  Stroke. E274-E274. 2009
  • Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction.  Journal of the American College of Cardiology. A467-A467. 2009
  • WOMEN WHO HEAD HOUSEHOLDS FROM RURAL SOUTH INDIA ARE FOOD INSECURE.  Annals of Nutrition and Metabolism. 664-664. 2009
  • An Indirect Comparison of the Efficacy and Safety of Factor Xa Inhibitors with Thrombin Inhibitors nn Preventing Various Thromboembolism after Hip or Knee Surgery.  Circulation. S1051-S1051. 2008
  • Effect of Rosiglitazone on Left Ventricular Systolic and Diastolic Function and on NT-proBNP: Results of the Echocardiographic and Biomarker Substudy of the DREAM Trial.  Circulation. S723-S723. 2008
  • Efficacy and Safety of Clopidogrel in Acute Coronary Syndrome Patients at High Risk of Bleeding: Data from the CURE Trial.  Circulation. S916-S916. 2008
  • High Mortality Rates are Associated with Withdrawal of Beta Blockers and Ace Inhibitors in Chemotherapy-induced Heart Failure.  Circulation. S797-S797. 2008
  • No Clear Association Between Candidate Gene Variants and Outcomes In 3239 Patients with Chronic Heart Failure: Results from the CHARM Program.  Circulation. S623-S624. 2008
  • Paradoxical Low Use of Coronary interventions in High-Risk Non-st Segment Acute Coronary Syndromes with Heart Failure. Data from the Oasis-5 Randomized Trial.  Circulation. S975-S976. 2008
  • Blood pressure analyses from 25 595 patients (from 25 620 randomised) during the ONTARGET trial: reflections on current guidelines.  Journal of Human Hypertension. 728-728. 2008
  • Anticoagulant intensity of enoxaparin compared with fondaparinux in the OASIS-5 trial.  European Heart Journal. 746-746. 2008
  • Cognitive function and anticoagulation control in patients with atrial fibrillation.  European Heart Journal. 258-258. 2008
  • Fondaparinux administration according to its European labeling improves outcome in patients with ST elevation acute myocardial infarction (STEMI): a subanalysis of the OASIS-6 study.  European Heart Journal. 329-329. 2008
  • Impact of ramipril on the development of prolonged QT interval: results of the Heart Outcomes Prevention Evaluation (HOPE) study.  European Heart Journal. 604-604. 2008
  • Long-term net clinical benefit in favor of fondaparinux compared with enoxaparin in European patients with non-ST elevation acute coronary syndromes: a subgroup analysis of OASIS-5.  European Heart Journal. 327-328. 2008
  • Risk factors associated with myocardial infarction in China: The INTERHEART China.  Journal of Hypertension. S15-S15. 2008
  • High rates of preventable latrogenic adverse events in patients admitted to the coronary care unit.  Journal of the American College of Cardiology. A237-A237. 2008
  • Cardiovascular Sequelae of Preeclampsia/Eclampsia: A Systematic Review and Meta-Analyses.  Hypertension in Pregnancy. 547-547. 2008
  • The perioperative ischemic evaluation (POISE) trial: A randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery.  Circulation. 2632-2632. 2007
  • Spironolactone therapy helps to improve probrain natriuretic peptide levels in patients with congestive heart failure.  Cardiovascular Drugs and Therapy. S31-S31. 2007
  • Elevated in-hospital glucose level, and not known history of diabetes mellitus, predicts 30-day mortality following acute ST-elevation myocardial infarction.  Circulation. 824-824. 2007
  • Genetic variants associated with acute myocardial infarction risk in five ethnic groups: The INTERHEART genetics study.  Circulation. 806-806. 2007
  • Glucose levels predict incident cardiovascular events in a large international multiethnic cohort.  Circulation. 835-835. 2007
  • Household car and television ownership are associated with an increased risk of myocardial infarction: Results from the INTERHEART study.  Circulation. 845-845. 2007
  • Obesity metrics and their associations with type 2 diabetes and glucose levels in a large international multi-ethnic cohort.  Circulation. 318-319. 2007
  • Work and leisure time related physical activity and the risk of myocardial infarction: Results of the INTERHEART study.  Circulation. 834-834. 2007
  • Best independent predictor for cardiovascular events in high-risk patients: Body mass index, waist circumference or waist-to-hip ratio? (substudy of the ontarget/transcend trials).  Canadian Journal of Cardiology. 161C-161C. 2007
  • Bleeding risk of glycoprotein (GP) IIB IIIA inhibitors or thienopyridines with fondaparinux vs enoxaparin in acute coronary syndromes: Insights from the oasis 5 trial.  Canadian Journal of Cardiology. 223C-223C. 2007
  • Congestive heart failure assessment and management in primary care (CHAMP-C).  Canadian Journal of Cardiology. 298C-298C. 2007
  • Effect of homocysteine lowering B vitamins on carotid atherosclerosis: The homocysteine and atherosclerosis reduction trial (HART).  Canadian Journal of Cardiology. 298C-298C. 2007
  • The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: Insights from the OASIS 5 trial.  Canadian Journal of Cardiology. 121C-122C. 2007
  • Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial.  European Heart Journal. 516-516. 2007
  • Discontinuation of clopidogrel within the year following a non-ST-segment elevation acute coronary syndrome has a deleterious effect: evidence from the CURE trial.  European Heart Journal. 193-193. 2007
  • Risks and patterns of bleeding in patients with atrial fibrillation.  European Heart Journal. 534-534. 2007
  • The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial.  European Heart Journal. 187-187. 2007
  • Weight loss is associated with increased mortality risk in patients with chronic heart failure: evidence from the CHARM program.  European Heart Journal. 270-270. 2007
  • The risk associated with diabetes mellitus in patients with preserved and low ejection fraction heart failure. An analysis of the candesartan in heart failure: Assessment of reduction in mortality and morbidity programme.  Heart. A40-A41. 2007
  • Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program..  Journal of the American College of Cardiology. 331A-331A. 2007
  • Black patients with symptomatic heart failure have similar outcomes and response to angiotensin receptor blockade as white patients.  Journal of the American College of Cardiology. 75A-75A. 2007
  • Candesartan benefits and safety observed regardless of age. Insights from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program..  Journal of the American College of Cardiology. 55A-55A. 2007
  • Comparison of the risk associated with diabetes mellitus in patients with preserved and low ejection fraction heart failure: An analysis of the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program.  Journal of the American College of Cardiology. 61A-61A. 2007
  • Effects of aspirin dose on ischemic events and bleeding after percutaneous coronary intervention: Insights from the PCI-CURE study.  Journal of the American College of Cardiology. 46B-46B. 2007
  • Efficacy and safety of fonclaparinux in elderly patients with ST segment elevation myocardial infarction: Data from the OASIS 6 trial.  Journal of the American College of Cardiology. 242A-242A. 2007
  • Liver function test abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program.  Journal of the American College of Cardiology. 44A-44A. 2007
  • Red cell distribution width as a novel prognostic marker in heart failure: Data from the CHARM program and the duke databank.  Journal of the American College of Cardiology. 88A-88A. 2007
  • Dietary patterns and risk of myocardial infarction in 52 countries: Results of the INTERHEART study.  Circulation. E220-E220. 2007
  • Refinement and validation of a food frequency questionnaire to estimate nutrient intake in South Indians.  Circulation. E239-E239. 2007
  • Regional differences in stroke subtypes in clinical trials of secondary prevention: The profess experience.  Stroke. 526-526. 2007
  • Aspirin and the Risk of Heart Failure Hospitalization in Patients with Atrial Fibrillation and a Prior History of Heart Failure: An ACTIVE-W Analysis.  Journal of Cardiac Failure. 762-762. 2006
  • Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the heart outcomes prevention evaluation (HOPE) Study.  Circulation. 871-871. 2006
  • Effects of fondaparinux in patients with ST-Segment elevation acute myocardial infarction non-eligible for reperfusion treatment.  Circulation. 699-700. 2006
  • Fasting plasma glucose is an independent predictor of hospitalization for congestive heart failure in high-risk patients.  Circulation. 530-530. 2006
  • Fondaparinux versus control (placebo or unfractionated heparin) as an adjunct to thrombolytic therapy in acute myocardial infarction: an OASIS 6 substudy.  Circulation. 699-699. 2006
  • Impact of vascular events on mortality in AF patients: Insights from ACTIVE W.  Circulation. 790-791. 2006
  • Increase in risk of death in early months following hospitalization for heart failure: Observations from the CHARM program.  Circulation. 670-671. 2006
  • Lack of interaction between angiotensin receptor blocker and aspirin in patients with heart failure.  Circulation. 767-767. 2006
  • Major bleeding in patients with acute coronary syndrome undergoing early invasive management can be reduced by fondaparinux, even in the context of trans-radial coronary intervention: Insights from OASIS-5 trial.  Circulation. 552-552. 2006
  • Diabetes status and fasting plasma glucose are independent determinants of cognitive status in people at high risk for cardiovascular disease.  Diabetologia. 76-76. 2006
  • Effect of underlying risk of stroke on treatment effects in the ACTIVE-W Trial.  European Heart Journal. 35-36. 2006
  • Fasting glucose as a predictor of cardiovascular events in high-risk patients.  European Heart Journal. 171-171. 2006
  • Fasting plasma glucose and new onset of diabetes type 2 in high-risk patients.  European Heart Journal. 520-520. 2006
  • Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes.  European Heart Journal. 448-448. 2006
  • Incidence of stroke in paroxysmal versus persistent/permanent atrial fibrillation and effects of oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy.  European Heart Journal. 446-446. 2006
  • Predictors of out-of-range INR for patients with atrial fibrillation on oral anticoagulation: results from ACTIVE.  European Heart Journal. 38-38. 2006
  • Relationship of baseline hemoglobin levels with short term outcome in acute coronary syndromes. Insights from the OASIS 5 and 6 trials.  European Heart Journal. 160-160. 2006
  • Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial.  European Heart Journal. 331-331. 2006
  • Beneficial effects of ramipril on cardiovascular events in high-risk patients >= 70 years: A subgroup analysis of the HOPE study.  Journal of Hypertension. S91-S91. 2006
  • Adverse impact of bleeding in patients with acute coronary syndromes.  Journal of the American College of Cardiology. 197A-197A. 2006
  • Bleeding complications predict major cardiovascular outcomes in non ST-elevation acute coronary syndromes: Results from the OASIS-5 trial.  Journal of the American College of Cardiology. 195A-195A. 2006
  • Candesartan improves outcome in patients with low ejection fraction heart failure, irrespective of background dose of ACE inhibitor: An analysis of the CHARM-added trial.  Journal of the American College of Cardiology. 52A-52A. 2006
  • Fondaparinux is associated with substantially less major bleeding and vascular access site complications compared with enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the OASIS 5 trial.  Journal of the American College of Cardiology. 205A-205A. 2006
  • Fondaparinux versus enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Impact of risk according to the GRACE score.  Journal of the American College of Cardiology. 223A-223A. 2006
  • Should warfarin be monitored by anticoagulation clinics or by physician practices?.  Journal of the American College of Cardiology. 259A-259A. 2006
  • The efficacy and safety of fondaparinux versus enoxaparin in non-ST elevation ACS: Impact of renal dysfunction (OASIS 5).  Journal of the American College of Cardiology. 195A-195A. 2006
  • Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: A meta-analysis of the randomized trials.  Journal of the American College of Cardiology. 228A-229A. 2006
  • We-W31:5 Homocysteine and folic acid levels and relation to carotid atherosclerosis in high-risk individuals.  Atherosclerosis Plus. 308-308. 2006
  • Atrial fibrillation carries similar risks in heart failure irrespective of ejection fraction-results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM).  European Heart Journal. 378-379. 2005
  • Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme.  European Heart Journal. 381-381. 2005
  • Erectile dysfunction in high risk cardiovascular patients - insights from the erectile dysfunction substudy of the ONTARGET/TRANSCEND trials.  European Heart Journal. 700-700. 2005
  • Factors precipitating heart failure hospitalisation: a novel analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.  European Heart Journal. 280-280. 2005
  • Female gender is an independent predictor of better outcome in chronic heart failure: results from the CHARM programme.  European Heart Journal. 184-184. 2005
  • Predictors of quality of life in symptomatic heart failure patients across the left ventricular ejection fraction spectrum.  European Heart Journal. 600-600. 2005
  • Women (especially younger women) with chronic heart failure are less adherent to medication: results from the CHARM program.  European Heart Journal. 185-185. 2005
  • Need for substantial revision of criteria for overweight and obese among South Asians and chinese compared to Europeans to predict the risk of metabolic abnormalities.  Circulation. E254-E254. 2005
  • Direct bilirubin and red cell distribution width (RDW) are powerful independent predictors of outcome in chronic heart failure: Results from the CHARM program.  Journal of the American College of Cardiology. 176A-176A. 2005
  • Electrocardiographic left ventricular hypertrophy is associated with worse clinical outcomes in heart failure: Evidence from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) programme.  Journal of the American College of Cardiology. 146A-146A. 2005
  • Impact of a simple regimen of low molecular weight heparin (reviparin) in preventing mortality, reinfarction, and strokes in over 15,500 patients with ST-elevation acute myocardial infarction: The CREATE trial.  American Heart Journal. 244-245. 2005
  • Adherence, even to placebo, is strongly and independently related to outcome in patients with chronic heart failure: Results from the CHARM program.  Circulation. 557-557. 2004
  • Baseline high-sensitivity C-reactive protein offers prognostic value in addition to contemporary risk stratification in non-ST-segment elevation acute coronary syndrome: Results from the CURE inflammatory marker substudy.  Circulation. 499-499. 2004
  • Early enalapril therapy reduced cardiovascular morbidity and mortality in patients with left ventricular systolic dysfunction: Results at 15 years in SOLVD.  Circulation. 367-367. 2004
  • Impact of candesartan in preventing myocardial infarction: Results of the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) programme.  Circulation. 514-514. 2004
  • Predicting mortality and morbidity in chronic heart failure independent of left ventricular systolic function: Results from the CHARM program.  Circulation. 752-752. 2004
  • Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis.  Circulation. 461-461. 2004
  • Early enalapril therapy in patients with left ventricular systolic dysfunction reduced cardiovascular morbidity and mortality at 15-years in SOLVD.  Journal of Cardiac Failure. S97-S97. 2004
  • Low haemoglobin is associated with more evidence of congestion but less severe systolic dysfunction in patients with chronic heart failure.  European Heart Journal. 498-498. 2004
  • Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials.  Journal of Cardiac Failure. S76-S76. 2004
  • Substantial reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials.  European Heart Journal. 487-487. 2004
  • Design and baseline characteristics of the DREAM (diabetes REduction assessment with ramipril and rosiglitazone medication) trial.  Diabetes. A483-A483. 2004
  • Red meat protein intake is associated with carotid artery intima media thickness..  American Journal of Epidemiology. S55-S55. 2004
  • 1034-212 5-Hydroxytryptamine 4 (5HT4) receptor mRNA processing in favor of the ‘b’ isoform correlates with left atrial dilatation and may predispose to atrial fibrillation after coronary artery bypass grafting.  Journal of the American College of Cardiology. A111-A111. 2004
  • 1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study.  Journal of the American College of Cardiology. A180-A180. 2004
  • 1098-79 Renal function predicts outcomes in acute coronary syndromes: Insights from the CURE trial.  Journal of the American College of Cardiology. A278-A278. 2004
  • 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM).  Journal of the American College of Cardiology. A197-A197. 2004
  • 1128-120 Importance of an oral glucose tolerance test in identifying high prevalence of dysglycemia in individuals at high cardiovascular risk.  Journal of the American College of Cardiology. A211-A211. 2004
  • 1137-77 Long-term cost-effectiveness of clopidogrel in patients having percutaneous coronary intervention early after acute coronary syndrome: Results from PCI-CURE.  Journal of the American College of Cardiology. A296-A296. 2004
  • 1145-122 Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM.  Journal of the American College of Cardiology. A222-A222. 2004
  • 810-1 Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure.  Journal of the American College of Cardiology. A473-A473. 2004
  • 827-5 Diabetic patients with acute myocardial infarction have larger infarct size, lower ejection fraction, and higher mortality.  Journal of the American College of Cardiology. A284-A284. 2004
  • 835-5 Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: Results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme (CHARM).  Journal of the American College of Cardiology. A206-A206. 2004
  • Modulation of 5-hydroxytryptamine 4 (5HT4) receptor isoform expression predisposes to atrial fibrillation after coronary artery bypass surgery..  American Journal of Human Genetics. 343-343. 2003
  • Early treatment with enalapril in patients with left ventricular systolic dysfunction protected against death and serious cardiovascular morbid events at 12 years in SOLVD.  Circulation. 692-692. 2003
  • Interleukin 18 as a predictor of myocardial infarction in the Heart Outcomes Prevention Evaluation (HOPE) study.  Circulation. 747-747. 2003
  • Long-term cost effectiveness of platelet inhibition with clopidogrel in patients presenting with acute coronary syndromes: Results from the CURE trial.  Circulation. 417-417. 2003
  • Long-term cost effectiveness of platelet inhibition with clopidogrel in patients undergoing PCI after presenting with an acute coronary syndrome: Results from PCI-CURE.  Circulation. 576-576. 2003
  • Viral pathogen scores and subsequent cardiac events in the HOPE study.  Circulation. 751-751. 2003
  • Evaluating the validity of record linkages in the ascertainment of vital status for post-trial follow-up of a heart failure clinical trial.  Contemporary Clinical Trials. 143S-144S. 2003
  • Evaluating the health economic impact of clopidogrel for acute coronary syndromes in five countries, based on the CURE study.  Heart. A22-A22. 2003
  • Long term follow up of patients with acute coronary syndromes without ST elevation: PrAIS-UK.  Heart. A22-A22. 2003
  • Benefit of clopidogrel in patients undergoing percutaneous coronary intervention in the CURE trial receiving and not receiving an intracoronary Stent.  Journal of the American College of Cardiology. 45A-45A. 2003
  • Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary infarction in the CURE trial: The PCI-CURE economic analysis.  Journal of the American College of Cardiology. 383A-383A. 2003
  • Plasma norepinephrine, predicts 12-year survival in patients with reduced ejection fractions from the studies of left ventricular dysfunction (SOLVD).  Journal of the American College of Cardiology. 141A-142A. 2003
  • 2047 Consistent benefit of clopidogrel in patients with non-ST-elevation acute coronary syndromes undergoing very early, early or later percutaneous coronary intervention in the CURE study.  European Heart Journal. 377-377. 2003
  • P1572 In the fibrillating atria the mitochondrial sublimons are significantly correlated with both left atrial diameter and atrial fibrillation duration.  European Heart Journal. 286-286. 2003
  • Aspirin dose and bleeding events in the CURE study.  Circulation. 456-456. 2002
  • Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation (ACS) in various risk groups.  Circulation. 455-455. 2002
  • Effect of direct thrombin inhibitors on reducing death and myocardial infarction in acute coronary syndromes is greater in patients undergoing percutaneous coronary intervention.  Circulation. 494-494. 2002
  • Impact of cigarette smoking in patients at high risk of cardiovascular disease. The heart outcomes prevention evaluation (HOPE) Study.  Circulation. 666-666. 2002
  • Infarct size is smaller in women versus men with acute myocardial infarction.  Circulation. 189-189. 2002
  • Long-term prognosis of patients with heart failure and reduced ejection fractions - 12-year follow-up of the studies of left ventricular dysfunction.  Circulation. 724-724. 2002
  • Racial differences in outcome and treatment effect in heart failure (HF) in Digitalis Investigation Group (DIG) trial.  Circulation. 473-473. 2002
  • Rapid emergence of benefit with clopidogrel followed by incremental reduction in major cardiovascular events with long term therapy after acute coronary syndrome: Insights from the CURE trial.  Circulation. 493-493. 2002
  • The cost-effectiveness of the use of Clopidogrel in acute coronary syndromes based upon the CURE study.  Circulation. 758-758. 2002
  • Aspirin dose and bleeding events in the CURE study.  European Heart Journal. 510-510. 2002
  • Mortality in left ventricular dysfunction treated with angiotensin-converting enzyme inhibitors. Ten-years follow-up post SOLVD close out.  European Heart Journal. 31-31. 2002
  • The risks versus benefits of clopidogrel treatment in acute coronary syndrome patients overall, and those undergoing CABG: the CURE trial.  European Heart Journal. 510-510. 2002
  • Prevention of post-cardiac surgery atrial fibrillation is not associated with decrease in post-operative stroke: Meta-analysis.  Journal of the American College of Cardiology. 85A-85A. 2002
  • Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients.  Journal of the American College of Cardiology. 291-291. 2002
  • Natriuretic peptides predict left ventricular remodeling in response to metoprolol CR in patients with congestive heart failure: the RESOLVD phase II neurohumoral substudy.  Journal of the American College of Cardiology. 139-139. 2002
  • Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial.  Journal of the American College of Cardiology. 290-291. 2002
  • American Journal of Cardiology: Introduction.  American Journal of Cardiology. 2002
  • Cardiovascular events still drive mortality in patients with asymptomatic left ventricular dysfunction treated with ACE-inhibitors.  Circulation. 662-662. 2001
  • Cardiovascular morbid events in left ventricular dysfunction treated by ACE-inhibitors: Ten-years follow-up post SOLVD close out.  Circulation. 662-662. 2001
  • Impact of abdominal obesity on the occurrence of diabetes in subjects with ischemic cardiovascular disease.  Circulation. 833-833. 2001
  • Infections as risk markers for subsequent cardiovascular events in the HOPE trial.  Circulation. 805-805. 2001
  • Inflammatory markers and risk of subsequent cardiovascular events in the HOPE trial.  Circulation. 791-791. 2001
  • Prevention of atrial fibrillation after cardiac surgery: A meta-analysis.  Circulation. 773-773. 2001
  • Variations in practice patterns and clinical outcomes in 12,512 patients with non-ST elevation acute coronary syndromes (ACS) recruited in 13 countries and 5 continents..  Circulation. 626-+. 2001
  • What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial.  Circulation. 798-798. 2001
  • Direct thrombin inhibitors in acute coronary syndromes: a meta-analysis based on individual patient data.  European Heart Journal. 593-593. 2001
  • Predictive value of natriuretic peptides and endothelin-1 for LV remodelling in response to candesartan and enalapril: the RESOLVD neurohumoral ancillary study.  European Heart Journal. 40-40. 2001
  • Validity of the US behavior risk factor surveillance system?s Health related quality of life survey tool in a group of older Canadians..  American Journal of Epidemiology. S88-S88. 2001
  • Ankle-brachial blood pressure index is a strong predictor for mortality and cardiovascular events: Results from the HOPE-trial.  Journal of the American College of Cardiology. 277A-277A. 2001
  • Comparison of the effects of ramipril on ambulatory and office blood pressures. A HOPE substudy.  Journal of the American College of Cardiology. 286A-287A. 2001
  • Effects of ramipril on left ventricular mass and function in normotensive, high-risk patients with normal ejection fraction. A substudy of HOPE.  Journal of the American College of Cardiology. 165A-165A. 2001
  • Does larger infarct size explain the higher mortality in the elderly with acute myocardial infarction?.  Circulation. 793-793. 2000
  • Effects of ramipril on the incidence of myocardial infarction in high risk patients: The HOPE Study.  Circulation. 705-705. 2000
  • Metabolic and hematological effects of ramipril in the HOPE trial.  Circulation. 408-408. 2000
  • Predictive value of natriuretic peptides and endothelin-1 for LV remodeling in response to candesartan and enalapril: The RESOLVD neurohumoral ancillary study.  Circulation. 27-27. 2000
  • Renal insufficiency as a predictor of cardiovascular outcomes and impact of ramipril: The HOPE study.  Circulation. 655-655. 2000
  • OASIS Registry 2-year follow-up: outcomes in patients with unstable angina or myocardial infarction without ST-segment elevation admitted to hospitals with or without catheterisation facilities.  European Heart Journal. 247-247. 2000
  • Persistence of long-term benefit of hirudin compared to heparin in unstable angina and non-Q-wave infarction.  European Heart Journal. 186-186. 2000
  • Prognostic importance of weight loss in chronic heart failure and the impact of treatment with ACE inhibitors.  European Heart Journal. 376-376. 2000
  • Long-term management of unstable angina and non-Q-wave myocardial infarction.  European Heart Journal, Supplement. E6-E12. 2000
  • Abdominal adiposity as a prognostic factor for persons at high risk of cardiovascular events.  Journal of the American College of Cardiology. 284A-284A. 2000
  • Differences in cardiovascular disease between ethnic groups are not explained by conventional risk factors or atherosclerosis. The study of health assessment and risk in ethnic groups (SHARE).  Journal of the American College of Cardiology. 283A-284A. 2000
  • Impact of Ramipril and vitamin A on cerebrovascular events in the HOPE (Heart outcomes prevention evaluation) trial.  Journal of the American College of Cardiology. 324A-324A. 2000
  • Left ventricular hypertrophy predicts death and development of heart failure in high risk patients without systolic dysfunction.  Journal of the American College of Cardiology. 212A-212A. 2000
  • Prevention of heart failure by Ramipril in high risk patients without heart failure or systolic dysfunction.  Journal of the American College of Cardiology. 203A-203A. 2000
  • Ramipril prevents cardiovascular events in high risk diabetic participants: Results of the HOPE study.  Journal of the American College of Cardiology. 301A-301A. 2000
  • Reduction of events by ramipril in high risk subjects is largely unrelated to blood pressure decrease.  Journal of the American College of Cardiology. 284A-284A. 2000
  • Substantial benefit of hirudin compared to heparin among unstable angina patients undergoing early percutaneous coronary intervention.  Journal of the American College of Cardiology. 357A-357A. 2000
  • Vascular disease - HOPE (Heart Outcomes Prevention Evaluation).  Circulation. E126-E126. 1999
  • Effects of digoxin on worsening of symptoms of congestive heart failure in the digitalis investigation group (DIG) trial.  Circulation. 537-537. 1999
  • Impact of a history of heart failure on outcome in patients with acute coronary syndromes: An analysis from the OASIS registry.  Circulation. 641-641. 1999
  • Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS registry.  Circulation. 640-640. 1999
  • Increased morbidity and mortality in diabetic patients with acute myocardial infarction is not explained by larger infarct size or poorer left ventricular systolic dysfunction: insights from the CORE study..  Circulation. 640-640. 1999
  • Invasive versus conservative management of unstable angina and non-Q-wave infarction: A meta-analysis.  Circulation. 775-775. 1999
  • Metoprolol in chronic heart failure: Natriuretic peptides involved in mechanism of action?.  Circulation. 783-783. 1999
  • Results of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).  Circulation. 185-185. 1999
  • Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in unstable angina (USA) and Non-Q-Wave myocardial infarction (NQMI): A mete-analysis.  Circulation. 621-621. 1999
  • Weight loss in chronic heart failure (CHF) and the impact of treatment with ACE inhibitors - Results from the SOLVD treatment trial.  Circulation. 781-781. 1999
  • Relationship between occasional fill consumption and acute myocardial infarction in South Asian Indians.  Circulation. 1122-1122. 1999
  • Effect of age on mortality, hospitalizations, and response to digoxin in patients with heart failure: The DIG study.  Circulation. 301-301. 1998
  • Effects of long term oral anticoagulation therapy in addition to aspirin in patients with acute coronary syndromes without ST elevation: a substudy of the OASIS-2 trial..  Circulation. 867-867. 1998
  • Effects of recombinant hirudin compared to heparin in patients with acute ischemia without ST elevation - Results of the OASIS-2 trial..  Circulation. 504-504. 1998
  • Increased winter mortality from myocardial infarction and stroke: The effect of age..  Circulation. 720-721. 1998
  • Is there gender bias in the referral of patients with myocardial ischemia to coronary angiography?.  Circulation. 274-274. 1998
  • Risk factors for stroke in patients with unstable angina (UA) or suspected myocardial infarction (MI) without ST segment elevation. Results from the OASIS registry..  Circulation. 280-280. 1998
  • Single versus double versus triple therapy to block neurohormonal effects on ventricular remodeling.  Circulation. 780-780. 1998
  • Discussion.  Journal of the American College of Cardiology. 1-7. 1998
  • Phase I results of the randomized evaluation of left ventricular dysfunction (RESOLVD) trial.  American Journal of Managed Care. S380-S383. 1998
  • Phase I results of the randomized evaluation of left ventricular dysfunction (RESOLVD) trial.  American Journal of Managed Care. 1998
  • Incidence, Predictive Factors and Prognostic Significance of Supraventricular Tachyarrhythmias in Congestive Heart Failure.  Journal of the American College of Cardiology. 218A-218A. 1998
  • Increased Insulin and Glucose Levels in Heart Failure (HF).  Journal of the American College of Cardiology. 249A-249A. 1998
  • Randomized Controlled Trial of Exercise Training in Patients With Congestive Heart Failure (EXERT).  Journal of the American College of Cardiology. 508A-509A. 1998
  • The Impact of Time to Thrombolytic Therapy on Outcome in Patients With Acute Myocardial Infarction (AMI).  Journal of the American College of Cardiology. 453A-453A. 1998
  • Albuminuria is highly prevalent and predicts cardiovascular events in high risk diabetic and nondiabetic patients.  Circulation. 1245-1245. 1997
  • Effects of Candesartan, enalapril or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: Randomized evaluation of strategies for left ventricular dysfunction (resolved).  Circulation. 2527-2527. 1997
  • Factors affecting the use of invasive facilities in patients with unstable angina or suspected non-q wave infarction.  Circulation. 3000-3000. 1997
  • Is there a gender bias in the cardiovascular drug treatment of high-risk women?.  Circulation. 143-143. 1997
  • Left ventricular hypertrophy is a potent independent risk factor for adverse cardiovascular outcomes.  Circulation. 2600-2600. 1997
  • Long-term anticoagulation in patients with unstable angina: The OASIS pilot study.  Circulation. 212-212. 1997
  • Meta-analysis of individual patient data from trials of long-term ACE-inhibitor treatment after acute myocardial infarction (SAVE, AIRE, and TRACE studies).  Circulation. 3951-3951. 1997
  • Risk of death, myocardial infarction and strokes in relationship to an invasive or conservative strategy in unstable angina or non-Qwave myocardial infarction.  Circulation. 3336-3336. 1997
  • Pathophysiology and management of patients with acute ischaemic syndromes: Some perspectives.  International Journal of Clinical Practice, Supplement. 1-6. 1997
  • Right ventricular infarction: Prognostic value of radionuclide measurements..  Journal of Nuclear Medicine. 405-405. 1997
  • Continuous relationship of glucose with cardiovascular events in non diabetic subjects: A meta regression analysis of 18 studies in 88,000 individuals..  Circulation. 1245-1245. 1996
  • Diabetes is an independent risk factor for increased left ventricular mass.  Circulation. 2935-2935. 1996
  • Effect of baseline characteristics on outcomes in an international prospective registry of acute myocardial ischemia without ST elevation.  Circulation. 1139-1139. 1996
  • Hirudin (HBW-023) suppresses markers of coagulation more effectively than heparin.  Circulation. 4070-4070. 1996
  • LV function and infarct size predict six-month mortality post MI treated by thrombolysis.  Circulation. 3829-3829. 1996
  • Which heart failure patients benefit the most from long term digoxin therapy?.  Circulation. 131-131. 1996
  • Why do patients with right ventricular infarction have a poor prognosis?.  Circulation. 4291-4291. 1996
  • Data consistency checking for meta-analysis of large scale clinical trials.  AMERICAN STATISTICAL ASSOCIATION - 1996 PROCEEDINGS OF THE BIOPHARMACEUTICAL SECTION. 261-266. 1996
  • EFFECTS OF ORAL ANTICOAGULANTS ON MORTALITY, REINFARCTION AND STROKE AFTER MYOCARDIAL-INFARCTION.  Circulation. 1632-1632. 1995
  • EVALUATION OF RHEOTHRX(R), A NOVEL HEMORHEOLOGIC AGENT, IN ACUTE MYOCARDIAL-INFARCTION.  Circulation. 109-109. 1995
  • EVIDENCE FOR REBOUND ACTIVATION OF THE COAGULATION SYSTEM AFTER CESSATION OF INTRAVENOUS ANTICOAGULANT-THERAPY FOR ACUTE MYOCARDIAL-ISCHEMIA.  Circulation. 2314-2314. 1995
  • The cost of different choices for the treatment of hypertension.  British Journal of Clinical Practice. 17-21. 1995
  • IMPORTANCE OF INSULIN-RESISTANCE AND BODY-FAT DISTRIBUTION IN ADDITION TO CONVENTIONAL RISK-FACTORS FOR THE DEVELOPMENT OF MYOCARDIAL-INFARCTION IN ASIAN INDIANS.  Circulation. 472-472. 1994
  • THE RANDOMIZED CONTROLLED CLINICAL-TRIALS OF PTCA IN ACUTE MYOCARDIAL-INFARCTION - A SYSTEMATIC OVERVIEW (METAANALYSIS.  Circulation. 432-432. 1994
  • INCLUSION OF PATIENTS ONLY WITH LOW EJECTION FRACTION IN HEART-FAILURE TRIAL BIASES THE POPULATION AGAINST WOMEN AND THE ELDERLY.  Journal of the American College of Cardiology. A429-A429. 1994
  • LEFT-VENTRICULAR VOLUMES PREDICT DEVELOPMENT OF HEART-FAILURE AND POTENTIAL CLINICAL UTILITY OF ACE-INHIBITORS IN PATIENTS WITH ASYMPTOMATIC SYSTOLIC DYSFUNCTION.  Journal of the American College of Cardiology. A382-A382. 1994
  • PLASMA NOREPINEPHRINE AND ATRIAL-NATRIURETIC-PEPTIDE LEVELS PREDICT PROGNOSIS IN PATIENTS WITH ASYMPTOMATIC LEFT-VENTRICULAR DYSFUNCTION.  Journal of the American College of Cardiology. A429-A429. 1994
  • WOMEN ARE AT HIGHER RISK FOR EARLY CORONARY-ARTERY BYPASS GRAFT CLOSURE.  Journal of the American College of Cardiology. A346-A346. 1994
  • BASE-LINE QUALITY-OF-LIFE PREDICTS MORBIDITY AND MORTALITY IN 5210 PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION (SOLVD PREVENTION AND TREATMENT TRIALS).  Circulation. 359-359. 1993
  • COMPARATIVE NEUROHORMONAL RESPONSES IN PATIENTS WITH PRESERVED AND IMPAIRED LEFT-VENTRICULAR EJECTION FRACTION - RESULTS OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) REGISTRY.  Journal of the American College of Cardiology. A146-A153. 1993
  • CURRENT AND ONGOING RANDOMIZED TRIALS IN HEART-FAILURE AND LEFT-VENTRICULAR DYSFUNCTION.  Journal of the American College of Cardiology. A194-A197. 1993
  • DIABETES PREDICTS MORBIDITY AND MORTALITY IN THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION TRIALS.  Circulation. 604-604. 1993
  • ECHOCARDIOGRAPHIC PREDICTORS OF ONE-YEAR CLINICAL OUTCOME IN THE STUDY OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) TRIAL AND REGISTRY - AN ANALYSIS OF 1172 PATIENTS.  Circulation. 304-304. 1993
  • EFFECTS OF LONG-TERM ENALAPRIL ON ADRENERGIC ACTIVITY AND SENSITIVITY DURING EXERCISE IN PATIENTS WITH LEFT-VENTRICULAR SYSTOLIC DYSFUNCTION.  Circulation. 293-293. 1993
  • IN ASYMPTOMATIC PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION, NOT ON ENALAPRIL, THE PROGRESSION OF VENTRICULAR DILATION CORRELATES WITH PLASMA NOREPINEPHRINE LEVELS.  Circulation. 107-107. 1993
  • NATURAL-HISTORY AND PATTERNS OF CURRENT PRACTICE IN HEART-FAILURE.  Journal of the American College of Cardiology. A14-A19. 1993
  • Clinical experience in protecting the failing heart.  Clinical Cardiology. 25-29. 1993
  • Assessment of clinical outcome in heart failure: Discussion IX.  Journal of the American College of Cardiology. 1993
  • Discission: Nancy Geller and M Stylianou, practical issues in data monitoring of clinical trials: Summary of responses to a questionnaire at NIH.  Statistics in Medicine. 553. 1993
  • Discussion: Frank W Rockhold and G Enas, data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations: George W Williams et al, monitoring of clinical trials and interim analyses from a drug sponsor's point of view.  Statistics in Medicine. 493-495. 1993
  • Discussion: Stephen George, a survey of monitoring practices in cancer clinical trials: Stephanie Green and John Crowley, data monitoring committees for Southwest Oncology Group clinical trials.  Statistics in Medicine. 457-459. 1993
  • Epidemiology: Discussion I.  Journal of the American College of Cardiology. 1993
  • Neurohormonal inhibitors: Discussion VII.  Journal of the American College of Cardiology. 1993
  • Positive inotropic agents: Discussion V.  Journal of the American College of Cardiology. 1993
  • DIFFERENCES IN PRESENTATION, MORBIDITY AND MORTALITY BETWEEN MEN AND WOMEN WITH LEFT-VENTRICULAR DYSFUNCTION.  Circulation. 253-253. 1992
  • Design and implementation of the NHLBI and the VA cooperative studies program collaborative study, “trial to evaluate the effect of digitalis on motality in heart failure”.  Contemporary Clinical Trials. 386-386. 1992
  • HEPARIN IN THE PRESENCE OR ABSENCE OF ANTIPLATELET THERAPY - AN OVERVIEW OF RANDOMIZED TRIALS IN ACUTE MYOCARDIAL-INFARCTION.  Circulation. 259-259. 1992
  • LONG-TERM EFFECTS OF ENALAPRIL ON LEFT-VENTRICULAR DIASTOLIC PROPERTIES - EVIDENCE FOR REVERSED REMODELING.  Circulation. 120-120. 1992
  • LONG-TERM EFFECTS OF ENALAPRIL ON LEFT-VENTRICULAR DILATATION IN ASYMPTOMATIC PATIENTS WITH REDUCED EJECTION FRACTION - COMPARISON WITH SYMPTOMATIC PATIENTS.  Circulation. 251-251. 1992
  • OVERVIEW OF RANDOMIZED TRIALS OF LOW-DOSE AMIODARONE ON MORTALITY IN CARDIAC PATIENTS.  Circulation. 534-534. 1992
  • PROGNOSTIC IMPORTANCE OF INFARCTION AND UNSTABLE ANGINA IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION.  Circulation. 135-135. 1992
  • DIFFERENCES BETWEEN MEN AND WOMEN WITH LEFT-VENTRICULAR DYSFUNCTION.  Circulation. 733-733. 1991
  • EFFECT OF ANTIARRHYTHMIC DRUG-THERAPY ON MORTALITY FOLLOWING MYOCARDIAL-INFARCTION.  Circulation. 197-197. 1990
  • EFFECT OF INTRAVENOUS MAGNESIUM ON MORTALITY IN MYOCARDIAL-INFARCTION.  Circulation. 393-393. 1990
  • INOTROPIC AGENTS INCREASE MORTALITY IN PATIENTS WITH CONGESTIVE-HEART-FAILURE.  Circulation. 673-673. 1990
  • PROGRESSION OF LEFT-VENTRICULAR DYSFUNCTION - REMODELING OR DEPRESSED CONTRACTILITY.  Circulation. 123-123. 1990
  • EFFECT OF ACUTE ANGIOTENSIN CONVERTING ENZYME-INHIBITION ON LEFT-VENTRICULAR FILLING IN PATIENTS WITH CONGESTIVE HEART-FAILURE - RELATION TO RIGHT VENTRICULAR VOLUMES.  Circulation. 115-122. 1990
  • REDUCTION IN MAJOR MORBIDITY AND MORTALITY BY HEPARIN IN ACUTE MYOCARDIAL-INFARCTION.  Heart. 118-118. 1989
  • Differences in methodology betweem randomized trials comparing treatments and those evaluating diagnostic tests.  Contemporary Clinical Trials. 255-255. 1988
  • The use of an FDA-NDA database to assess the risk of exposing patients with chronic stable angina to placebo-controlled trials.  Contemporary Clinical Trials. 249-250. 1988
  • DIFFERENCES IN TRENDS IN CONGESTIVE-HEART-FAILURE (CHF) DEATHS BY RACE AND AGE IN THE UNITED-STATES FROM 1968 TO 1978.  Circulation. 436-436. 1987
  • DO BASE-LINE CLINICAL CHARACTERISTICS PREDICT INITIAL RESPONSE TO ANTIARRHYTHMIC THERAPY.  Journal of the American College of Cardiology. A71-A71. 1987
  • EFFECT OF ACUTE OR CHRONIC ADMINISTRATION OF CALCIUM-ANTAGONISTS ON MORTALITY FOLLOWING MYOCARDIAL-INFARCTION.  Journal of the American College of Cardiology. A24-A24. 1987
  • THE EFFECTS OF LIDOCAINE ON VENTRICULAR-FIBRILLATION AND ASYSTOLE FOLLOWING SUSPECTED ACUTE MYOCARDIAL-INFARCTION.  Circulation. 43-43. 1986
  • Prerandomization adherence aids for clinical trials.  Contemporary Clinical Trials. 242-242. 1986
  • Surrogate endpoint use in cardiovascular clinical trials.  Contemporary Clinical Trials. 241-241. 1986
  • DIFFERENTIAL EFFECT OF BETA-BLOCKADE ON THE INNERVATED AND DENERVATED HUMAN-HEART DURING EXERCISE AND EXOGENOUS CATECHOLAMINE STIMULATION.  Journal of the American College of Cardiology. A26-A26. 1986
  • MECHANISM OF CARDIAC-OUTPUT INCREASE DURING DYNAMIC EXERCISE IN CARDIAC TRANSPLANT PATIENTS.  Journal of the American College of Cardiology. A225-A225. 1986
  • Clinical trials in hypertension and congestive heart failure.  Journal of Molecular and Cellular Cardiology. 29-29. 1986
  • Current treatments of cardiovascular diseases are unlikely to produce more than moderate reductions in mortality.  Contemporary Clinical Trials. 222-222. 1985
  • Surrogate endpoints in clinical trials.  Contemporary Clinical Trials. 222-222. 1985
  • BETA-BLOCKADE PRODUCES GREATER ATTENUATION OF EXERCISE TACHYCARDIA IN THE DENERVATED HUMAN-HEART.  Heart. 108-109. 1985
  • CHOLESTEROL-LOWERING TRIAL RESULTS IN THEIR EPIDEMIOLOGIC CONTEXT.  Circulation. 451-451. 1985
  • INCREASED SENSITIVITY OF THE DENERVATED HUMAN-HEART TO ISOPRENALINE BEFORE AND AFTER BETA-BLOCKADE.  Heart. 108-108. 1985
  • INCREASED SENSITIVITY OF THE DENERVATED HUMAN-HEART TO ISOPRENALINE BEFORE AND AFTER BETABLOCKADE.  Journal of the American College of Cardiology. 516-516. 1985
  • IV NITROGLYCERIN (NG) AND NITROPRUSSIDE (NP) THERAPY IN ACUTE MYOCARDIAL-INFARCTION REDUCES MORTALITY - EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS).  Circulation. 224-224. 1985
  • Q-WAVE DEVELOPMENT AND REGRESSION ONE YEAR FOLLOWING MYOCARDIAL-INFARCTION.  Circulation. A414-A414. 1985
  • 24 Hour Changes in Heart Rate of the Transplanted and Innervated Human Hearts.  Clinical Science. 31P-31P. 1984
  • BETA-BLOCKERS WITH INTRINSIC SYMPATHOMIMETIC ACTIVITY ARE LESS BENEFICIAL AFTER MYOCARDIAL-INFARCTION.  Circulation. 6-6. 1984
  • DIURETICS IN PREGNANCY - OVERVIEW OF RANDOMIZED TRIALS - IMPLICATIONS FOR TRIALS OF OTHER AGENTS IN PREGNANCY.  Hypertension in Pregnancy. 130-130. 1984
  • DOES TREATMENT OF CHRONIC HEART-FAILURE WITH ORAL VASODILATORS IMPROVE SURVIVAL.  Circulation. 112-112. 1984
  • EXERCISE AFTER MYOCARDIAL-INFARCTION REDUCES MORTALITY - EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS).  Journal of the American College of Cardiology. 622-622. 1984
  • EFFICACY OF INTRAVENOUS STREPTOKINASE DURING ACUTE MYOCARDIAL-INFARCTION - POOLED RESULTS FROM RANDOMIZED TRIALS.  Journal of the American College of Cardiology. 615-615. 1983
  • ENTRY CLINICAL AND ECG VARIABLES PREDICTIVE OF EVENTUAL INFARCT SIZE AND MORTALITY IN PATIENTS WITH SUSPECTED MYOCARDIAL-INFARCTION.  Clinical Science. P5-P5. 1983
  • REDUCTION IN INFARCT SIZE, MORBIDITY AND SHORT-TERM MORTALITY BY EARLY INTRAVENOUS BETABLOCKADE.  Journal of the American College of Cardiology. 676-676. 1983
  • REDUCTION IN MORTALITY AFTER MYOCARDIAL-INFARCTION BY ACUTE INTERVENTION.  Clinical Science. P72-P73. 1983
  • Reduction in Infarct Size, Arrhythmias and Morbidity by Early Intravenous Beta Blockade.  Clinical Science. 2P-2P. 1982
  • Pain relief in acute myocardial infarction by intravenous atenolol.  American Journal of Cardiology. 489-489. 1981
  • Reduction in infarct size and morbidity by early intravenous betablockade.  American Journal of Cardiology. 490-490. 1981
  • NEED FOR LARGE (BUT SIMPLE) TRIALS.  Thrombosis and Haemostasis. 325-325. 1981
  • IMPROVEMENT OF ELECTROCARDIOGRAM BY CHRONIC BETA-ADRENOCEPTOR BLOCKADE DURING HEALING PHASE OF CLINICAL AND EXPERIMENTAL MYOCARDIAL-INFARCTION.  Heart. 99-99. 1980
  • NORMALIZATION OF ELECTROCARDIOGRAM IN SURVIVORS OF MYOCARDIAL-INFARCTION ON BETA-BLOCKERS.  Heart. 364-365. 1979
  • NORMALIZATION OF THE ECG IN SURVIVORS OF MYOCARDIAL-INFARCTION ON BETA-ADRENO-RECEPTOR-BLOCKING AGENTS.  Clinical Science. P4-P4. 1979
  • RELATIONSHIP BETWEEN INFARCT SIZE AND THE P-WAVE TERMINAL FORCE IN ACUTE MYOCARDIAL-INFARCTION.  Clinical Science. P24-P24. 1979
  • SERUM MYOGLOBIN DETERMINATION IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION.  Heart. 370-370. 1979
  • Absence of Relation between Severity of Myocardial Infarction and Ventricular Arrhythmias.  Clinical Science. 17P-17P. 1978
  • Evolution and Prediction of Infarct Size after Acute Myocardial Infarction in Man.  Clinical Science. 1P-1P. 1978
  • ELECTROCARDIOGRAPHIC AND ENZYME EVOLUTION OF INFARCT SIZE IN MAN.  Circulation. 172-172. 1978

• journal articles

  • Association of Vascular Risk With Severe vs Non-Severe Stroke: An Analysis of the INTERSTROKE Study..  Neurology.  103:e210087. 2024
  • Pragmatic monitoring of emerging efficacy data in randomized controlled trials..  Clinical Trials.  17407745241290729. 2024
  • Assessing the built environment through photographs and its association with obesity in 21 countries: the PURE Study..  The Lancet Global Health.  12:e1794-e1806. 2024
  • Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial.  Circulation.  150:1315-1323. 2024
  • Tea and coffee consumption and risk of acute stroke: The INTERSTROKE Study.  International Journal of Stroke.  19:1053-1063. 2024
  • Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetes..  Cardiovascular Diabetology.  23:325. 2024
  • Carbonated Beverage, Fruit Drink, and Water Consumption and Risk of Acute Stroke: the INTERSTROKE Case-Control Study..  Journal of Stroke.  26:391-402. 2024
  • Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial..  European Heart Journal Open.  4:oeae083. 2024
  • Activity limitations, use of assistive devices, and mortality and clinical events in 25 high-income, middle-income, and low-income countries: an analysis of the PURE study.  The Lancet.  404:554-569. 2024
  • Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study – Authors' reply.  The Lancet Diabetes and Endocrinology.  12:519-519. 2024
  • Blood pressure variability in acute stroke: Risk factors and association with functional outcomes at 1 month.  European Journal of Neurology.  31:e16314. 2024
  • Markers of periodontal disease and risk of stroke: INTERSTROKE case-control study.  Journal of Stroke and Cerebrovascular Diseases.  33:107803-107803. 2024
  • Mortality, Cardiovascular Disease, and Their Associations With Risk Factors in Southeast Asia.  JACC Asia.  4:624-633. 2024
  • Perioperative management and outcomes in patients receiving low-dose rivaroxaban and/or aspirin: a subanalysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial.  Journal of Thrombosis and Haemostasis.  22:2227-2233. 2024
  • Stuart J. Connolly, MD, April 9, 1949–June 2, 2024.  Heart Rhythm.  21:1456-1457. 2024
  • External validation and comparison of six cardiovascular risk prediction models in the Prospective Urban Rural Epidemiology (PURE)-Colombia study.  European Journal of Preventive Cardiology (EJPC).  zwae242. 2024
  • Mortality and Morbidity in Adults With Rheumatic Heart Disease.  Journal of the American Medical Association (JAMA).  332:133-133. 2024
  • Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis.  EClinicalMedicine.  73:102651-102651. 2024
  • Counting the dead in Gaza: difficult but essential.  The Lancet.  404:237-238. 2024
  • Impact of seasonal blood pressure changes on visit-to-visit blood pressure variability and related cardiovascular outcomes.  Journal of Hypertension.  42:1269-1281. 2024
  • Physical Activity and Obesity Risk in Adults in Colombia: The Prospective Urban Rural Epidemiology (PURE) Study.  Medicine & Science in Sports & Exercise.  56:1291-1296. 2024
  • Sodium Intake and Incident Atrial Fibrillation in Individuals With Vascular Disease.  JAMA network open.  7:e2421589-e2421589. 2024
  • Stuart J. Connolly, MD, April 9, 1949–June 2, 2024.  JACC: Clinical Electrophysiology.  S2405-500X(24)00562-0. 2024
  • The Effects of Pantoprazole on Kidney Outcomes.  Journal of the American Society of Nephrology.  35:901-909. 2024
  • Revisiting Race and the Benefit of RAS Blockade in Heart Failure.  Journal of the American Medical Association (JAMA).  331:2094-2094. 2024
  • Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial.  Canadian Journal of Cardiology.  S0828-282X(24)00506-3. 2024
  • Pre‐morbid sleep disturbance and its association with stroke severity: results from the international INTERSTROKE study.  European Journal of Neurology.  31:e16193. 2024
  • Variations in the prevalence of atrial fibrillation, and in the strength of its association with ischemic stroke, in countries with different income levels: INTERSTROKE case–control study.  International Journal of Stroke.  19:559-568. 2024
  • Clinical significance of new-onset atrial fibrillation in patients with coronary artery or peripheral artery disease: results from the COMPASS trial.  Europace.  26:euae102.024. 2024
  • Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study.  European Heart Journal.  45:1738-1749. 2024
  • The circulating proteome and brain health: Mendelian randomisation and cross-sectional analyses.  Translational Psychiatry.  14:204. 2024
  • Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy.  European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy.  10:201-209. 2024
  • Associations of perceived built environment characteristics using NEWS questionnaires with all-cause mortality and major cardiovascular diseases: The prospective urban rural epidemiology (PURE)-China study.  Environment International.  187:108627-108627. 2024
  • Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study.  The Lancet Diabetes and Endocrinology.  12:330-338. 2024
  • Relationship Between Social Support and Clinical Outcomes: An Evaluation of Participant-Nominated Treatment Supporters in the HOPE 4 Intervention.  Circulation. Cardiovascular Quality and Outcomes.  17:e009342. 2024
  • Tobacco use and risk of acute stroke in 32 countries in the INTERSTROKE study: a case–control study.  EClinicalMedicine.  70:102515-102515. 2024
  • Characteristics, management, and outcomes in women and men with congestive heart failure in 40 countries at different economic levels: an analysis from the Global Congestive Heart Failure (G-CHF) registry.  The Lancet Global Health.  12:e396-e405. 2024
  • Coronary artery bypass grafting versus medical therapy in patients with stable coronary artery disease: An individual patient data pooled meta-analysis of randomized trials.  Journal of Thoracic and Cardiovascular Surgery.  167:1022-1032.e14. 2024
  • Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials.  European Journal of Preventive Cardiology (EJPC).  31:311-319. 2024
  • Risk factors for recognized and unrecognized SARS-CoV-2 infection: a seroepidemiologic analysis of the Prospective Urban Rural Epidemiology (PURE) study.  Microbiology spectrum.  12:e0149223. 2024
  • Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants.  The Lancet Diabetes and Endocrinology.  12:107-118. 2024
  • Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk.  Diabetes Care.  47:259-266. 2024
  • Exposure to air pollutants and subclinical carotid atherosclerosis measured by magnetic resonance imaging: A cross-sectional analysis..  PLoS ONE.  19:e0309912. 2024
  • Sex Differences in Cardiovascular Disease Risk Factor Prevalence, Morbidity, and Mortality in Colombia: Findings from the Prospective Urban Rural Epidemiology (PURE) Study.  Global Heart.  19:10-10. 2024
  • The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.  American Journal of Cardiovascular Drugs.  24:117-127. 2024
  • Use of Cardiovascular Disease Secondary Prevention Medications in Four Middle East Countries in a Community Setting..  Global Heart.  19:70. 2024
  • Associations of dietary copper intake with cardiovascular disease and mortality: findings from the Chinese Perspective Urban and Rural Epidemiology (PURE-China) Study.  BMC International Health and Human Rights.  23:2525. 2023
  • Potassium intake: the Cinderella electrolyte.  European Heart Journal.  44:4925-4934. 2023
  • A novel multi-ancestry proteome-wide Mendelian randomization study implicates extracellular proteins, tubular cells, and fibroblasts in estimated glomerular filtration rate regulation.  Kidney International.  104:1170-1184. 2023
  • Cognitive performance following stroke, transient ischaemic attack, myocardial infarction, and hospitalisation: an individual participant data meta-analysis of six randomised controlled trials.  The Lancet Healthy Longevity.  4:e665-e674. 2023
  • Socioeconomic disparity in mortality and the burden of cardiovascular disease: analysis of the Prospective Urban Rural Epidemiology (PURE)-China cohort study.  The Lancet Public Health.  8:e968-e977. 2023
  • Frailty and outcomes in heart failure patients from high-, middle-, and low-income countries.  European Heart Journal.  44:4435-4444. 2023
  • Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD.  American Society of Nephrology. Clinical Journal.  18:1408-1415. 2023
  • Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery.  ACP journal club.  176:eL230324. 2023
  • IDENTIFICATION OF PAM AS NOVEL MONOGENIC DIABETES GENE.  Canadian Journal of Diabetes.  47:S169-S170. 2023
  • Individual- and supply-level macronutrient intakes are well correlated over a 50-year period (1961–2011) in 18 countries in Asia, North America, and Europe.  Progress in Food and Nutrition Science.  119:109-118. 2023
  • Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III.  Circulation.  148:1298-1304. 2023
  • Coordinating Efforts to Reduce the Global Incidence of Cardiovascular Disease.  New England Journal of Medicine.  389:1329-1331. 2023
  • Characteristics, clinical practice patterns, and outcomes of strokes in India: INSPIRE—A multicentre prospective study.  International Journal of Stroke.  18:965-975. 2023
  • IDENTIFICATION OF PAM AS NOVEL MONOGENIC DIABETES GENE.  Canadian Journal of Cardiology.  39:S205-S206. 2023
  • Global Variations in Heart Failure—Reply.  Journal of the American Medical Association (JAMA).  330:1192-1192. 2023
  • Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment.  European Heart Journal Open.  3:oead089. 2023
  • Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study.  Clinical Gastroenterology and Hepatology.  21:2649-2659.e16. 2023
  • Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.  Heart.  109:1372-1379. 2023
  • The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.  European Heart Journal - Quality of Care and Clinical Outcomes.  9:502-510. 2023
  • Global mean potassium intake: a systematic review and Bayesian meta-analysis.  European Journal of Nutrition.  62:2027-2037. 2023
  • Risk Factors, Use of Preventive Drugs, and Cardiovascular Events in Diabetes Mellitus: The PURE Türkiye Cohort.  Anatolian Journal of Cardiology.  27:453-461. 2023
  • Diet, cardiovascular disease, and mortality in 80 countries.  European Heart Journal.  44:2560-2579. 2023
  • Biomarkers Associated With Severe COVID-19 Among Populations With High Cardiometabolic Risk.  JAMA network open.  6:e2325914-e2325914. 2023
  • The Data Monitoring Committee: A Collective or a Collection?.  Therapeutic Innovation and Regulatory Science.  57:653-655. 2023
  • 221-LB: Identification of PAM as Novel Monogenic Diabetes Gene.  Diabetes.  72. 2023
  • Validation of Urinary Thiocyanate as a Robust Biomarker of Active Tobacco Smoking in the Prospective Urban and Rural Epidemiological Study.  Nicotine and Tobacco Research.  25:1291-1301. 2023
  • ACT trials: long-term outcomes.  The Lancet Respiratory Medicine.  11:e50-e50. 2023
  • Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort.  European Journal of Preventive Cardiology (EJPC).  30:709-718. 2023
  • The authors reply.  Kidney International.  103:1201-1201. 2023
  • Sleep Patterns and the Risk of Acute Stroke.  Neurology.  100:e2191-e2203. 2023
  • Global Variations in Heart Failure Etiology, Management, and Outcomes.  Journal of the American Medical Association (JAMA).  329:1650-1650. 2023
  • Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery.  ACP journal club.  176:605-614. 2023
  • The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial.  Atherosclerosis.  372:41-47. 2023
  • Dietary Sodium Restriction in Patients with Heart Failure.  New England Journal of Medicine.  388:1621-1623. 2023
  • Depressive Symptoms and Risk of Acute Stroke.  Neurology.  100:e1787-e1798. 2023
  • Associations of outdoor fine particulate air pollution and cardiovascular disease: Results from the Prospective Urban and Rural Epidemiology Study in China (PURE-China).  Environment International.  174:107829-107829. 2023
  • Changes in energy, macronutrient, and food consumption in 47 countries over the last 70 years (1950-2019): a systematic review and meta-analysis.  Nutrition.  108:111941-111941. 2023
  • Event Adjudication Is Unnecessary in Blinded Trials and May Be Detrimental.  JACC: Heart Failure.  11:422-424. 2023
  • Household Air Pollution and Adult Lung Function Change, Respiratory Disease, and Mortality across Eleven Low- and Middle-Income Countries from the PURE Study.  Environmental Health Perspectives.  131:47015. 2023
  • Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.  American Heart Journal.  258:60-68. 2023
  • Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation.  Circulation.  147:925-929. 2023
  • Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation..  Global Heart.  44:931-934. 2023
  • Dietary counselling to reduce moderate sodium intake: effects on cardiovascular and renal biomarkers: primary findings of the COSIP and STICK phase II feasibility randomised controlled trials.  EClinicalMedicine.  57:101856-101856. 2023
  • Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes.  JAMA Neurology.  80:251-251. 2023
  • The impact of HIV co-infection on presentation and outcome in adults with tuberculous pericarditis: Findings from the IMPI trial.  SAMJ - South African Medical Journal.  113:1109-1115. 2023
  • The severe presentation and poor outcomes of rheumatic heart disease in Namibia: Lessons from the REMEDY study.  SAMJ - South African Medical Journal.  113:1104-1108. 2023
  • Improving precision in estimating diet–disease relationships with metabolomics.  European Heart Journal.  44:570-572. 2023
  • Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.  Kidney International.  103:403-410. 2023
  • Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial.  Nutrition, Metabolism and Cardiovascular Diseases.  33:434-440. 2023
  • Alcohol Intake as a Risk Factor for Acute Stroke.  Neurology.  100:e142-e153. 2023
  • Urbanization and physical activity in the global Prospective Urban and Rural Epidemiology study.  Scientific Reports.  13:290. 2023
  • New Approaches Needed to Improve Prevention of Cardiovascular Disease.  JAMA network open.  6:e2251162-e2251162. 2023
  • Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study.  The Lancet Healthy Longevity.  4:e23-e33. 2023
  • Perceived built environment characteristics associated with walking and cycling across 355 communities in 21 countries.  Cities.  132:104102-104102. 2023
  • Regional differences in the contribution of smoking, dietary and cooking behaviours to airflow obstruction in China: A population‐based case–control study.  Respirology.  28:37-46. 2023
  • Risk Factors for Stroke in the Young (18–45 Years): A Case-Control Analysis of INTERSTROKE Data from 32 Countries.  Neuroepidemiology.  57:275-283. 2023
  • Social isolation as a risk factor for all-cause mortality: Systematic review and meta-analysis of cohort studies.  PLoS ONE.  18:e0280308-e0280308. 2023
  • Ultra-processed foods and mortality: analysis from the Prospective Urban and Rural Epidemiology study.  American Journal of Clinical Nutrition.  117:55-63. 2023
  • Waist circumference cut-off points to identify major cardiovascular events and incident diabetes in Latin America: findings from the prospective Urban rural epidemiology study Colombia.  Frontiers in Cardiovascular Medicine.  10:1204885. 2023
  • World-wide variations in tests of cognition and activities of daily living in participants of six international randomized controlled trials.  Cerebral Circulation - Cognition and Behavior.  5:100176-100176. 2023
  • Interaction of Depression and Unhealthy Diets on the Risk of Cardiovascular Diseases and All-Cause Mortality in the Chinese Population: A PURE Cohort Substudy.  Nutrients.  14:5172-5172. 2022
  • Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.  European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy.  8:786-795. 2022
  • Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.  Cardiovascular Diabetology.  21:12. 2022
  • Association of Psychosocial Stress With Risk of Acute Stroke.  JAMA network open.  5:e2244836-e2244836. 2022
  • Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.  The Lancet Respiratory Medicine.  10:1160-1168. 2022
  • Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.  The Lancet Respiratory Medicine.  10:1169-1177. 2022
  • DNA methylation changes in cord blood and the developmental origins of health and disease – a systematic review and replication study.  BMC Genomics.  23:221. 2022
  • Developing indicators of age-friendly neighbourhood environments for urban and rural communities across 20 low-, middle-, and high-income countries.  BMC International Health and Human Rights.  22:87. 2022
  • Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial.  The Lancet Global Health.  10:e1835-e1844. 2022
  • Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery.  Trials.  23:101. 2022
  • Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation.  New England Journal of Medicine.  387:2100-2101. 2022
  • The cost implications of a polypill for primary prevention in the TIPS-3 trial.  European Heart Journal - Quality of Care and Clinical Outcomes.  8:899-908. 2022
  • Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events.  JAMA network open.  5:e2243201-e2243201. 2022
  • Machine learning for detecting centre-level irregularities in randomized controlled trials: A pilot study.  Contemporary Clinical Trials.  122:106963-106963. 2022
  • Multi-Ancestry Proteo-Genomic Association Study of eGFR.  Journal of the American Society of Nephrology.  33:259-259. 2022
  • The polypill: from concept and evidence to implementation.  The Lancet.  400:1661-1663. 2022
  • Medications for blood pressure, blood glucose, lipids, and anti-thrombotic medications: relationship with cardiovascular disease and death in adults from 21 high-, middle-, and low-income countries with an elevated body mass index.  European Journal of Preventive Cardiology (EJPC).  29:1817-1826. 2022
  • Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.  European Heart Journal.  43:3542-3552. 2022
  • Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: results of the global congestive heart failure research program.  European Heart Journal.  43:ehac544.879. 2022
  • Pharmacogenomic study of heart failure and candesartan response from the CHARM programme.  ESC heart failure.  9:2997-3008. 2022
  • Unraveling the Protective Effects of Cognitive Reserve on Cognition and Brain: A Cross-Sectional Study.  International Journal of Environmental Research and Public Health.  19:12228-12228. 2022
  • Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation.  New England Journal of Medicine.  387:978-988. 2022
  • Settling the controversy of salt substitutes and stroke: sodium reduction or potassium increase?.  European Heart Journal.  43:3365-3367. 2022
  • Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.  The Lancet Diabetes and Endocrinology.  10:645-654. 2022
  • Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.  The Lancet.  400:832-845. 2022
  • Factors associated with health‐related quality of life in heart failure in 23 000 patients from 40 countries: results of the G‐CHF research programme.  European Journal of Heart Failure.  24:1478-1490. 2022
  • Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study.  The Lancet.  400:811-821. 2022
  • Personal and household PM2.5 and black carbon exposure measures and respiratory symptoms in 8 low- and middle-income countries.  Environmental Research.  212:113430-113430. 2022
  • Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial.  European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy.  8:462-473. 2022
  • Variations in the association of height with mortality, cardiovascular disease and cancer in low-, middle- and high-income countries.  International Journal of Epidemiology.  51:1304-1316. 2022
  • Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy.  European Heart Journal.  43:2831-2840. 2022
  • Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy.  European Heart Journal.  43:2852-2863. 2022
  • Risk factors, cardiovascular disease, and mortality in South America: a PURE substudy.  European Heart Journal.  43:2841-2851. 2022
  • Association of Sitting Time With Mortality and Cardiovascular Events in High-Income, Middle-Income, and Low-Income Countries.  JAMA cardiology.  7:796-796. 2022
  • Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.  Cardiovascular Research (CVR).  118:2112-2123. 2022
  • Ethnic Differences in the Prevalence of Hypertension in Colombia: Association With Education Level.  American Journal of Hypertension.  35:610-618. 2022
  • Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis.  Circulation.  145:1875-1877. 2022
  • The Prevalence and Risk Factors Associated with Iodine Deficiency in Canadian Adults.  Nutrients.  14:2570-2570. 2022
  • A polypill for cardiovascular disease prevention with a focus on non-alcohol steatohepatitis.  European Heart Journal.  43:2034-2036. 2022
  • Impact of Bioelectrical Impedance–Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial.  American Journal of Kidney Diseases.  79:820-831. 2022
  • Neighborhood Greenspace and Socioeconomic Risk are Associated with Diabetes Risk at the Sub-neighborhood Scale: Results from the Prospective Urban and Rural Epidemiology (PURE) Study.  Journal of Urban Health.  99:506-518. 2022
  • The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges.  CJC OPEN.  4:568-576. 2022
  • Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE).  Journal of Stroke.  24:224-235. 2022
  • Tranexamic Acid in Patients Undergoing Noncardiac Surgery.  New England Journal of Medicine.  386:1986-1997. 2022
  • Author Correction: Identification of genetic effects underlying type 2 diabetes in South Asian and European populations.  Communications Biology.  5:441. 2022
  • Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.  European Journal of Preventive Cardiology (EJPC).  29:e181-e189. 2022
  • Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation.  Nature Genetics.  54:560-572. 2022
  • Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial.  Journal of Stroke and Cerebrovascular Diseases.  31:106404-106404. 2022
  • Identification of genetic effects underlying type 2 diabetes in South Asian and European populations.  Communications Biology.  5:329. 2022
  • Measuring and predicting personal and household Black Carbon levels from 88 communities in eight countries.  Science of the Total Environment.  818:151849-151849. 2022
  • ‘Corrigendum to “Association of bedtime with mortality and major cardiovascular events: an analysis of 112,198 individuals from 21 countries in the PURE study” [Sleep Medicine 80 (2021) 265–272]’.  Sleep Medicine.  92:108-108. 2022
  • High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality.  New England Journal of Medicine.  386:827-836. 2022
  • Availability and Affordability of Medicines for Diabetes and Cardiovascular Disease across Countries: Information Learned from the Prospective Urban Rural Epidemiological Study.  Diabetology.  3:236-245. 2022
  • Terapia combinada para la prevención cardiovascular: la ruta recorrida.  Revista Colombiana de Cardiologia.  28:299-301. 2022
  • Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials.  Cardiovascular Research (CVR).  118:897-903. 2022
  • Evaluation of Adiposity and Cognitive Function in Adults.  JAMA network open.  5:e2146324-e2146324. 2022
  • Mitochondrial DNA Copy Number as a Marker and Mediator of Stroke Prognosis.  Neurology.  98:e470-e482. 2022
  • Variations in risks from smoking between high-income, middle-income, and low-income countries: an analysis of data from 179 000 participants from 63 countries.  The Lancet Global Health.  10:e216-e226. 2022
  • Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis.  EClinicalMedicine.  44:101284-101284. 2022
  • Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study.  European Heart Journal.  43:202-209. 2022
  • Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease.  Cardiovascular Research (CVR).  118:295-304. 2022
  • Association of Household Utility of Cleaner Fuel With Lower Hypertension Prevalence and Blood Pressure in Chinese Adults.  Gesundheit und Wohlfahrt. Revue suisse d'hygi�ne.  67:1605193. 2022
  • Differences and agreement between two portable hand-held spirometers across diverse community-based populations in the Prospective Urban Rural Epidemiology (PURE) study.  PLOS Global Public Health.  2:e0000141-e0000141. 2022
  • Multinational prediction of household and personal exposure to fine particulate matter (PM2.5) in the PURE cohort study.  Environment International.  159:107021-107021. 2022
  • Role of Proxy Respondents in International Stroke Research: Experience of the INTERSTROKE Study.  Neuroepidemiology.  56:355-364. 2022
  • Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19.  JAMA network open.  4:e2141328-e2141328. 2021
  • Measuring sodium intake: research and clinical applications.  Journal of Hypertension.  39:2344-2352. 2021
  • Psychosocial Risk Factors and Cardiovascular Disease and Death in a Population-Based Cohort From 21 Low-, Middle-, and High-Income Countries.  JAMA network open.  4:e2138920-e2138920. 2021
  • The association of grip strength with cardiovascular diseases and all-cause mortality in people with hypertension: Findings from the Prospective Urban Rural Epidemiology China Study.  Journal of Sport and Health Science.  10:629-636. 2021
  • The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone.  Cardiovascular Diabetology.  20:68. 2021
  • Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease.  Heart.  107:1739-1747. 2021
  • Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.  Journal of Thrombosis and Haemostasis.  19:2726-2737. 2021
  • Effect of Cognitive Reserve on the Association of Vascular Brain Injury With Cognition.  Neurology.  97:e1707-e1716. 2021
  • Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study.  Gastroenterology.  161:1333-1335.e1. 2021
  • Pharmacogenomic study of heart failure and candesartan response from the CHARM programme 2021
  • Dietary Saturated Fats and Health: Are the U.S. Guidelines Evidence-Based?.  Nutrients.  13:3305-3305. 2021
  • LVS‐HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World‐Wide Registry.  Journal of the American Heart Association.  10:e017735. 2021
  • Sodium Intake and Health: What Should We Recommend Based on the Current Evidence?.  Nutrients.  13:3232-3232. 2021
  • Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.  The Lancet.  398:1053-1064. 2021
  • Associations of unprocessed and processed meat intake with mortality and cardiovascular disease in 21 countries [Prospective Urban Rural Epidemiology (PURE) Study]: a prospective cohort study.  American Journal of Clinical Nutrition.  114:1049-1058. 2021
  • Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.  The Lancet.  398:1133-1146. 2021
  • Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.  European Heart Journal.  42:2995-3007. 2021
  • Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial.  Stroke.  52:2494-2501. 2021
  • Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke.  Journal of Hypertension.  39:1602-1610. 2021
  • Fishing for an Association With Sudden Cardiac Death—Reply.  JAMA Internal Medicine.  181:1140-1140. 2021
  • Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease.  International Journal of Cardiology.  337:9-15. 2021
  • Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality.  New England Journal of Medicine.  385:378-380. 2021
  • Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study.  The BMJ.  374:n1554-n1554. 2021
  • COVID-19 Vaccination Prioritization on the Basis of Cardiovascular Risk Factors and Number Needed to Vaccinate to Prevent Death.  Canadian Journal of Cardiology.  37:1112-1116. 2021
  • Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.  Heart.  107:1130-1137. 2021
  • Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.  Journal of the American College of Cardiology.  78:14-23. 2021
  • Reply.  Journal of Hypertension.  39:1467-1469. 2021
  • New‐Onset Perioperative Atrial Fibrillation After Coronary Artery Bypass Grafting and Long‐Term Risk of Adverse Events: An Analysis From the CORONARY Trial.  Journal of the American Heart Association.  10:e020426. 2021
  • Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke.  New England Journal of Medicine.  384:2081-2091. 2021
  • Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial).  American Journal of Cardiology.  149:27-35. 2021
  • Fruit, vegetable, and legume intake and the risk of all-cause, cardiovascular, and cancer mortality: A prospective study.  Clinical Nutrition.  40:4316-4323. 2021
  • Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries.  Circulation.  143:2129-2142. 2021
  • Sodium and health: another challenge to the current dogma.  European Heart Journal.  42:2116-2118. 2021
  • Timing and Length of Nocturnal Sleep and Daytime Napping and Associations With Obesity Types in High-, Middle-, and Low-Income Countries.  JAMA network open.  4:e2113775-e2113775. 2021
  • Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals.  Cardiovascular Research (CVR).  117:1523-1531. 2021
  • Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries.  JAMA Internal Medicine.  181:631-631. 2021
  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.  The Lancet.  397:1625-1636. 2021
  • Polypill in Persons without Cardiovascular Disease.  New England Journal of Medicine.  384:1673-1677. 2021
  • Urinary Sodium and Potassium, and Risk of Ischemic and Hemorrhagic Stroke (INTERSTROKE): A Case–Control Study.  American Journal of Hypertension.  34:414-425. 2021
  • Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:.  Circulation.  143:1468-1480. 2021
  • Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality.  New England Journal of Medicine.  384:1312-1322. 2021
  • Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.  The Lancet Oncology.  22:558-570. 2021
  • Association of bedtime with mortality and major cardiovascular events: an analysis of 112,198 individuals from 21 countries in the PURE study.  Sleep Medicine.  80:265-272. 2021
  • Associations of household solid fuel for heating and cooking with hypertension in Chinese adults.  Journal of Hypertension.  39:667-676. 2021
  • Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES.  Thrombosis and Haemostasis.  121:518-528. 2021
  • Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk.  Journal of Hypertension.  39:766-774. 2021
  • COVID-19 Vaccination Prioritization Based on Cardiovascular Risk Factors and Number-Needed-to-Vaccinate to Prevent Death 2021
  • Associations of estimated 24-h urinary sodium excretion with mortality and cardiovascular events in Chinese adults: a prospective cohort study.  Journal of Hypertension.  39:484-493. 2021
  • Exploring New Models for Cardiovascular Risk Reduction: The Heart Outcomes Prevention and Evaluation 4 (HOPE 4) Canada Pilot Study.  CJC OPEN.  3:267-275. 2021
  • Impact of social isolation on mortality and morbidity in 20 high-income, middle-income and low-income countries in five continents.  BMJ Global Health.  6:e004124-e004124. 2021
  • Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.  Cardiovascular Research (CVR).  117:942-949. 2021
  • Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study.  The BMJ.  372:m4948-m4948. 2021
  • Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.  Journal of the American College of Cardiology.  77:511-525. 2021
  • Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease:a Subanalysis of the COMPASS Randomized Clinical Trial (vol 6, pg 21, 2021).  JAMA cardiology.  6:246-246. 2021
  • Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level.  Heart.  107:282-289. 2021
  • “Cerebral small vessel disease and other influential factors of cognitive impairment in the middle-aged: a long-term observational cohort PURE-MIND study in Poland”.  GeroScience.  43:279-295. 2021
  • Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study.  Journal of Clinical Endocrinology and Metabolism (JCEM).  106:e891-e898. 2021
  • Polypill with or without Aspirin in Persons without Cardiovascular Disease.  New England Journal of Medicine.  384:216-228. 2021
  • Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries.  Cardiovascular Research (CVR).  117:576-584. 2021
  • Peter Sleight, Emeritus Professor of Cardiovascular Medicine, Oxford University, Chairman of the ISIS Trials Steering Committee.  European Heart Journal.  42:221-223. 2021
  • Causal ordering among risk factors in the PURE study – Authors' reply.  The Lancet.  397:279-279. 2021
  • Clarifying Optimal Sodium InTake In Cardiovasular and Kidney (COSTICK) Diseases: a study protocol for two randomised controlled trials.  HRB Open Research.  4:14-14. 2021
  • Clarifying Optimal Sodium InTake In Cardiovasular and Kidney (COSTICK) Diseases: a study protocol for two randomised controlled trials.  HRB Open Research.  4:14-14. 2021
  • Clinical Profiles and Outcomes of Heart Failure in Five African Countries: Results from INTER-CHF Study.  Global Heart.  16:50. 2021
  • Prevalence of metabolic syndrome and diabetes mellitus type-2 and their association with intake of dairy and legume in Andean communities of Ecuador.  PLoS ONE.  16:e0254812-e0254812. 2021
  • Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study.  Neuroepidemiology.  55:206-215. 2021
  • Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease.  JAMA cardiology.  6:21-29. 2021
  • The Indirect Consequences of the Response to the COVID-19 Pandemic.  Journal of the American College of Cardiology.  77:186-188. 2021
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation.  Journal of the American Heart Association.  9:e018984. 2020
  • Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study.  Diabetes Care.  43:3094-3101. 2020
  • Demographic, behavioral, and cardiovascular disease risk factors in the Saudi population: results from the Prospective Urban Rural Epidemiology study (PURE-Saudi).  BMC International Health and Human Rights.  20:1213. 2020
  • What is the Association Between Depression and Cardiovascular Disease?—Reply.  JAMA psychiatry.  77:1308-1308. 2020
  • Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation.  Circulation.  142:1697-1699. 2020
  • Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.  European Heart Journal.  41:4037-4046. 2020
  • Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries.  BMJ Global Health.  5:e002640-e002640. 2020
  • White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries.  Diabetes Care.  43:2643-2650. 2020
  • Population attributable fraction for continuously distributed exposures 2020
  • Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries.  JAMA psychiatry.  77:1052-1052. 2020
  • Facing cardiovascular risk in Ibero-America.  Revista española de cardiología (English ed.).  73:799-801. 2020
  • Household and personal air pollution exposure measurements from 120 communities in eight countries: results from the PURE-AIR study.  The Lancet Planetary Health.  4:e451-e462. 2020
  • La realidad del riesgo cardiovascular en Iberoamérica.  Revista Espanola de Cardiologia.  73:799-801. 2020
  • Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis.  The Lancet.  396:968-976. 2020
  • Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline.  Stroke.  51:2901-2909. 2020
  • Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials.  Journal of Hypertension.  38:2050-2058. 2020
  • Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials..  Journal of Hypertension.  38:2050-2058. 2020
  • Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake.  European Heart Journal.  41:3363-3373. 2020
  • A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry.  American Heart Journal.  227:56-63. 2020
  • Adverse health impacts of cooking with kerosene: A multi-country analysis within the Prospective Urban and Rural Epidemiology Study.  Environmental Research.  188:109851-109851. 2020
  • Air pollution health impacts: the knowns and unknowns for reliable global burden calculations.  Cardiovascular Research (CVR).  116:1794-1796. 2020
  • Eggs and diabetes: 1 daily egg a safe bet?.  American Journal of Clinical Nutrition.  112:503-504. 2020
  • Low levels of awareness, treatment, and control of hypertension in Andean communities of Ecuador.  Journal of Clinical Hypertension.  22:1530-1537. 2020
  • Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials.  Journal of Thrombosis and Haemostasis.  18:2287-2295. 2020
  • Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk.  Circulation.  142:621-642. 2020
  • Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.  European Heart Journal.  41:2848-2859. 2020
  • Cardiovascular risk in hypertension: open questions about HOPE 4 – Authors' reply.  The Lancet.  396:310-311. 2020
  • Myocardial Infarction in Heart Failure With Preserved Ejection Fraction.  JACC: Heart Failure.  8:618-626. 2020
  • Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations.  Journal of the American College of Cardiology.  76:844-857. 2020
  • Associations of Household Solid Fuel for Heating and Cooking With Hypertension in Chinese Adults 2020
  • Demographic, Behavioral, and Cardiovascular Disease Risk Factors in the Saudi Population: Results from the Prospective Urban Rural Epidemiology study (PURE-Saudi) 2020
  • Diet and health: the need for new and reliable approaches.  European Heart Journal.  41:2641-2644. 2020
  • The COMPASS Trial.  Circulation.  142:40-48. 2020
  • Association of nut intake with risk factors, cardiovascular disease, and mortality in 16 countries from 5 continents: analysis from the Prospective Urban and Rural Epidemiology (PURE) study.  American Journal of Clinical Nutrition.  112:208-219. 2020
  • Long-term exposure to outdoor and household air pollution and blood pressure in the Prospective Urban and Rural Epidemiological (PURE) study.  Environmental Pollution.  262:114197-114197. 2020
  • The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.  American Heart Journal.  225:69-77. 2020
  • Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.  The Lancet.  396:97-109. 2020
  • Adverse health impacts of cooking with kerosene: A multi-country analysis within the Prospective Urban and Rural Epidemiology Study 2020
  • Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries.  Circulation.  141:2004-2025. 2020
  • Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease.  Circulation.  141:1841-1854. 2020
  • Associations of outdoor fine particulate air pollution and cardiovascular disease in 157 436 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.  The Lancet Planetary Health.  4:e235-e245. 2020
  • Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease.  European Heart Journal-Cardiovascular Imaging.  21:692-700. 2020
  • Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis.  Europace.  22:870-877. 2020
  • In Reply.  Oncologist.  25:E1252-E1253. 2020
  • Association Between Myocardial Injury and Cardiovascular Outcomes of Orthopaedic Surgery.  Journal of Bone and Joint Surgery. American volume.  102:880-888. 2020
  • Self-Reported Prevalence of Chronic Non-Communicable Diseases in Relation to Socioeconomic and Educational Factors in Colombia: A Community-Based Study in 11 Departments.  Global Heart.  15:35. 2020
  • Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI).  Circulation.  141:1141-1151. 2020
  • ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study.  Diabetes Care.  43:835-842. 2020
  • Association of dairy consumption with metabolic syndrome, hypertension and diabetes in 147 812 individuals from 21 countries.  BMJ Open Diabetes Research and Care.  8:e000826-e000826. 2020
  • Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries.  American Journal of Clinical Nutrition.  111:795-803. 2020
  • One-year Results of a Factorial Randomized Trial of Aspirin versus Placebo and Clonidine versus Placebo in Patients Having Noncardiac Surgery.  Anesthesiology.  132:692-701. 2020
  • Reduced Cognitive Assessment Scores Among Individuals With Magnetic Resonance Imaging–Detected Vascular Brain Injury.  Stroke.  51:1158-1165. 2020
  • Corrigendum to “Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design” [212 (2019) 36–44].  American Heart Journal.  221:180-180. 2020
  • Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.  The Lancet.  395:795-808. 2020
  • Reply.  Gastroenterology.  158:1175-1176. 2020
  • Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study.  The Lancet.  395:785-794. 2020
  • Are large simple trials for dementia prevention possible?.  Age and Ageing.  49:154-160. 2020
  • Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals.  Journal of the American Heart Association.  9:e014686. 2020
  • CT imaging improves histopathological grading of retroperitoneal leiomyosarcomas.  European Journal of Surgical Oncology.  46:288-292. 2020
  • Leaders in Cardiovascular Research: Salim Yusuf.  Cardiovascular Research (CVR).  116:e26-e28. 2020
  • Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.  European Journal of Preventive Cardiology (EJPC).  27:296-307. 2020
  • Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery.  European Heart Journal.  41:645-651. 2020
  • The household economic burden of non-communicable diseases in 18 countries.  BMJ Global Health.  5:e002040-e002040. 2020
  • Population attributable fractions for continuously distributed exposures.  Epidemiologic Methods.  9:20190037. 2020
  • Preoperative N-Terminal Pro–B-Type Natriuretic Peptide and Cardiovascular Events After Noncardiac Surgery.  ACP journal club.  172:96-96. 2020
  • Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials.  European Heart Journal.  41:231-238. 2020
  • Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.  The Lancet.  395:698-708. 2020
  • Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes.  JAMA Neurology.  77:43-43. 2020
  • Ethnic differences in maternal diet in pregnancy and infant eczema.  PLoS ONE.  15:e0232170-e0232170. 2020
  • Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study.  PLoS ONE.  15:e0226259-e0226259. 2020
  • Reply.  Gastroenterology.  158:285-286. 2020
  • The Effect of Steroids in Patients Undergoing Cardiopulmonary Bypass: An Individual Patient Meta-Analysis of Two Randomized Trials.  Journal of Cardiothoracic and Vascular Anesthesia.  34:99-105. 2020
  • The Local Food Environment and Obesity: Evidence from Three Cities.  Obesity.  28:40-45. 2020
  • The risk of cardiovascular events in patients with metabolic syndrome: The results of a population based prospective cohort study (PURE Turkey).  Anatolian Journal of Cardiology.  24:192-200. 2020
  • Access to Essential Medicines for Circulatory Diseases: A Call to Action.  Global Heart.  14:399-399. 2019
  • Challenges in management and prevention of ischemic heart disease in low socioeconomic status people in LLMICs.  BMC Medicine.  17:209. 2019
  • Developing the Core Pillars of Training Global Cardiovascular Health Researchers: Companionship, Light, and Fuel.  Global Heart.  14:387-387. 2019
  • Graphical comparisons of relative disease burden across multiple risk factors.  BMC Medical Research Methodology.  19:186. 2019
  • Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.  BMC Cardiovascular Disorders.  19:240. 2019
  • Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.  Circulation.  140:1451-1459. 2019
  • Digoxin–mortality: randomized vs. observational comparison in the DIG trial.  European Heart Journal.  40:3336-3341. 2019
  • A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.  The Lancet.  394:1231-1242. 2019
  • Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial.  American Heart Journal.  216:9-19. 2019
  • THE HEART OUTCOMES PREVENTION EVALUATION 4 CANADA: A PILOT STUDY OF A COMMUNITY-BASED, MULTI-FACETED INTERVENTION, LED BY NON-PHYSICIANS TO REDUCE CARDIOVASCULAR RISK IN PEOPLE WITH HYPERTENSION.  Canadian Journal of Cardiology.  35:S22-S23. 2019
  • Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk.  Diabetes Care.  42:1800-1808. 2019
  • Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.  Journal of the American College of Cardiology.  74:1519-1528. 2019
  • Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study.  The Lancet.  394:1022-1029. 2019
  • Prevalence, awareness, treatment and control of hypertension in rural and urban communities in Latin American countries.  Journal of Hypertension.  37:1813-1821. 2019
  • Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.  Gastroenterology.  157:682-691.e2. 2019
  • Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.  Circulation.  140:529-537. 2019
  • From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).  Journal of the American College of Cardiology.  74:683-698. 2019
  • Household, community, sub-national and country-level predictors of primary cooking fuel switching in nine countries from the PURE study.  Environmental Research Letters.  14:085006-085006. 2019
  • Letter by Mente et al Regarding Article “Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease”.  Hypertension.  74:e26. 2019
  • Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.  Gastroenterology.  157:403-412.e5. 2019
  • The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5).  Journal of the American College of Cardiology.  74:672-682. 2019
  • Association between complications and death within 30 days after noncardiac surgery.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  191:E830-E837. 2019
  • Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.  European Heart Journal.  40:2032-2043. 2019
  • Publisher Correction: Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.  Nature Genetics.  51:1192-1193. 2019
  • Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial.  Europace.  21:1023-1030. 2019
  • Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial.  Journal of the American College of Cardiology.  73:3271-3280. 2019
  • The cost implication of primary prevention in the HOPE 3 trial.  European Heart Journal - Quality of Care and Clinical Outcomes.  5:266-271. 2019
  • Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial.  Diabetes, Obesity and Metabolism.  21:1502-1505. 2019
  • Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent.  Journal of the American College of Cardiology.  73:2769-2772. 2019
  • Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design.  American Heart Journal.  212:36-44. 2019
  • Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study.  The Lancet Global Health.  7:e748-e760. 2019
  • The spectrum of the dyslipidemia in Colombia: The PURE study.  International Journal of Cardiology.  284:111-117. 2019
  • Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries.  European Heart Journal.  40:1620-1629. 2019
  • Systematic scoping review protocol of methodologies of chronic respiratory disease surveys in low/middle-income countries.  Primary Care Respiratory Journal.  29:17. 2019
  • Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?.  European Heart Journal.  40:1466-1471. 2019
  • Health Effects of Household Solid Fuel Use: Findings from 11 Countries within the Prospective Urban and Rural Epidemiology Study.  Environmental Health Perspectives.  127:57003. 2019
  • Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.  European Journal of Preventive Cardiology (EJPC).  26:681-697. 2019
  • Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC).  BMJ Open.  9:e028698-e028698. 2019
  • Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study.  The Lancet Global Health.  7:e613-e623. 2019
  • Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction.  Journal of the American College of Cardiology.  73:2243-2250. 2019
  • Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients.  Canadian Journal of Cardiology.  35:644-652. 2019
  • Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.  International Journal of Stroke.  14:270-281. 2019
  • Effects of blood pressure and lipid lowering on cognition.  Neurology.  92:e1435-e1446. 2019
  • Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups.  Circulation.  139:1472-1482. 2019
  • Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study.  The BMJ.  364:l772-l772. 2019
  • Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  191:E247-E256. 2019
  • Digoxin and clinical outcomes in the Global Rheumatic Heart Disease Registry.  Heart.  105:363-369. 2019
  • Urinary sodium excretion measures and health outcomes – Authors' reply.  The Lancet.  393:1295-1296. 2019
  • Stroke Outcomes in the COMPASS Trial.  Circulation.  139:1134-1145. 2019
  • Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy.  Journal of the American Society of Echocardiography.  32:286-295.e3. 2019
  • Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.  The Lancet.  393:407-415. 2019
  • Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial.  Journal of the American Heart Association.  8:e010107. 2019
  • Associations of cardiometabolic outcomes with indices of obesity in children aged 5 years and younger.  PLoS ONE.  14:e0218816-e0218816. 2019
  • Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean.  Journal of Hypertension.  37:16-23. 2019
  • Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion.  Journal of the American College of Cardiology.  73:121-130. 2019
  • The MANAGE trial – Authors' reply.  The Lancet.  393:228-228. 2019
  • Implementation of 100% smoke-free law in Uganda: a qualitative study exploring civil society’s perspective.  BMC International Health and Human Rights.  18:927. 2018
  • The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.  American Heart Journal.  206:72-79. 2018
  • Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.  The Lancet.  392:2288-2297. 2018
  • Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.  The Lancet Diabetes and Endocrinology.  6:798-808. 2018
  • Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia.  Journal of the American College of Cardiology.  72:2152-2163. 2018
  • Varying Effects of Body Mass Index and Mortality in Different Risk Groups.  American Journal of Cardiology.  122:1155-1160. 2018
  • Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.  European Heart Journal.  39:3105-3114. 2018
  • Evolving evidence about diet and health.  The Lancet Public Health.  3:e408-e409. 2018
  • Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study.  American Heart Journal.  203:57-66. 2018
  • Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial.  Journal of the American Heart Association.  7:e008918. 2018
  • Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.  European Journal of Heart Failure.  20:1230-1239. 2018
  • Rivaroxaban with or without aspirin for prevention of cardiovascular disease.  Coronary Artery Disease.  29:361-365. 2018
  • Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.  The Lancet.  392:496-506. 2018
  • Adiposity and mortality in South Asians: challenges to the existing paradigm.  The Lancet Global Health.  6:e712-e713. 2018
  • Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease.  Journal of the American College of Cardiology.  72:300-310. 2018
  • Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.  Journal of the American College of Cardiology.  72:255-267. 2018
  • Polypill Variants (Quarter Pill Trials).  American Journal of Hypertension.  31:758-761. 2018
  • Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.  The Lancet.  391:2325-2334. 2018
  • Development, Testing, and Implementation of a Training Curriculum for Nonphysician Health Workers to Reduce Cardiovascular Disease.  Global Heart.  13:93-93. 2018
  • Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 2018
  • Characterizing exposure to household air pollution within the Prospective Urban Rural Epidemiology (PURE) study.  Environment International.  114:307-317. 2018
  • Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease.  Journal of the American College of Cardiology.  71:2306-2315. 2018
  • Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.  The Lancet.  391:2019-2027. 2018
  • Associations of fats and carbohydrates with cardiovascular disease and mortality—PURE and simple? – Authors' reply.  The Lancet.  391:1681-1682. 2018
  • Blood HER2 and Uromodulin as Causal Mediators of CKD.  Journal of the American Society of Nephrology.  29:1326-1335. 2018
  • Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis.  American Heart Journal.  198:169-177. 2018
  • Improving worldwide access to inexpensive and effective treatments for common cardiovascular diseases.  European Heart Journal, Supplement.  20:C18-C22. 2018
  • Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.  Nature Genetics.  50:524-537. 2018
  • Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world.  Heart.  104:581-587. 2018
  • Response to: ‘More on dissidents and dietary sodium’.  International Journal of Epidemiology.  47:673-674. 2018
  • Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data.  PLoS Medicine.  15:e1002538-e1002538. 2018
  • Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE‐LY trial.  Journal of Internal Medicine.  283:282-292. 2018
  • Contribution of cardiac and extra‐cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.  European Journal of Heart Failure.  20:504-510. 2018
  • Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE).  Canadian Journal of Cardiology.  34:295-302. 2018
  • External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.  European Heart Journal.  39:750-757a. 2018
  • Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study.  The Lancet Global Health.  6:e292-e301. 2018
  • Insulin resistance and cardiovascular outcomes in the ORIGIN trial.  Diabetes, Obesity and Metabolism.  20:564-570. 2018
  • Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery.  ACP journal club.  168:237-237. 2018
  • A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.  European Heart Journal.  39:477-485. 2018
  • Impact of abdominal aortic aneurysm screening on quality of life.  British Journal of Surgery.  105:203-208. 2018
  • Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.  Europace.  20:253-262. 2018
  • Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality.  European Journal of Heart Failure.  20:295-303. 2018
  • Classification rules for identifying individuals at high risk of developing myocardial infarction based on ApoB, ApoA1 and the ratio were determined using a Bayesian approach.  Journal of Applied Statistics.  45:210-224. 2018
  • Rivaroxaban in Stable Cardiovascular Disease.  New England Journal of Medicine.  378:395-398. 2018
  • Risks of Overinterpreting Interim Data.  Circulation.  137:206-209. 2018
  • Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization.  Circulation.  137:88-90. 2018
  • Bongani Mayosi, a hero remembered..  SAMJ - South African Medical Journal.  29:206. 2018
  • Identifying and Treating Young Patients at Risk for Cardiovascular Events.  Journal of the American College of Cardiology.  71:303-305. 2018
  • Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease.  Circulation: Cardiovascular Interventions.  11:e005795. 2018
  • Knowledge, opinions and compliance related to the 100% smoke-free law in hospitality venues in Kampala, Uganda: cross-sectional results from theKOMPLY Project.  BMJ Open.  8:e017601-e017601. 2018
  • Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial.  Canadian Journal of Cardiology.  34:38-44. 2018
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.  The Lancet.  391:205-218. 2018
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.  The Lancet.  391:219-229. 2018
  • Developing consensus measures for global programs: lessons from the Global Alliance for Chronic Diseases Hypertension research program.  Globalization and Health.  13:17. 2017
  • Does greater individual social capital improve the management of hypertension? Cross-national analysis of 61 229 individuals in 21 countries.  BMJ Global Health.  2:e000443-e000443. 2017
  • Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution.  American Journal of Human Genetics.  101:925-938. 2017
  • Physical Activity to Prevent Cardiovascular Disease.  JAMA cardiology.  2:1358-1358. 2017
  • Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes.  Cardiovascular Drugs and Therapy.  31:545-549. 2017
  • Secondary CV Prevention in South America in a Community Setting: The PURE Study.  Global Heart.  12:305-305. 2017
  • The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.  The Lancet.  390:2643-2654. 2017
  • Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.  The Lancet.  390:2050-2062. 2017
  • Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.  Journal of the American Heart Association.  6:e006577. 2017
  • Effect of Body Mass Index on Clinical Events After Acute Coronary Syndromes.  American Journal of Cardiology.  120:1453-1459. 2017
  • Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study.  The Lancet.  390:2037-2049. 2017
  • Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.  Hypertension.  70:938-948. 2017
  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.  New England Journal of Medicine.  377:1319-1330. 2017
  • Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study.  The Lancet Diabetes and Endocrinology.  5:774-787. 2017
  • WHF Emerging Leaders Program.  European Heart Journal.  38:2800-2803. 2017
  • Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data.  The Lancet Public Health.  2:e411-e419. 2017
  • Effective approaches to address the global cardiovascular disease burden.  Current Opinion in Cardiology.  32:557-566. 2017
  • Reducing the Global Burden of Cardiovascular Disease, Part 1.  Circulation Research.  121:677-694. 2017
  • Reducing the Global Burden of Cardiovascular Disease, Part 2.  Circulation Research.  121:695-710. 2017
  • World Heart Federation Cholesterol Roadmap.  Global Heart.  12:179-179. 2017
  • Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.  American Heart Journal.  190:94-103. 2017
  • Mendelian Genes and Risk of Intracerebral Hemorrhage and Small-Vessel Ischemic Stroke in Sporadic Cases.  Stroke.  48:2263-2265. 2017
  • Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial.  Canadian Journal of Cardiology.  33:1027-1035. 2017
  • Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial.  TH Open.  01:e139-e145. 2017
  • Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation.  Current Problems in Cardiology.  42:198-225. 2017
  • Effects of dabigatran according to age in atrial fibrillation.  Heart.  103:1015-1023. 2017
  • Eliminating acute rheumatic fever and rheumatic heart disease.  The Lancet.  390:212-213. 2017
  • Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study.  The Lancet Global Health.  5:e665-e672. 2017
  • Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study.  Anesthesia and Analgesia.  125:162-169. 2017
  • Prevalence, awareness, treatment and control of hypertension in four Middle East countries.  Journal of Hypertension.  35:1457-1464. 2017
  • Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.  The Lancet.  389:2226-2237. 2017
  • Primary Prevention With Statin Therapy in the Elderly.  Circulation.  135:1979-1981. 2017
  • Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation.  Clinical Gastroenterology and Hepatology.  15:682-690. 2017
  • Joint Communication from Davos Cardiology Update, February 2017.  European Heart Journal.  38:1188-1188. 2017
  • Association of Household Wealth Index, Educational Status, and Social Capital with Hypertension Awareness, Treatment, and Control in South Asia.  American Journal of Hypertension.  30:373-381. 2017
  • On the economics of managing blood pressure.  The Lancet.  389:1294-1295. 2017
  • Geographic Variations in Controlled Trials.  New England Journal of Medicine.  376:1196-1198. 2017
  • Response by Smyth et al to Letters Regarding Article, “Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study”.  Circulation.  135:e644-e645. 2017
  • Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.  European Heart Journal.  38:ehw509-ehw509. 2017
  • Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting.  New England Journal of Medicine.  376:894-895. 2017
  • Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.  Kidney International.  91:683-690. 2017
  • Can We Eliminate Rheumatic Fever and Premature Deaths From RHD?.  Global Heart.  12:3-3. 2017
  • Imaging Asymptomatic Individuals for Coronary Disease ∗.  JACC Cardiovascular Imaging.  10:318-320. 2017
  • The epidemic of cardiovascular disease in South Asians: Time for action.  American Heart Journal.  185:150-153. 2017
  • Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic  T. Cruzi Carriers.  Journal of the American College of Cardiology.  69:939-947. 2017
  • Effects of bidi smoking on all-cause mortality and cardiorespiratory outcomes in men from south Asia: an observational community-based substudy of the Prospective Urban Rural Epidemiology Study (PURE).  The Lancet Global Health.  5:e168-e176. 2017
  • Low sodium intake and cardiovascular health: an unanswered question. Response to: Letter from Dr N. Campbell, ‘Dissidents and dietary sodium. Concerns about the commentary by O’Donnellet al.’.  International Journal of Epidemiology.  46:dyw297-dyw297. 2017
  • PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.  The Lancet Diabetes and Endocrinology.  5:97-105. 2017
  • Patients with Small Abdominal Aortic Aneurysm are at Significant Risk of Cardiovascular Events and this Risk is not Addressed Sufficiently.  European Journal of Vascular and Endovascular Surgery.  53:255-260. 2017
  • Thrombus Aspiration in ST-Segment–Elevation Myocardial Infarction.  Circulation.  135:143-152. 2017
  • Population Muscle Strength Predicts Olympic Medal Tallies: Evidence from 20 Countries in the PURE Prospective Cohort Study.  PLoS ONE.  12:e0169821-e0169821. 2017
  • The Effects of Steroids on Coagulation Dysfunction Induced by Cardiopulmonary Bypass: A Steroids in Cardiac Surgery (SIRS) Trial Substudy.  Seminars in Thoracic and Cardiovascular Surgery.  29:35-44. 2017
  • The INTERSTROKE study on risk factors for stroke – Authors' reply.  The Lancet.  389:36-36. 2017
  • HOPE­‑3, BP treatment, milestones in CV prevention. Dr. Salim Yusuf in an interview with Dr. Akbar Panju and Dr. Roman Jaeschke.  Polskie Archiwum Medycyny Wewnetrznej.  126:1033-1035. 2016
  • Dietary Sodium and Cardiovascular Disease Risk.  New England Journal of Medicine.  375:2404-2408. 2016
  • Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting.  New England Journal of Medicine.  375:2359-2368. 2016
  • Interpreting Geographic Variations in Results of Randomized, Controlled Trials.  New England Journal of Medicine.  375:2263-2271. 2016
  • Challenges to conducting epidemiology research in chronic conflict areas: examples from PURE- Palestine.  Conflict and Health.  10:33. 2016
  • Could patents interfere with the development of a cardiovascular polypill?.  Journal of Translational Medicine.  14:242. 2016
  • Impact of a Genetic Risk Score on Myocardial Infarction Risk Across Different Ethnic Populations.  Canadian Journal of Cardiology.  32:1440-1446. 2016
  • Perioperative Aspirin for Prevention of Venous Thromboembolism.  Anesthesiology.  125:1121-1129. 2016
  • Social disparities explain differences in hypertension prevalence, detection and control in Colombia.  Journal of Hypertension.  34:2344-2352. 2016
  • Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme.  European Journal of Heart Failure.  18:1508-1517. 2016
  • Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.  Circulation.  134:1697-1707. 2016
  • Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries.  Circulation.  134:1456-1466. 2016
  • A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score.  Canadian Journal of Cardiology.  32:1332-1339. 2016
  • Interpretation of the evidence for the efficacy and safety of statin therapy.  The Lancet.  388:2532-2561. 2016
  • Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target?.  Circulation.  134:1311-1313. 2016
  • The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure–Lowering Trials.  JAMA cardiology.  1:857-857. 2016
  • Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction.  Circulation.  134:1059-1067. 2016
  • Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol.  Journal of the American Heart Association.  5:e003665. 2016
  • Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: findings from the Prospective Urban Rural Epidemiology (PURE) study.  The Lancet Global Health.  4:e695-e703. 2016
  • How Robust Is the Evidence for Recommending Very Low Salt Intake in Entire Populations? ∗.  Journal of the American College of Cardiology.  68:1618-1621. 2016
  • Long‐Term Follow‐Up of Isolated Epicardial Left Ventricular Lead Implant Using a Minithoracotomy Approach for Cardiac Resynchronization Therapy.  PACE - Pacing and Clinical Electrophysiology.  39:1052-1060. 2016
  • Sodium and cardiovascular disease – Authors' reply.  The Lancet.  388:2113-2114. 2016
  • Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial.  New England Journal of Medicine.  375:1190-1194. 2016
  • Diet and Major Renal Outcomes: A Prospective Cohort Study. The NIH-AARP Diet and Health Study.  Journal of Renal Nutrition.  26:288-298. 2016
  • Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study.  The Lancet.  388:1161-1169. 2016
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non‐vitamin K antagonist oral anticoagulant dose adjustment.  European Journal of Heart Failure.  18:1162-1171. 2016
  • Why do people not take life-saving medications? The case of statins.  The Lancet.  388:943-945. 2016
  • Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease.  Circulation.  134:589-598. 2016
  • Toward Fairness in Data Sharing.  New England Journal of Medicine.  375:405-407. 2016
  • Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study.  American Heart Journal.  178:145-150. 2016
  • Genetic Determinants of Warfarin Maintenance Dose and Time in Therapeutic Treatment Range: A RE-LY Genomics Substudy.  Pharmacogenomics.  17:1425-1439. 2016
  • Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.  The Lancet.  388:761-775. 2016
  • Numbers can save lives: Janice Pogue (1962–2016).  Clinical Trials.  13:464-465. 2016
  • Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk.  ACP journal club.  165:JC8-JC8. 2016
  • Association of Urinary Sodium Excretion With Blood Pressure and Cardiovascular Clinical Events in 17,033 Latin Americans.  American Journal of Hypertension.  29:796-805. 2016
  • Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.  The Lancet.  388:465-475. 2016
  • Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.  Europace.  18:973-978. 2016
  • Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study.  American Journal of Kidney Diseases.  68:29-40. 2016
  • The Global Alliance for Chronic Diseases Supports 15 Major Studies in Hypertension Prevention and Control in Low‐ and Middle‐Income Countries.  Journal of Clinical Hypertension.  18:600-605. 2016
  • Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis.  QJM - Monthly Journal of the Association of Physicians.  109:377-382. 2016
  • The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.  The Lancet.  387:2302-2311. 2016
  • Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.  New England Journal of Medicine.  374:2009-2020. 2016
  • Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.  New England Journal of Medicine.  374:2032-2043. 2016
  • Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.  New England Journal of Medicine.  374:2021-2031. 2016
  • Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE).  Diabetes Care.  39:709-716. 2016
  • Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study.  Diabetes Care.  39:780-787. 2016
  • Assessing global risk factors for non-fatal injuries from road traffic accidents and falls in adults aged 35–70 years in 17 countries: a cross-sectional analysis of the Prospective Urban Rural Epidemiological (PURE) study.  Injury Prevention.  22:92-98. 2016
  • Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events.  Thrombosis Research.  140:81-88. 2016
  • Nutrition labelling, marketing techniques, nutrition claims and health claims on chip and biscuit packages from sixteen countries – CORRIGENDUM.  Public Health Nutrition.  19:1145-1145. 2016
  • Telomere Length and Risk of Myocardial Infarction in a MultiEthnic Population.  Journal of the American College of Cardiology.  67:1863-1865. 2016
  • Assessment of Dietary Sodium and Potassium in Canadians Using 24-Hour Urinary Collection.  Canadian Journal of Cardiology.  32:319-326. 2016
  • Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial.  The Lancet Diabetes and Endocrinology.  4:244-253. 2016
  • Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.  Canadian Journal of Cardiology.  32:311-318. 2016
  • Peripheral Blood MCEMP1 Gene Expression as a Biomarker for Stroke Prognosis.  Stroke.  47:652-658. 2016
  • Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial.  Thrombosis Research.  139:77-81. 2016
  • Resource Effective Strategies to Prevent and Treat Cardiovascular Disease.  Circulation.  133:742-755. 2016
  • CardioPulse: Prevention of global cardiovascular disease..  European Heart Journal.  37:505-507. 2016
  • Prevention of global cardiovascular disease.  European Heart Journal.  37:505-507. 2016
  • Commentary: Accepting what we don’t know will lead to progress.  International Journal of Epidemiology.  45:260-262. 2016
  • Corrigendum to “Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF)” (Am Heart J. 2015;170[4]:627-634).  American Heart Journal.  172:201-201. 2016
  • Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study.  International Journal of Cardiology.  204:133-141. 2016
  • New Medications for the Treatment of Diabetes.  Diabetes Technology and Therapeutics.  18:S112-S129. 2016
  • Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study.  Scientific Reports.  6:18672. 2016
  • Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data..  The Lancet.  387:61-69. 2016
  • Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.  The Lancet.  387:61-69. 2016
  • D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy.  Thrombosis and Haemostasis.  115:921-930. 2016
  • Dabigatran etexilate and reduction in serum apolipoprotein B.  Heart.  102:57-62. 2016
  • Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.  Age and Ageing.  45:77-83. 2016
  • GUEST EDITORS' PREFACE.  Indian Heart Journal.  48:XI-XI. 2016
  • Hypertension prevalence, awareness, treatment, and control in 115 rural and urban communities involving 47 000 people from China.  Journal of Hypertension.  34:39-46. 2016
  • Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial.  The Lancet.  387:127-135. 2016
  • Patient and System-Related Delays of Emergency Medical Services Use in Acute ST-Elevation Myocardial Infarction: Results from the Third Gulf Registry of Acute Coronary Events (Gulf RACE-3Ps).  PLoS ONE.  11:e0147385-e0147385. 2016
  • Obesity Genes and Risk of Major Depressive Disorder in a Multiethnic Population.  Journal of Clinical Psychiatry.  76:e1611-e1618. 2015
  • A 35-year journey to evidence-based medicine: a personal story.  European Heart Journal.  36:3460-3466. 2015
  • Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia.  Circulation.  132:2297-2304. 2015
  • Behaviour change strategies for reducing blood pressure-related disease burden: findings from a global implementation research programme.  Implementation Science.  10:158. 2015
  • Methylprednisolone Does Not Reduce Persistent Pain after Cardiac Surgery.  Anesthesiology.  123:1404-1410. 2015
  • Reply.  Journal of the American College of Cardiology.  66:2682-2682. 2015
  • The environmental profile of a community’s health: a cross-sectional study on tobacco marketing in 16 countries.  Bulletin of the World Health Organization.  93:851-861G. 2015
  • Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approach.  BMC Health Services Research.  15:254. 2015
  • World Heart Federation Emerging Leaders Program: An Innovative Capacity Building Program to Facilitate the 25 × 25 Goal.  Global Heart.  10:229-229. 2015
  • RESPONSE: Why Are Population Health, Health Systems, and Clinical Medicine Equally Important?.  Journal of the American College of Cardiology.  66:2262-2262. 2015
  • Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study.  The Lancet.  386:1945-1954. 2015
  • Correction.  Journal of the American College of Cardiology.  66:2269-2269. 2015
  • Measuring Sodium Intake in Populations: Simple Is Best?.  American Journal of Hypertension.  28:1303-1305. 2015
  • Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial).  American Journal of Cardiology.  116:1204-1209. 2015
  • Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial.  International Journal of Cardiology.  196:127-131. 2015
  • Correction.  Journal of the American College of Cardiology.  66:1948-1948. 2015
  • Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System.  Journal of the American College of Cardiology.  66:1590-1614. 2015
  • Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF).  American Heart Journal.  170:627-634.e1. 2015
  • Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy.  New England Journal of Medicine.  373:1295-1306. 2015
  • Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study.  European Journal of Preventive Cardiology (EJPC).  22:1261-1271. 2015
  • Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction.  European Heart Journal.  36:2364-2372. 2015
  • Correction.  Global Heart.  10:225-225. 2015
  • Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation.  Circulation.  132:796-803. 2015
  • Low resting heart rates are associated with new‐onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies.  Journal of Internal Medicine.  278:303-312. 2015
  • Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial.  The Lancet.  386:1243-1253. 2015
  • Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.  Journal of the American College of Cardiology.  66:1119-1128. 2015
  • The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada.  Canadian Journal of Cardiology.  31:1189-1194. 2015
  • Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union.  Nephrology Dialysis Transplantation.  30:iv76-iv85. 2015
  • Psychosocial factors and obesity in 17 high-, middle- and low-income countries: the Prospective Urban Rural Epidemiologic study.  International Journal of Obesity.  39:1217-1223. 2015
  • Same-day cardiac catheter ablation is safe and cost-effective: Experience from a UK tertiary center.  Heart Rhythm.  12:1756-1761. 2015
  • CardioPulse ArticlesLeaders in cardiovascular medicineSalim Yusuf MD: the physician who wants to improve the world's cardiovascular healthSpreading the success of cardiovascular medicine worldwideWomen in Cardiology: Elyse Foster MDCentre of excellenceCardiocentro Ticino in Lugano, Switzerland.  European Heart Journal.  36:1560-1565. 2015
  • Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.  Journal of Clinical Endocrinology and Metabolism (JCEM).  100:2682-2689. 2015
  • Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study.  The Lancet.  386:266-273. 2015
  • Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies.  Journal of Internal Medicine.  278:38-49. 2015
  • Spreading the success of cardiovascular medicine worldwide..  European Heart Journal.  36:1562-1563. 2015
  • The World Heart Federation's vision for worldwide cardiovascular disease prevention.  The Lancet.  386:399-402. 2015
  • Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals.  Human Molecular Genetics.  24:3582-3594. 2015
  • Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease.  European Heart Journal.  36:1454-1462. 2015
  • Healthy eating and reduced risk of cognitive decline.  Neurology.  84:2258-2265. 2015
  • Adapting the World Heart Federation Roadmaps at the National Level: Next Steps and Conclusions.  Global Heart.  10:135-135. 2015
  • Changes in Renal Function in Patients With Atrial Fibrillation.  Journal of the American College of Cardiology.  65:2481-2493. 2015
  • Dietary Sodium and Cardiovascular Disease.  Current Hypertension Reports.  17:559. 2015
  • Reducing Cardiovascular Disease Globally: The World Heart Federation’s Roadmaps.  Global Heart.  10:93-93. 2015
  • Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease.  Global Heart.  10:99-99. 2015
  • Reducing Premature Cardiovascular Mortality By 2025: The World Heart Federation Roadmap.  Global Heart.  10:97-97. 2015
  • Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study).  European Heart Journal.  36:1115-1122. 2015
  • Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‐LY trial.  Journal of Thrombosis and Haemostasis.  13:699-707. 2015
  • Regular Wine Consumption in Chronic Heart Failure.  Circulation. Heart Failure.  8:428-437. 2015
  • Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy.  New England Journal of Medicine.  372:1389-1398. 2015
  • Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials.  The Lancet.  385:1397-1405. 2015
  • Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians.  European Journal of Preventive Cardiology (EJPC).  22:468-477. 2015
  • Global Cardiovascular Research Training for Implementation Science, Health Systems Research, and Health Policy Research.  Journal of the American College of Cardiology.  65:1371-1372. 2015
  • Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus.  Kidney International.  87:784-791. 2015
  • Response to ‘Estimation of sodium excretion should be made as simple as possible, but not simpler.  Journal of Hypertension.  33:887-890. 2015
  • Sodium Intake and Cardiovascular Health.  Circulation Research.  116:1046-1057. 2015
  • Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials.  The Lancet.  385:867-874. 2015
  • Influence of Tea Consumption on Acute Myocardial Infarction in China Population.  Angiology.  66:265-270. 2015
  • Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.  European Heart Journal.  36:669-675. 2015
  • Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure.  Stroke.  46:667-672. 2015
  • Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk.  Hypertension.  65:651-661. 2015
  • Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.  European Journal of Heart Failure.  17:196-204. 2015
  • Early cerebral small vessel disease and brain volume, cognition, and gait.  Annals of Neurology.  77:251-261. 2015
  • The burden of disease in older people and implications for health policy and practice.  The Lancet.  385:549-562. 2015
  • Cardiovascular Risk and Events and Country Income Stratum.  New England Journal of Medicine.  372:288-290. 2015
  • International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction.  Circulation.  131:43-53. 2015
  • Patients’ Knowledge, Attitudes, Behaviour and Health Care Experiences on the Prevention, Detection, Management and Control of Hypertension in Colombia: A Qualitative Study.  PLoS ONE.  10:e0122112-e0122112. 2015
  • Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease.  Hypertension.  65:108-114. 2015
  • Perioperative Aspirin and Clonidine and Risk of Acute Kidney Injury.  Journal of the American Medical Association (JAMA).  312:2254-2254. 2014
  • Reply to both letters.  Journal of Hypertension.  32:2501-2503. 2014
  • Sleep duration, snoring habits and risk of acute myocardial infarction in China population: results of the INTERHEART study.  BMC International Health and Human Rights.  14:531. 2014
  • The relationship between estimated sodium and potassium excretion and subsequent renal outcomes.  Kidney International.  86:1205-1212. 2014
  • Sodium and Cardiovascular Disease.  New England Journal of Medicine.  371:2134-2139. 2014
  • Sodium and cardiovascular disease..  New England Journal of Medicine.  371:2134. 2014
  • Response to Letter Regarding Article, “Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis”.  Circulation.  130:e195. 2014
  • Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction.  Circulation. Heart Failure.  7:895-902. 2014
  • Rationale and design of a randomized controlled trial evaluating community health worker–based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD).  American Heart Journal.  168:690-697. 2014
  • The Cost Implications of Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery at One Year.  Annals of Thoracic Surgery.  98:1620-1625. 2014
  • Additional Events in the RE-LY Trial.  New England Journal of Medicine.  371:1464-1465. 2014
  • Differences in Ischemic and Hemorrhagic Recurrence Rates among Race-Ethnic Groups in the PRoFESS Secondary Stroke Prevention Trial.  International Journal of Stroke.  9:43-47. 2014
  • Evidence Relating Sodium Intake to Blood Pressure and CVD.  Current Cardiology Reports.  16:529. 2014
  • Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies.  Diabetologia.  57:2019-2029. 2014
  • Multidetector CT assessment of partial anomalous pulmonary venous return in association with sinus venosus type atrial septal defect..  Quantitative Imaging in Medicine and Surgery.  4:433-434. 2014
  • Sodium Intake and Renal Outcomes: A Systematic Review.  American Journal of Hypertension.  27:1277-1284. 2014
  • Prednisolone andMycobacterium indicus praniiin Tuberculous Pericarditis.  New England Journal of Medicine.  371:1121-1130. 2014
  • Predictors of early and late stroke following cardiac surgery.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  186:905-911. 2014
  • Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”.  Circulation.  130:e95. 2014
  • Association of cyclooxygenase-2 genetic variant with cardiovascular disease.  European Heart Journal.  35:2242-2248. 2014
  • Impact of lifestyle factors on fracture risk in older patients with cardiovascular disease: a prospective cohort study of 26,335 individuals from 40 countries.  Age and Ageing.  43:629-635. 2014
  • Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub‐study of the DREAM trial.  Diabetic Medicine.  31:1086-1092. 2014
  • Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries.  New England Journal of Medicine.  371:818-827. 2014
  • Response to Letter Regarding Article, “Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study”.  Circulation.  130:e85. 2014
  • Association of Urinary Sodium and Potassium Excretion with Blood Pressure.  New England Journal of Medicine.  371:601-611. 2014
  • Urinary Sodium and Potassium Excretion, Mortality, and Cardiovascular Events.  New England Journal of Medicine.  371:612-623. 2014
  • Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data.  The Lancet.  384:591-598. 2014
  • Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy.  Heart.  100:1193-1200. 2014
  • The Mini‐Mental State Examination, Clinical Factors, and Motor Vehicle Crash Risk.  Journal of The American Geriatrics Society.  62:1419-1426. 2014
  • Patterns of Alcohol Consumption and Myocardial Infarction Risk.  Circulation.  130:390-398. 2014
  • Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.  European Heart Journal.  35:1856-1863. 2014
  • Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial.  European Heart Journal.  35:1743-1751. 2014
  • Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial.  Diabetologia.  57:1325-1331. 2014
  • Cost implications of the use of basal insulin glargine in people with early dysglycemia: The ORIGIN trial.  Journal of Diabetes and its Complications.  28:553-558. 2014
  • Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.  The Lancet Diabetes and Endocrinology.  2:562-572. 2014
  • Incidental Magnetic Resonance Diffusion-Weighted Imaging–Positive Lesions Are Rare in Neurologically Asymptomatic Community-Dwelling Adults.  Stroke.  45:2115-2117. 2014
  • Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction.  Circulation. Heart Failure.  7:590-595. 2014
  • Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation.  Stroke.  45:2127-2130. 2014
  • Reply.  Journal of the American College of Cardiology.  63:2885-2886. 2014
  • Reply: regarding the effect of dabigatran plasma concentrations..  Journal of the American College of Cardiology.  63:2885-2886. 2014
  • Kidney Function After Off-Pump or On-Pump Coronary Artery Bypass Graft Surgery.  Journal of the American Medical Association (JAMA).  311:2191-2191. 2014
  • Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial.  International Journal of Cardiology.  174:458-461. 2014
  • Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk.  Journal of Hypertension.  32:1334-1341. 2014
  • Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: An international 2 × 2 factorial randomized controlled trial of acetyl-salicylic acid vs placebo and clonidine vs placebo in patients undergoing noncardiac surgery.  American Heart Journal.  167:804-809.e4. 2014
  • The cost implications of an early versus delayed invasive strategy in acute coronary syndromes: the TIMACS study.  Journal of Medical Economics.  17:415-422. 2014
  • Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved’ [Eur J Heart Fail 2014;16:33–40].  European Journal of Heart Failure.  16:592-592. 2014
  • Incremental Value of Left Ventricular Systolic and Diastolic Function to Determine Outcome in Patients with Acute ST‐Segment Elevation Myocardial Infarction: The Echocardiographic Substudy of the OASIS‐6 Trial.  Echocardiography.  31:569-578. 2014
  • Rationale and design of the Steroids in Cardiac Surgery trial.  American Heart Journal.  167:660-665. 2014
  • The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia.  Diabetes Care.  37:1360-1366. 2014
  • The Population Risks of Dietary Salt Excess Are Exaggerated.  Canadian Journal of Cardiology.  30:507-512. 2014
  • Towards better hypertension management in India..  Indian Journal of Medical Research.  139:657-660. 2014
  • Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries.  Journal of Hypertension.  32:1005-1015. 2014
  • Aspirin in Patients Undergoing Noncardiac Surgery.  New England Journal of Medicine.  370:1494-1503. 2014
  • Clonidine in Patients Undergoing Noncardiac Surgery.  New England Journal of Medicine.  370:1504-1513. 2014
  • Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries.  Circulation.  129:1568-1576. 2014
  • Documenting the Global Burden of Cardiovascular Disease.  Circulation.  129:1459-1462. 2014
  • Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study.  European Journal of Preventive Cardiology (EJPC).  21:400-410. 2014
  • Polypills.  Journal of the American College of Cardiology.  63:1368-1370. 2014
  • Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI.  Diabetologia.  57:738-745. 2014
  • Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation.  Circulation.  129:961-970. 2014
  • The association between ownership of common household devices and obesity and diabetes in high, middle and low income countries.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  186:258-266. 2014
  • Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI.  American Heart Journal.  167:315-321.e1. 2014
  • Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.  European Journal of Heart Failure.  16:325-333. 2014
  • Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients.  European Journal of Preventive Cardiology (EJPC).  21:272-280. 2014
  • Myocardial Injury after Noncardiac Surgery.  Anesthesiology.  120:564-578. 2014
  • Procedural Volume and Outcomes With Radial or Femoral Access for Coronary Angiography and Intervention.  Journal of the American College of Cardiology.  63:954-963. 2014
  • Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial.  BMJ Open.  4:e004842-e004842. 2014
  • The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial.  European Journal of Preventive Cardiology (EJPC).  21:299-309. 2014
  • Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.  European Heart Journal.  35:353-364. 2014
  • Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND.  Clinical Research in Cardiology.  103:149-159. 2014
  • Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial.  Blood Pressure.  23:54-60. 2014
  • Physical Activity Levels, Sport Activities, and Risk of Acute Myocardial Infarction.  Angiology.  65:113-121. 2014
  • Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study).  American Journal of Cardiology.  113:669-675. 2014
  • The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients.  Journal of the American College of Cardiology.  63:321-328. 2014
  • A Novel Method to Evaluate the Community Built Environment Using Photographs – Environmental Profile of a Community Health (EPOCH) Photo Neighbourhood Evaluation Tool.  PLoS ONE.  9:e110042-e110042. 2014
  • Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved.  European Journal of Heart Failure.  16:33-40. 2014
  • Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies.  PLoS ONE.  9:e84238-e84238. 2014
  • Patient outcomes using the European label for dabigatran.  Thrombosis and Haemostasis.  112:933-942. 2014
  • Differences in perceptions and fast food eating behaviours between Indians living in high- and low-income neighbourhoods of Chandigarh, India.  Nutrition Journal.  12:4. 2013
  • Erratum: The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression.  Molecular Psychiatry.  18:1324-1324. 2013
  • The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression.  Molecular Psychiatry.  18:1281-1286. 2013
  • Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin.  Circulation.  128:2325-2332. 2013
  • When It Comes to Trials, Do We Get What We Pay For?.  New England Journal of Medicine.  369:1962-1963. 2013
  • Causes of Death and Influencing Factors in Patients With Atrial Fibrillation.  Circulation.  128:2192-2201. 2013
  • Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure.  Journal of the American College of Cardiology.  62:1845-1854. 2013
  • Is the superiority of apoB over non–HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?.  Journal of Clinical Lipidology.  7:626-631. 2013
  • Left Atrial Appendage Occlusion Study II (LAAOS II).  Canadian Journal of Cardiology.  29:1443-1447. 2013
  • Risk factors for stroke in Tanzania.  The Lancet Global Health.  1:e241-e242. 2013
  • Secretory Phospholipase A2-IIA and Cardiovascular Disease.  Journal of the American College of Cardiology.  62:1966-1976. 2013
  • Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.  European Heart Journal.  34:3137-3144. 2013
  • Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus.  JAMA Internal Medicine.  173:1682-1692. 2013
  • Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.  The BMJ.  347:f5680-f5680. 2013
  • Extreme Sodium Reductions for the Entire Population: Zealotry or Evidence Based?.  American Journal of Hypertension.  26:1187-1190. 2013
  • Global differences in lung function by region (PURE): an international, community-based prospective study.  The Lancet Respiratory Medicine.  1:599-609. 2013
  • Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries.  American Heart Journal.  166:636-646.e4. 2013
  • Antithrombotic Therapy and Invasive Procedures.  New England Journal of Medicine.  369:1077-1080. 2013
  • Randomized Clinical Trials — Removing Unnecessary Obstacles.  New England Journal of Medicine.  369:1061-1065. 2013
  • Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries.  Journal of the American Medical Association (JAMA).  310:959-959. 2013
  • Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation.  Journal of the American College of Cardiology.  62:900-908. 2013
  • Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial.  European Journal of Heart Failure.  15:1053-1061. 2013
  • Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events.  Diabetes Care.  36:2466-2474. 2013
  • Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population.  Diabetes Care.  36:2836-2842. 2013
  • The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial.  European Heart Journal.  34:2752-2759. 2013
  • Polypill for Cardiovascular Disease Prevention—Reply.  Journal of the American Medical Association (JAMA).  310:749-749. 2013
  • Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.  American Heart Journal.  166:306-314.e7. 2013
  • Impact of access to hospitals with catheterization facilities in the second Gulf Registry of Acute Coronary Events (Gulf RACE-2).  Coronary Artery Disease.  24:412-418. 2013
  • The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.  Circulation.  128:237-243. 2013
  • Off-Pump or On-Pump Coronary-Artery Bypass Grafting.  New England Journal of Medicine.  369:194-197. 2013
  • Dabigatran Versus Warfarin.  Stroke.  44:1891-1896. 2013
  • Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia.  Atherosclerosis.  229:234-239. 2013
  • Rationale and design of the Primary pREvention strategies at the community level to Promote Adherence of treatments to pREvent cardiovascular diseases trial number (CTRI/2012/09/002981).  American Heart Journal.  166:4-12.e1. 2013
  • Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?.  European Heart Journal.  34:1630-1635. 2013
  • Mortality Benefits From US Population-Wide Reduction in Sodium Consumption: Projections From 3 Modeling Approaches.  Hypertension.  61:e59. 2013
  • Chronic Pain Syndromes After Ischemic Stroke.  Stroke.  44:1238-1243. 2013
  • Why are we failing to implement effective therapies in cardiovascular disease?.  European Heart Journal.  34:1262-1269. 2013
  • Combination Therapy to Prevent Cardiovascular Disease.  Journal of the American Medical Association (JAMA).  309:1595-1595. 2013
  • Prevalence of a Healthy Lifestyle Among Individuals With Cardiovascular Disease in High-, Middle- and Low-Income Countries.  Journal of the American Medical Association (JAMA).  309:1613-1613. 2013
  • Salt intake and cardiovascular disease: why are the data inconsistent?.  European Heart Journal.  34:1034-1040. 2013
  • Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding.  Circulation.  127:1404-1412. 2013
  • A cardiovascular study that includes a million subjects..  European Heart Journal.  34:945-946. 2013
  • Blockade of the renin–angiotensin–aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: A systematic review and meta analysis of randomized controlled trials.  International Journal of Cardiology.  165:17-24. 2013
  • Central statistical monitoring: Detecting fraud in clinical trials.  Clinical Trials.  10:225-235. 2013
  • Effects of Off-Pump and On-Pump Coronary-Artery Bypass Grafting at 1 Year.  New England Journal of Medicine.  368:1179-1188. 2013
  • Response to Letters Regarding Article, “Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.  Circulation.  127:E506-E506. 2013
  • Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”..  Circulation.  127:e506. 2013
  • Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial.  Circulation.  127:634-640. 2013
  • Albuminuria and Rapid Loss of GFR and Risk of New Hip and Pelvic Fractures.  American Society of Nephrology. Clinical Journal.  8:233-240. 2013
  • Clustering of diet, physical activity and overweight in parents and offspring in South India.  European Journal of Clinical Nutrition.  67:128-134. 2013
  • Dual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes.  Journal of Hypertension.  31:414-421. 2013
  • Influence of dietary patterns on the risk of acute myocardial infarction in China population: the INTERHEART China study.  National Medical Journal of China.  126:464-470. 2013
  • Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS ₂ and CHA ₂ DS ₂ -VASc Scores in Patients With Atrial Fibrillation.  Circulation: Arrhythmia and Electrophysiology.  6:31-38. 2013
  • Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: A 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis.  American Heart Journal.  165:109-115.e3. 2013
  • Response to Letter Regarding Article, “Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy”.  Circulation.  127:e278-e279. 2013
  • The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.  European Heart Journal.  34:170-176. 2013
  • Abstracts from the 7th Canadian Conference on Dementia (CCD) held in Vancouver, October 2013.  Canadian Geriatrics Journal.  16:196-199. 2013
  • CardioPulse Articles.  European Heart Journal.  34:1-6. 2013
  • Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population.  PLoS ONE.  8:e66808-e66808. 2013
  • Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk.  Atherosclerosis.  226:245-251. 2013
  • Hypertension and Diabetes: Entry Points for Prevention and Control of the Global Cardiovascular Epidemic.  International Journal of Hypertension.  2013:1-3. 2013
  • Increased cardiovascular risk after pre‐eclampsia in women with dysglycaemia.  Diabetic Medicine.  30:e1-e7. 2013
  • Maternal and Pregnancy Related Predictors of Cardiometabolic Traits in Newborns.  PLoS ONE.  8:e55815-e55815. 2013
  • Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population.  Clinical Biochemistry.  46:5-9. 2013
  • The perilous state of independent randomized clinical trials and related applied research in Canada.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  184:1997-2002. 2012
  • Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention.  Circulation.  126:2705-2712. 2012
  • Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).  Hypertension.  60:1400-1406. 2012
  • Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin.  Stroke.  43:3291-3297. 2012
  • Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study.  Atherosclerosis.  225:444-449. 2012
  • Effects of Radial Versus Femoral Artery Access in Patients With Acute Coronary Syndromes With or Without ST-Segment Elevation.  Journal of the American College of Cardiology.  60:2490-2499. 2012
  • Influence of socioeconomic status on acute myocardial infarction in the Chinese population: the INTERHEART China study..  National Medical Journal of China.  125:4214-4220. 2012
  • Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  184:E857-E866. 2012
  • Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries.  Circulation.  126:2309-2316. 2012
  • Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke.  European Heart Journal.  33:2804-2812. 2012
  • Enhancing Risk Prediction With PET Coronary Flow Reserve.  JACC Cardiovascular Imaging.  5:1035-1036. 2012
  • Letter to the Editor.  Clinical Cardiology.  35:646-646. 2012
  • Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk.  Circulation.  126:934-941. 2012
  • Off-Pump or On-Pump Coronary-Artery Bypass Grafting.  New England Journal of Medicine.  367:577-578. 2012
  • Off-Pump or On-Pump Coronary-Artery Bypass Grafting REPLY.  New England Journal of Medicine.  367:578-578. 2012
  • Canadian Surgery Forum1 Is laparoscopic sleeve gastrectomy a reasonable stand-alone procedure for super morbidly obese patients?2 Postoperative monitoring requirements of patients with obstructive sleep apnea undergoing bariatric surgery3 Role of relaparoscopy in the diagnosis and treatment of bariatric complications in the early postoperative period4 Changes of active and total ghrelin, GLP-1 and PYY following restrictive bariatric surgery and their impact on satiety: comparison of sleeve gastrectomy and adjustable gastric banding5 Prioritization and willingness to pay for bariatric surgery: the patient perspective6 Ventral hernia at the time of laparoscopic gastric bypass surgery: Should it be repaired?7 Linear stapled gastrojejunostomy with transverse handsewn enterotomy closure significantly reduces strictures for laparoscopic Roux-en-Y bypass8 Laparoscopic biliopancreatic diversion with duodenal switch as second stage for super super morbidly obese patients. Do all patients benefit?9 Sleeve gastrectomy in the super super morbidly obese (BMI > 60 kg/m²): a Canadian experience10 Laparoscopic gastric bypass for the treatment of refractory idiopathic gastroparesis: a report of 2 cases11 Duodeno-ileal switch as a primary bariatric and metabolic surgical option for the severely obese patient with comorbidities: review of a single-institution case series of duodeno-ileal intestinal bypass12 Management of large paraesophageal hernias in morbidly obese patients with laparoscopic sleeve gastrectomy: a case series13 Early results of the Ontario bariatric surgical program: using the bariatric registry14 Improving access to bariatric surgical care: Is universal health care the answer?15 Early and liberal postoperative exploration can reduce morbidity and mortality in patients undergoing bariatric surgery16 Withdrawn17 Identification and assessment of technical errors in laparoscopic Roux-en-Y gastric bypass18 A valid and reliable tool for assessment of surgical skill in laparoscopic Roux-en-Y gastric bypass19 Psychiatric predictors of presurgery drop-out following suitability assessment for bariatric surgery20 Predictors of outcomes following Roux-en-Y gastric bypass surgery at The Ottawa Hospital21 Prophylactic management of cholelithiasis in bariatric patients: Is routine cholecystectomy warranted?22 Early outcomes of Roux-en-Y gastric bypass in a publicly funded obesity program23 Similar incidence of gastrojejunal anastomotic stricture formation with hand-sewn and 21 mm circular stapler techniques during Roux-en-Y gastric bypass24 (CAGS Basic Science Award) Exogenous glucagon-like peptide-1 improves clinical, morphological and histological outcomes of intestinal adaptation in a distal-intestinal resection piglet model of short bowel syndrome25 (CAGS Clinical Research Award) Development and validation of a comprehensive curriculum to teach an advanced minimally invasive procedure: a randomized controlled trial26 Negative-pressure wound therapy (iVAC) on closed, high-risk incisions following abdominal wall reconstruction27 The impact of seed granting on research in the University of British Columbia Department of Surgery28 Quality of surgical care is inadequate for elderly patients29 Recurrence of inguinal hernia in general and hernia specialty hospitals in Ontario, Canada30 Oncostatin M receptor deficiency results in increased mortality in an intestinal ischemia reperfusion model in mice31 Laparoscopic repair of large paraesophageal hernias with anterior gastropexy: a multicentre trial32 Response to preoperative medical therapy predicts success of laparoscopic splenectomy for immune thrombocytopenic purpura33 Perioperative sepsis, but not hemorrhagic shock, promotes the development of cancer metastases in a murine model34 Measuring the impact of implementing an acute care surgery service on the management of acute biliary disease35 Patient flow and efficiency in an acute care surgery service36 The relationship between treatment factors and postoperative complications after radical surgery for rectal cancer37 Risk of ventral hernia after laparoscopic colon surgery38 Urinary metabolomics as a tool for early detection of Barrett’s and esophageal cancer39 Construct validity of individual and summary performance metrics associated with a computer-based laparo-scopic simulator40 Impact of a city-wide health system reorganization on emergency department visits in hospitals in surrounding communities41 Transcatheter aortic valve implantation for the nonoperative management of aortic stenosis: a cost-effectiveness analysis42 Breast cancer: racial differences in age of onset. A potential confounder in Canadian screening recommendations43 Risk taking in surgery: in and out of the comfort zone44 A tumour board in the office: Track those cancer patients!45 Increased patient BMI is not associated with advanced colon cancer stage or grade on presentation: a retrospective chart review46 Consensus statements regarding the multidisciplinary care of limb amputation patients in disasters or humanitarian emergencies. Report of the 2011 Humanitarian Action Summit Surgical Working Group on amputations following disasters or conflict47 Learning the CanMEDS role of professional: a pilot project of supervised discussion groups addressing the hidden curriculum48 Assessing the changing scope of training in Canadian general surgery programs: expected versus actual experience49 Predicting need for surgical management for massive gastrointestinal hemorrhage50 International health care experience: using CanMEDS to evaluate learning outcomes following a surgical mission in Mampong, Ghana51 The open abdomen: risk factors for mortality and rates of closure52 How surgeons think: an exploration of mental practice in surgical preparation53 The surgery wiki: a novel method for delivery of under-graduate surgical education54 Understanding surgical residents’ postoperative practices before implementing an enhanced recovery after surgery (ERAS) guideline at the University of Toronto55 From laparoscopic transabdominal to posterior retroperitoneal adrenalectomy: a paradigm shift in operative approach56 A retrospective audit of outcomes in patients over the age of 80 undergoing acute care abdominal surgery57 Canadian general surgery residents’ perspectives on work-hour regulations58 Timing of surgical intervention and its outcomes in acute appendicitis59 Preparing surgical trainees to deal with adverse events. An outline of learning issues60 Acute care surgical service: surgeon agreement at the time of handover61 Predicting discharge of elderly patients to prehospitalization residence following emergency general surgery62 Morbidity and mortality after emergency abdominal surgery in octo- and nonagenarians63 The impact of acute abdominal illness and urgent admission to hospital on the living situation of elderly patients64 A comparison of laparoscopic versus open subtotal gastrectomy for antral gastric adenocarcinoma: a North American perspective65 Minimally invasive excision of ectopic mediastinal parathyroid adenomas66 Perioperative outcomes of laparoscopic hernia repair in a tertiary care centre: a single institution’s experience67 Evaluation of a student-run, practical and didactic curriculum for preclerkship medical students68 Joseph Lister: Father of Modern Surgery69 Comparisons of melanoma sentinel lymph node biopsy prediction nomograms in a cohort of Canadian patients70 Local experience with myocutaneous flaps after extensive pelvic surgery71 The treatment of noncirrhotic splanchnic vein thrombosis: Is anticoagulation enough?72 Implementation of an acute care surgery service does not affect wait-times for elective cancer surgeries: an institutional experience73 Use of human collagen mesh for closure of a large abdominal wall defect, after colon cancer surgery, a case report74 The role of miR-200b in pulmonary hypoplasia associated with congenital diaphragmatic hernia75 Systematic review and meta-analysis of electrocautery versus scalpel for incising epidermis and dermis76 Accuracy of sentinel lymph node biopsy for early breast cancer in the community setting in St. John’s, New-foundland: results of a retrospective review77 Acute surgical outcomes in the 80 plus population78 The liberal use of platelets transfusions in the acute phase of trauma resuscitation: a systematic review79 Implementation of an acute care surgical on call program in a Canadian community hospital80 Short-term outcomes following paraesophageal hernia repair in the elderly patient81 First experience with single incision surgery: feasibility in the pediatric population and cost evaluation82 The impact of the establishment of an acute care surgery unit on the outcomes of appendectomies and cholecystectomies83 Description and preliminary evaluation of a low-cost simulator for training and evaluation of flexible endoscopic skills84 Tumour lysis syndrome in metastatic colon cancer: a case report85 Acute care surgery service model implementation study at a single institution86 Colonic disasters approached by emergent subtotal and total colectomy: lessons learned from 120 consecutive cases87 Acellular collagen matrix stent to protect bowel anastomoses88 Lessons we learned from preoperative MRI-guided wire localization of breast lesions: the University Health Network (UHN) experience89 Interim cost comparison for the use of platinum micro-coils in the operative localization of small peripheral lung nodules90 Routine barium esophagram has minimal impact on the postoperative management of patients undergoing esophagectomy for esophageal cancer91 Iron deficiency anemia is a common presenting issue with giant paraesophageal hernia and resolves following repair92 A randomized comparison of different ventilation strategies during thoracotomy and lung resection93 The Canadian Lung Volume Reduction Surgery study: an 8-year follow-up94 A comparison of minimally invasive versus open Ivor-Lewis esophagectomy95 A new paradigm in the follow-up after curative resection for lung cancer: minimal-dose CT scan allows for early detection of asymptomatic cancer activity96 Predictors of lymph node metastasis in early esophageal adenocarcinoma: Is endoscopic resection worth the risk?97 How well can thoracic surgery residents operate? Comparing resident and program director opinions98 The impact of extremes of age on short- and long-term outcomes following surgical resection of esophageal malignancy99 Epidermal growth factor receptor targeted gold nanoparticles for the enhanced radiation treatment of non–small cell lung cancer100 Laparoscopic Heller myotomy results in excellent outcomes in all subtypes of achalasia as defined by the Chicago classification101 Neoadjuvant chemoradiation versus surgery in managing esophageal cancer102 Quality of life postesophagectomy for cancer!103 The implementation, evolution and translocation of standardized clinical pathways can improve perioperative outcomes following surgical treatment of esophageal cancer104 A tissue-mimicking phantom for applications in thoracic surgical simulation105 Sublobar resection compared with lobectomy for early stage non–small cell lung cancer: a single institution study106 Not all reviews are equal: the quality of systematic reviews and meta-analyses in thoracic surgery107 Do postoperative complications affect health-related quality of life after video-assisted thoracoscopic lobectomy for patients with lung cancer? A cohort study108 Thoracoscopic plication for palliation of dyspnea secondary to unilateral diaphragmatic paralysis: A worthwhile venture?109 Thoracic surgery experience in Canadian general surgery residency programs110 Perioperative morbidity and pathologic response rates following neoadjuvant chemotherapy and chemoradiation for locally advanced esophageal carcinoma111 An enhanced recovery pathway reduces length of stay after esophagectomy112 Predictors of dysplastic and neoplastic progression of Barrett’s esophagus113 Recurrent esophageal cancer complicated by tracheoesophageal fistula: management by means of palliative airway stenting114 Pancreaticopleural fistula-induced empyema thoracis: principles and results of surgical management115 Prognostic factors of early postoperative mortality following right extended hepatectomy116 Optimizing steatotic livers for transplantation using a cell-penetrating peptide CPP-fused heme oxygenase117 Video outlining the technical steps for a robot-assisted laparoscopic pancreaticoduodenectomy118 Establishment of a collaborative group to conduct innovative clinical trials in Canada119 Hepatic resection for metastatic malignant melanoma: a systematic review and meta-analysis120 Acellular normothermic ex vivo liver perfusion for donor liver preservation121 Pancreatic cancer and predictors of survival: comparing the CA 19–9/bilirubin ratio with the McGill Brisbane Scoring System122 Staged liver resections for bilobar hepatic colorectal metastases: a single centre experience123 Economic model of observation versus immediate resection of hepatic adenomas124 Resection of colorectal liver metastasis in the elderly125 Acceptable long-term survival in patients undergoing liver resection for metastases from noncolorectal, non-neuroendocrine, nonsarcoma malignancies126 Patient and clinicopathological features and prognosis of CK19+ hepatocellular carcinomas: a case–control study127 The management of blunt hepatic trauma in the age of angioembolization: a single centre experience128 Liver resections for noncolorectal and non-neuroendocrine metastases: an evaluation of oncologic outcomes129 Developing an evidence-based clinical pathway for patients undergoing pancreaticoduodenectomy130 Hepatitis C infection and hepatocellular carcinoma in liver transplant: a 20 year experience131 The effect of medication on the risk of post-ERCP pancreatitis132 Temporal trends in the use of diagnostic imaging for patients with hepato-pancreato-biliary (HPB) conditions: How much ionizing radiation are we really using?196 A phase II study of aggressive metastasectomy for intra-and extrahepatic metastases from colorectal cancer133 Why do women choose mastectomy for breast cancer treatment? A conceptual framework for understanding surgical decision-making in early-stage breast cancer134 Synoptic operative reporting: documentation of quality of care data for rectal cancer surgery135 Learning curve analysis for cytoreductive surgery: a useful application of the cumulative sum (CUSUM) method136 Pancreatic cancer is strongly associated with a unique urinary metabolomic signature137 Concurrent neoadjuvant chemo/radiation in locally advanced breast cancer138 Impact of positron emission tomography on clinical staging of newly diagnosed rectal cancer: a specialized single centre retrospective study139 An evaluation of intraoperative Faxitron microradiography versus conventional specimen radiography for the excision of nonpalpable breast lesions140 Comparison of breast cancer treatment wait-times in the Southern Interior of British Columbia in 2006 and 2010141 Factors affecting lymph nodes harvest in colorectal carcinoma142 Laparoscopic adrenalectomy for metastases143 You have a message! Social networking as a motivator for fundamentals of laparoscopic surgery (FLS) training144 The evaluation and validation of a rapid diagnostic and support clinic for women assessment for breast cancer145 Oncoplastic breast surgery: oncologic benefits and limitations146 A qualitative study on rectal cancer patients’ preferences for location of surgical care147 The effect of surgery on local recurrence in young women with breast cancer148 Elevated IL-6 and IL-8 levels in tumour microenvironment is not associated with increased serum levels in humans with Pseudomyxoma peritonei and peritoneal mesothelioma149 Conversion from laparoscopic to open approach during gastrectomy: a population-based analysis150 A scoping review of surgical process improvement tools (SPITs) in cancer surgery151 Splenectomy during gastric cancer surgery: a population-based study152 Defining the polo-like kinase 4 (Plk4) interactome in cancer cell protrusions153 Neoadjuvant imatinib mesylate for locally advanced gastrointestinal stromal tumours154 Implementing results from ACOSOG Z0011: Practice-changing or practice-affirming?155 Should lymph node retrieval be a surgical quality indicator in colon cancer?156 Long-term outcomes following resection of retroperitoneal recurrence of colorectal cancer157 Clinical research in surgical oncology: an analysis of clinicaltrials.gov158 Radiation therapy after breast conserving surgery: When are we missing the mark?159 The accuracy of endorectal ultrasound in staging rectal lesions in patients undergoing transanal endoscopic microsurgery160 Quality improvement in gastrointestinal cancer surgery: expert panel recommendations for priority research areas161 Factors influencing the quality of local management of ductal carcinoma in situ: a cohort study162 Papillary thyroid microcarcinoma: Does size matter?163 Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials164 Adherence to antiestrogen therapy in seniors with breast cancer: How well are we doing?165 Parathyroid carcinoma: Challenging the surgical dogma?166 A qualitative assessment of the journey to delayed breast reconstruction195 The role of yoga therapy in breast cancer patients167 Outcomes reported in comparative studies of surgical interventions168 Enhanced recovery pathways decrease length of stay following colorectal surgery, but how quickly do patients actually recover?169 The impact of complications on bed utilization after elective colorectal resection170 Impact of trimodal prehabilitation program on functional recovery after colorectal cancer surgery: a pilot study171 Complex fistula-in-ano: Should the plug be abandoned in favour of the LIFT or BioLIFT?172 Prognostic utility of cyclooxygenase-2 expression by colon and rectal cancer173 Laparoscopic right hemicolectomy with complete mesocolic excision provides acceptable perioperative outcomes but is complex and time-consuming: analysis of learning curves for a novice minimally invasive surgeon174 Intraoperative quality assessment following double stapled circular colorectal anastomosis175 Improving patient outcomes through quality assessment of rectal cancer care176 Are physicians willing to accept a decrease in treatment effectiveness for improved functional outcomes for low rectal cancer?177 Turnbull-Cutait delayed coloanal anastomosis for the treatment of distal rectal cancer: a prospective cohort study178 Preoperative high-dose rate brachytherapy in preparation for sphincter preservation surgery for patients with advanced cancer of the lower rectum179 Impact of an enhanced recovery program on short-term outcomes after scheduled laparoscopic colon resection180 The clinical results of the Turnbull-Cutait delayed coloanal anastomosis: a systematic review181 Is a vertical rectus abdominus flap (VRAM) necessary? An analysis of perineal wound complications182 Fistula plug versus endorectal anal advancement flap for the treatment of high transsphincteric cryptoglandular anal fistulas: a systematic review and meta-analysis183 Maternal and neonatal outcomes following colorectal cancer surgery184 Transanal drainage to treat anastomotic leaks after low anterior resection for rectal cancer: a valuable option185 Trends in colon cancer in Ontario: 2002–2009186 Validation of electronically derived short-term outcomes in colorectal surgery187 A population-based assessment of transanal and endoscopic resection for adenocarcinoma of the rectum188 Laparoscopic colorectal surgery in the emergency setting: trends in the province of Ontario from 2002 to 2009189 Prevention of perineal hernia after laparoscopic and robotic abdominoperineal resection: review with case series of internal hernia through pelvic mesh which was placed in attempt to prevent perineal hernia190 Effect of rectal cancer treatments on quality of life191 The use of antibacterial sutures as an adjunctive preventative strategy for surgical site infection in Canada: an economic analysis192 Impact of socioeconomic status on colorectal cancer screening and stage at presentation: preliminary results of a population-based study from an urban Canadian centre193 Initial perioperative results of the first transanal endoscopic microsurgery (TEM) program in the province of Quebec194 Use of negative pressure wound therapy decreases perineal wound infections following abdominal perineal resection.  Canadian Journal of Surgery.  55:S63-S135. 2012
  • Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study.  European Journal of Preventive Cardiology (EJPC).  19:755-764. 2012
  • Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease.  Journal of Stroke and Cerebrovascular Diseases.  21:429-435. 2012
  • The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.  The Lancet.  380:581-590. 2012
  • Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia.  New England Journal of Medicine.  367:319-328. 2012
  • n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia.  New England Journal of Medicine.  367:309-318. 2012
  • Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients.  Circulation.  126:278-286. 2012
  • Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin.  Circulation.  126:343-348. 2012
  • Cognitive impairment and risk of cardiovascular events and mortality.  European Heart Journal.  33:1777-1786. 2012
  • The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.  European Heart Journal.  33:1750-1757. 2012
  • Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases.  Circulation. Cardiovascular Quality and Outcomes.  5:463-471. 2012
  • Error in Viewpoint in: Statin Therapy for Healthy Men Identified as ‘Increased Risk,’.  Journal of the American Medical Association (JAMA).  307:2590-2590. 2012
  • Association Between Postoperative Troponin Levels and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery.  Journal of the American Medical Association (JAMA).  307:2295-2295. 2012
  • Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran.  Stroke.  43:1511-1517. 2012
  • Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study.  Thrombosis Research.  129:715-719. 2012
  • The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.  The Lancet.  379:2352-2363. 2012
  • The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop.  Transfusion.  52:1363-1378. 2012
  • Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure.  Journal of the American College of Cardiology.  59:1785-1795. 2012
  • Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.  Journal of Hypertension.  30:1004-1014. 2012
  • Dabigatran efficacy‐safety assessment for stroke prevention in patients with atrial fibrillation.  Journal of Thrombosis and Haemostasis.  10:966-968. 2012
  • Off-Pump or On-Pump Coronary-Artery Bypass Grafting at 30 Days.  New England Journal of Medicine.  366:1489-1497. 2012
  • Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation.  Circulation.  125:1605-1616. 2012
  • Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  184:E329-E336. 2012
  • Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events.  Circulation. Genomic and precision medicine.  5:250-256. 2012
  • Rationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study.  American Heart Journal.  163:535-540.e1. 2012
  • Screening for Dysglycemia in Overweight Youth Presenting for Weight Management.  Diabetes Care.  35:711-716. 2012
  • Urinary Sodium Excretion and Cardiovascular Events—Reply.  Journal of the American Medical Association (JAMA).  307:1139-1139. 2012
  • Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.  Lancet Neurology.  11:225-231. 2012
  • Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal.  Journal of Thrombosis and Haemostasis.  10:502-504. 2012
  • Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial.  Circulation.  125:669-676. 2012
  • Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study.  European Heart Journal.  33:452-466. 2012
  • Reducing cardiovascular mortality through lifestyle change in Japan.  European Heart Journal.  33:428-429. 2012
  • Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation.  Journal of the American College of Cardiology.  59:854-855. 2012
  • Excess of Rare Variants in Non–Genome-Wide Association Study Candidate Genes in Patients With Hypertriglyceridemia.  Circulation. Genomic and precision medicine.  5:66-72. 2012
  • Homocysteine and Coronary Heart Disease: Meta-analysis of MTHFR Case-Control Studies, Avoiding Publication Bias.  PLoS Medicine.  9:e1001177-e1001177. 2012
  • Reply to Letters Regarding Article, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial”.  Circulation.  125:E293-E294. 2012
  • Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY): kidney substudy analytic protocol of an international randomised controlled trial.  BMJ Open.  2:e001080-e001080. 2012
  • Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.  Diabetologia.  55:36-45. 2012
  • Designing and Analyzing Clinical Trials with Composite Outcomes: Consideration of Possible Treatment Differences between the Individual Outcomes.  PLoS ONE.  7:e34785-e34785. 2012
  • Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials.  European Heart Journal.  33:51-60. 2012
  • Environmental Profile of a Community’s Health (EPOCH): An Ecometric Assessment of Measures of the Community Environment Based on Individual Perception.  PLoS ONE.  7:e44410-e44410. 2012
  • Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy.  PLoS ONE.  7:e29849-e29849. 2012
  • Marital Status, Education, and Risk of Acute Myocardial Infarction in Mainland China: The INTER-HEART Study.  Journal of Epidemiology.  22:123-129. 2012
  • Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit.  Diabetes Care.  35:19-24. 2012
  • Rationale and design of The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study: A large international randomized trial in cardiac surgery.  American Heart Journal.  163:1-6. 2012
  • Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes.  Journal of the American College of Cardiology.  59:74-83. 2012
  • The Cost of Clopidogrel Use in Atrial Fibrillation in the ACTIVE-A Trial.  Canadian Journal of Cardiology.  28:95-101. 2012
  • Dronedarone in High-Risk Permanent Atrial Fibrillation.  New England Journal of Medicine.  365:2268-2276. 2011
  • Author Response.  Clinical Trials.  8:726-726. 2011
  • Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group.  Trials.  12:48. 2011
  • What information should a sponsor of a randomized trial receive during its conduct?.  Clinical Trials.  8:716-719. 2011
  • Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events.  Journal of the American Medical Association (JAMA).  306:2229-2238. 2011
  • Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke.  Journal of the American Medical Association (JAMA).  306:2137-2144. 2011
  • Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial.  ACP journal club.  155:660-660. 2011
  • Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.  American Heart Journal.  162:900-906. 2011
  • Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable.  ACP journal club.  155:579-579. 2011
  • Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial.  Journal of Thrombosis and Haemostasis.  9:2168-2175. 2011
  • Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).  Circulation.  124:1727-1736. 2011
  • Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery.  ACP journal club.  155:477-477. 2011
  • Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study.  Journal of Thrombosis and Thrombolysis.  32:378-385. 2011
  • The Effect of Chromosome 9p21 Variants on Cardiovascular Disease May Be Modified by Dietary Intake: Evidence from a Case/Control and a Prospective Study.  PLoS Medicine.  8:e1001106-e1001106. 2011
  • Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.  The Lancet.  378:1231-1243. 2011
  • Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes.  Diabetes Care.  34:1902-1907. 2011
  • Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study.  European Heart Journal.  32:2135-2142. 2011
  • The Fluid Study Protocol: A Randomized Controlled Study on the Effects of Bioimpedance Analysis and Vitamin D on Left Ventricular Mass in Peritoneal Dialysis Patients.  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.  31:529-536. 2011
  • An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of Hypertriglyceridemia.  Arteriosclerosis, Thrombosis and Vascular Biology.  31:1916-1926. 2011
  • Commentary: 'The end of clinical freedom': relevance in the era of evidence-based medicine.  International Journal of Epidemiology.  40:855-858. 2011
  • High-Sensitivity Cardiac Troponin I Measurement for Risk Stratification in a Stable High-Risk Population.  Clinical Chemistry.  57:1146-1153. 2011
  • Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. (vol 377, pg 1409, 2011).  The Lancet.  378:30-30. 2011
  • Association of psychological risk factors and acute myocardial infarction in China: the INTER-HEART China study..  National Medical Journal of China.  124:2083-2088. 2011
  • Body-mass index, abdominal adiposity, and cardiovascular risk.  The Lancet.  378:226-227. 2011
  • Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease.  Journal of the American Society of Nephrology.  22:1353-1364. 2011
  • Department of Error.  The Lancet.  378:30-30. 2011
  • Apixaban in Patients with Atrial Fibrillation REPLY.  New England Journal of Medicine.  364:2363-2364. 2011
  • The authors reply.  New England Journal of Medicine.  364:2363-2364. 2011
  • Medical treatment, PCI, or CABG for coronary artery disease?.  The BMJ.  342:d966-d966. 2011
  • Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal.  Diabetes Care.  34:1265-1269. 2011
  • Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.  Kidney International.  79:1341-1352. 2011
  • Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation.  Circulation.  123:2363-2372. 2011
  • Cigarette pack labelling in 12 countries at different levels of economic development.  Journal of Public Health Policy.  32:146-164. 2011
  • Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes.  EuroIntervention.  7:91-97. 2011
  • Characteristics and Short-Term Prognosis of Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery.  ACP journal club.  154:523-523. 2011
  • Essay for the CIHR/CMAJ award: impact of the Perioperative Ischemic Evaluation (POISE) trial.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  183:E351-E353. 2011
  • A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease.  Nature Genetics.  43:339-344. 2011
  • Department of Error.  The Lancet.  377:1408-1408. 2011
  • Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals.  Journal of Hypertension.  29:623-635. 2011
  • Prognostic Value of Troponin and Creatine Kinase Muscle and Brain Isoenzyme Measurement after Noncardiac Surgery.  Anesthesiology.  114:796-806. 2011
  • Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.  The Lancet.  377:1409-1420. 2011
  • Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk.  Circulation.  123:1098-1107. 2011
  • Irbesartan in Patients with Atrial Fibrillation.  New England Journal of Medicine.  364:928-938. 2011
  • Apixaban in Patients with Atrial Fibrillation.  New England Journal of Medicine.  364:806-817. 2011
  • Estimated Glomerular Filtration Rate and Albuminuria as Predictors of Outcomes in Patients With High Cardiovascular Risk.  ACP journal club.  154:310-310. 2011
  • Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score.  European Heart Journal.  32:581-589. 2011
  • Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.  Diabetologia.  54:487-495. 2011
  • Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data.  The BMJ.  342:d548-d548. 2011
  • Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes.  American Heart Journal.  161:254-260.e4. 2011
  • Parental History and Myocardial Infarction Risk Across the World.  Journal of the American College of Cardiology.  57:619-627. 2011
  • Stemming the global tsunami of cardiovascular disease.  The Lancet.  377:529-532. 2011
  • Albuminuria and Decline in Cognitive Function<subtitle>The ONTARGET/TRANSCEND Studies</subtitle><alt-title>Albuminuria and Decline in Cognitive Function</alt-title>.  JAMA Internal Medicine.  171:142-142. 2011
  • Dabigatran Versus Warfarin in Patients With Atrial Fibrillation.  Circulation.  123:131-136. 2011
  • A Direct Assessment of “Obesogenic”Built Environments: Challenges and Recommendations.  Journal of Environmental and Public Health.  2011:1-8. 2011
  • Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE).  PLoS ONE.  6:e22112-e22112. 2011
  • An international prospective cohort study evaluating major vascular complications among patients undergoing noncardiac surgery: the VISION Pilot Study..  Open Medicine.  5:e193-e200. 2011
  • Double-dose clopidogrel in patients undergoing PCI for ACS – Authors' reply.  The Lancet.  377:298-298. 2011
  • Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -.  Circulation Journal.  75:800-805. 2011
  • Management of Concomitant Cancer and Abdominal Aortic Aneurysm.  Cardiology Research and Practice.  2011:1-10. 2011
  • Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.  Lancet Neurology.  10:43-53. 2011
  • The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.  Journal of Medical Economics.  14:792-797. 2011
  • In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events.  PLoS ONE.  5:e13694-e13694. 2010
  • Dosing of Clopidogrel and Aspirin in Acute Coronary Syndromes REPLY.  New England Journal of Medicine.  363:2467-2468. 2010
  • The authors reply.  New England Journal of Medicine.  363:2467-2468. 2010
  • Environmental Profile of a Community's Health (EPOCH): An Instrument to Measure Environmental Determinants of Cardiovascular Health in Five Countries.  PLoS ONE.  5:e14294-e14294. 2010
  • Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.  Lancet Neurology.  9:1157-1163. 2010
  • Damage to important clinical trials by over-regulation.  Clinical Trials.  7:622-625. 2010
  • Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study.  Diabetologia.  53:2509-2517. 2010
  • Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial.  American Heart Journal.  160:1049-1055. 2010
  • Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non–ST-segment elevation acute coronary syndromes initially treated with fondaparinux.  American Heart Journal.  160:1029-1034.e1. 2010
  • Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study.  American Heart Journal.  160:1178-1184. 2010
  • Testing for heterogeneity among the components of a binary composite outcome in a clinical trial.  BMC Medical Research Methodology.  10:49. 2010
  • Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation.  Circulation.  122:2246-2253. 2010
  • The Polypill in the Prevention of Cardiovascular Diseases.  Circulation.  122:2078-2088. 2010
  • Newly Identified Events in the RE-LY Trial.  New England Journal of Medicine.  363:1875-1876. 2010
  • Cardiovascular disease in India: lessons learnt & challenges ahead..  Indian Journal of Medical Research.  132:529-530. 2010
  • Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.  Diabetic Medicine.  27:1226-1232. 2010
  • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials.  The Lancet.  376:1670-1681. 2010
  • How generalisable is INTERSTROKE? – Authors' reply.  The Lancet.  376:1539-1539. 2010
  • Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.  American Heart Journal.  160:785-794.e10. 2010
  • Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment.  New England Journal of Medicine.  363:1704-1714. 2010
  • Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.  The Lancet.  376:1233-1243. 2010
  • Fine Mapping of the Insulin-Induced Gene 2 Identifies a Variant Associated With LDL Cholesterol and Total Apolipoprotein B Levels.  Circulation. Genomic and precision medicine.  3:454-461. 2010
  • Male and Female Sexual Function and Dysfunction; Andrology.  Investigative Urology.  184:1453-1456. 2010
  • Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study.  Diabetes Care.  33:2250-2253. 2010
  • Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration.  Blood.  116:2160-2163. 2010
  • Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial.  Journal of the American Medical Association (JAMA).  304:1339-1349. 2010
  • Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes.  New England Journal of Medicine.  363:930-942. 2010
  • C-reactive protein is a bystander of cardiovascular disease.  European Heart Journal.  31:2092-2096. 2010
  • C-reactive protein is a mediator of cardiovascular disease.  European Heart Journal.  31:2087-2091. 2010
  • Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.  The Lancet.  376:975-983. 2010
  • Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.  European Heart Journal.  31:2133-2140. 2010
  • Should treatment for heart failure with preserved ejection fraction differ from that for heart failure with reduced ejection fraction?.  The BMJ.  341:c4202-c4202. 2010
  • CANadian Network and Centre for Trials INternationally (CANNeCTIN): A national network for Canadian-led trials in cardiovascular diseases and diabetes mellitus.  Canadian Journal of Cardiology.  26:353-358. 2010
  • Response to Letter Regarding Article, “Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction”.  Circulation.  122:E397-E397. 2010
  • Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes.  Diabetologia.  53:1322-1330. 2010
  • Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: Implications for the evaluation of antidiabetic drugs.  American Heart Journal.  160:1-2. 2010
  • Deciphering the Causes of Cardiovascular and Other Complex Diseases in Populations: Achievements, Challenges, Opportunities, and Approaches.  Progress in Cardiovascular Diseases.  53:62-67. 2010
  • Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme.  European Journal of Heart Failure.  12:738-745. 2010
  • Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance.  Diabetes Care.  33:1629-1634. 2010
  • Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance.  Diabetes Care.  33:1629-1634. 2010
  • Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.  The Lancet.  376:112-123. 2010
  • Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme.  European Journal of Heart Failure.  12:557-565. 2010
  • Does dabigatran improve stroke‐prevention in atrial fibrillation? Reply to a rebuttal.  Journal of Thrombosis and Haemostasis.  8:1438-1439. 2010
  • Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation.  Circulation. Cardiovascular Quality and Outcomes.  3:277-283. 2010
  • Metabolic Syndrome and Risk of Acute Myocardial Infarction.  Journal of the American College of Cardiology.  55:2390-2398. 2010
  • Effect of Combined Aspirin and Extended-Release Dipyridamole Versus Clopidogrel on Functional Outcome and Recurrence in Acute, Mild Ischemic Stroke.  Stroke.  41:732-738. 2010
  • Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients.  Thrombosis Research.  125:e128-e131. 2010
  • Unresolved Issues in the Management of Hypertension.  Hypertension.  55:832-834. 2010
  • Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both.  Circulation.  121:1439-1446. 2010
  • Novel therapeutic concepts * The epidemic of cardiovascular disease in the developing world: global implications.  European Heart Journal.  31:642-648. 2010
  • Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose.  Diabetes Care.  33:608-613. 2010
  • Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.  American Heart Journal.  159:348-353.e1. 2010
  • Which antithrombotic to use during PCI?.  European Heart Journal.  31:522-524. 2010
  • Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes.  Circulation.  121:750-758. 2010
  • Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth.  Atherosclerosis.  208:501-505. 2010
  • Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)‐5 trial.  Journal of Thrombosis and Haemostasis.  8:243-249. 2010
  • Comprehensive Analysis of Genomic Variation in the LPA Locus and Its Relationship to Plasma Lipoprotein(a) in South Asians, Chinese, and European Caucasians.  Circulation. Genomic and precision medicine.  3:39-46. 2010
  • Rationale and Design of INTERSTROKE: A Global Case-Control Study of Risk Factors for Stroke.  Neuroepidemiology.  35:36-44. 2010
  • Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.  European Heart Journal.  31:50-58. 2010
  • Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction.  Circulation.  120:2429-2437. 2009
  • Education and risk for acute myocardial infarction in 52 high, middle and low-income countries: INTERHEART case-control study.  Heart.  95:2014-2022. 2009
  • Environmental and societal influences acting on cardiovascular risk factors and disease at a population level: a review.  International Journal of Epidemiology.  38:1580-1594. 2009
  • Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).  American Journal of Cardiology.  104:1484-1489. 2009
  • Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China study.  Heart.  95:1857-1864. 2009
  • Adherence to medication according to sex and age in the CHARM programme.  European Journal of Heart Failure.  11:1092-1098. 2009
  • Effect of Telmisartan on Functional Outcome, Recurrence, and Blood Pressure in Patients With Acute Mild Ischemic Stroke.  Stroke.  40:3541-3546. 2009
  • Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.  Circulation.  120:1380-1389. 2009
  • Is a Pre-Operative Brain Natriuretic Peptide or N-Terminal Pro–B-Type Natriuretic Peptide Measurement an Independent Predictor of Adverse Cardiovascular Outcomes Within 30 Days of Noncardiac Surgery?.  Journal of the American College of Cardiology.  54:1599-1606. 2009
  • Meta-Analysis of the INSIG2 Association with Obesity Including 74,345 Individuals: Does Heterogeneity of Estimates Relate to Study Design?.  PLoS Genetics.  5:e1000694-e1000694. 2009
  • Multi-Ethnic Genetic Association Study of Carotid Intima-Media Thickness Using a Targeted Cardiovascular SNP Microarray.  Stroke.  40:3173-3179. 2009
  • The Family Atherosclerosis Monitoring In earLY life (FAMILY) study.  American Heart Journal.  158:533-539. 2009
  • Clopidogrel plus aspirin in atrial fibrillation..  New England Journal of Medicine.  361:1314. 2009
  • The authors reply.  New England Journal of Medicine.  361:1314-1315. 2009
  • Dabigatran versus Warfarin in Patients with Atrial Fibrillation.  New England Journal of Medicine.  361:1139-1151. 2009
  • Iatrogenic Adverse Events in the Coronary Care Unit.  Circulation. Cardiovascular Quality and Outcomes.  2:437-442. 2009
  • The Indian Polycap Study (TIPS) – Authors' reply.  The Lancet.  374:782-782. 2009
  • The functional variant rs1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population.  Atherosclerosis.  206:199-203. 2009
  • Acute Coronary Syndromes REPLY.  New England Journal of Medicine.  361:926-927. 2009
  • The authors reply.  New England Journal of Medicine.  361:926-927. 2009
  • Albuminuria in chronic heart failure: prevalence and prognostic importance.  The Lancet.  374:543-550. 2009
  • Big trials, big results, and huge rewards for medicine.  European Heart Journal.  30:1813-1815. 2009
  • Management of stable angina.  The BMJ.  339:b2789-b2789. 2009
  • Dual Renin-Angiotensin System Blockade in Heart Failure.  Journal of the American College of Cardiology.  54:278-278. 2009
  • Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines.  Journal of the American College of Cardiology.  54:468-476. 2009
  • Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.  Journal of Hypertension.  27:1360-1369. 2009
  • Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample.  Journal of Lipid Research.  50:1487-1496. 2009
  • The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease.  Memorias do Instituto Oswaldo Cruz.  104:319-324. 2009
  • The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries.  American Heart Journal.  158:1-7.e1. 2009
  • The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.  Clinical Research in Cardiology.  98:421-433. 2009
  • Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose.  Journal of the American College of Cardiology.  53:2028-2035. 2009
  • Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs.  Clinical Trials.  6:239-251. 2009
  • Prevalence of cardiovascular risk factors in the Middle East: a systematic review.  European Journal of Preventive Cardiology (EJPC).  16:268-280. 2009
  • Early versus Delayed Invasive Intervention in Acute Coronary Syndromes.  New England Journal of Medicine.  360:2165-2175. 2009
  • Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation.  New England Journal of Medicine.  360:2066-2078. 2009
  • Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program.  Diabetes Care.  32:915-920. 2009
  • Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.  American Heart Journal.  157:805-810.e2. 2009
  • Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.  The Lancet.  373:1341-1351. 2009
  • Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.  European Heart Journal.  30:900-907. 2009
  • Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.  Therapeutic Advances in Cardiovascular Disease.  3:113-121. 2009
  • Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction.  American Heart Journal.  157:763-770. 2009
  • Lipid lowering for primary prevention.  The Lancet.  373:1152-1155. 2009
  • Tackling the global burden of stroke: the need for large-scale international studies.  Lancet Neurology.  8:306-307. 2009
  • Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk.  American Heart Journal.  157:502-508. 2009
  • Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme.  Diabetes Research and Clinical Practice.  83:387-393. 2009
  • Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.  European Heart Journal.  30:655-661. 2009
  • Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada.  Atherosclerosis.  203:192-200. 2009
  • Telmisartan did not prevent recurrent stroke or major cardiovascular events.  ACP journal club.  150:JC2-JC2. 2009
  • Genetic Variants Associated With Myocardial Infarction Risk Factors in Over 8000 Individuals From Five Ethnic Groups.  Circulation. Genomic and precision medicine.  2:16-25. 2009
  • Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.  European Heart Journal.  30:338-345. 2009
  • Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.  European Journal of Heart Failure.  11:170-177. 2009
  • Telmisartan in high-risk patients intolerant of ACE inhibitors – Authors' reply.  The Lancet.  373:459-459. 2009
  • The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.  Nature Reviews Cardiology.  6:96-97. 2009
  • Telmisartan for Prevention of Cardiovascular Events Reply.  New England Journal of Medicine.  360:303-303. 2009
  • The authors reply.  New England Journal of Medicine.  360:303. 2009
  • Lipid Profile, Plasma Apolipoproteins, and Risk of a First Myocardial Infarction Among Asians.  Journal of the American College of Cardiology.  53:244-253. 2009
  • Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials.  American Heart Journal.  157:132-140. 2009
  • The repeatability of self reported physical activity patterns in rural South India..  Asia Pacific Journal of Clinical Nutrition.  18:71-75. 2009
  • Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.  European Heart Journal.  29:3022-3028. 2008
  • Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample.  Cardiovascular Diabetology.  7:5. 2008
  • Cardioprotective Effects of Nigella sativa Oil on Cyclosporine A‐Induced Cardiotoxicity in Rats.  Basic and Clinical Pharmacology and Toxicology.  103:574-580. 2008
  • Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program.  Journal of the American College of Cardiology.  52:2000-2007. 2008
  • Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy.  American Heart Journal.  156:1080-1088.e1. 2008
  • Doctors' strikes and mortality: A review.  Social Science and Medicine.  67:1784-1788. 2008
  • Renal outcomes in the ONTARGET study – Authors' reply.  The Lancet.  372:2020-2021. 2008
  • Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes.  Circulation.  118:2038-2046. 2008
  • Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range.  Circulation.  118:2029-2037. 2008
  • Dietary Patterns and the Risk of Acute Myocardial Infarction in 52 Countries.  Circulation.  118:1929-1937. 2008
  • APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia.  Nature Reviews Cardiology.  5:730-737. 2008
  • Cardiovascular sequelae of preeclampsia/eclampsia: A systematic review and meta-analyses.  American Heart Journal.  156:918-930. 2008
  • Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART).  Vascular Medicine.  13:245-253. 2008
  • Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials.  European Heart Journal.  29:2669-2680. 2008
  • Erratum.  Lancet Neurology.  7:985-985. 2008
  • Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.  European Heart Journal.  29:2641-2650. 2008
  • Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial (vol 372, pg 1174, 2008).  The Lancet.  372:1384-1384. 2008
  • Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.  Lancet Neurology.  7:875-884. 2008
  • Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke.  New England Journal of Medicine.  359:1238-1251. 2008
  • Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events.  New England Journal of Medicine.  359:1225-1237. 2008
  • Polygenic determinants of severe hypertriglyceridemia.  Human Molecular Genetics.  17:2894-2899. 2008
  • Does metoprolol prevent adverse outcomes for high-risk patients undergoing noncardiac surgery?.  Journal of Family Practice.  57:573. 2008
  • Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.  The Lancet.  372:1174-1183. 2008
  • β-blocker therapy in non-cardiac surgery – Authors' reply.  The Lancet.  372:1146-1146. 2008
  • The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure.  JAMA Internal Medicine.  168:1699-1699. 2008
  • Dysglycemia and a History of Reproductive Risk Factors.  Diabetes Care.  31:1635-1638. 2008
  • Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.  The Lancet.  372:547-553. 2008
  • Reply.  Journal of the American College of Cardiology.  52:584-586. 2008
  • Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study.  The Lancet.  372:224-233. 2008
  • RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.  Clinical Research in Cardiology.  97:418-431. 2008
  • Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).  American Heart Journal.  156:37-43. 2008
  • Response to Letter Regarding Article, “Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure”.  Circulation.  118:E8-E8. 2008
  • Effects of Intensive Glucose Lowering in Type 2 Diabetes.  New England Journal of Medicine.  358:2545-2559. 2008
  • Erratum.  Clinical Trials.  5:283-283. 2008
  • Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.  European Heart Journal.  29:1377-1385. 2008
  • Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose.  Diabetes Care.  31:1007-1014. 2008
  • Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.  The Lancet.  371:1839-1847. 2008
  • Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk.  Stroke.  39:1482-1486. 2008
  • Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events.  New England Journal of Medicine.  358:1547-1559. 2008
  • Risk factors for myocardial infarction in women and men: insights from the INTERHEART study.  European Heart Journal.  29:932-940. 2008
  • Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data.  The Lancet.  371:1435-1442. 2008
  • Revascularization for Unprotected Left Main Stem Coronary Artery Stenosis.  Journal of the American College of Cardiology.  51:885-892. 2008
  • Response to Letter Regarding Article, “Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation”.  Circulation.  117:E150-E150. 2008
  • Combined Metabolomic and Proteomic Analysis of Human Atrial Fibrillation.  Journal of the American College of Cardiology.  51:585-594. 2008
  • Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.  European Heart Journal.  29:315-323. 2008
  • Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin‐converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Added trial.  European Journal of Heart Failure.  10:157-163. 2008
  • Sensible guidelines for the conduct of large randomized trials.  Clinical Trials.  5:38-39. 2008
  • Specific barriers to the conduct of randomized trials.  Clinical Trials.  5:40-48. 2008
  • The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial.  European Heart Journal.  29:324-331. 2008
  • Correction of Population Stratification in Large Multi-Ethnic Association Studies.  PLoS ONE.  3:e1382-e1382. 2008
  • Development of food frequency questionnaires and a nutrient database for the Prospective Urban and Rural Epidemiological (PURE) pilot study in South India: methodological issues..  Asia Pacific Journal of Clinical Nutrition.  17:178-185. 2008
  • Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis.  The Lancet.  371:117-125. 2008
  • Epidemiology and causation of coronary heart disease and stroke in India.  Heart.  94:16-26. 2008
  • Interrelation of saturated fat, trans fat, alcohol intake, and subclinical atherosclerosis.  American Journal of Clinical Nutrition.  87:168-174. 2008
  • Polypharmacotherapy for primary prevention of cardiovascular disease..  Indian Heart Journal.  60:B29-B33. 2008
  • Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).  American Heart Journal.  155:26.e1-26.e13. 2008
  • Association between the -455T>C promoter polymorphism of the APOC3gene and the metabolic syndrome in a multi-ethnic sample.  BMC Medical Genetics.  8:80. 2007
  • Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?.  Nature Reviews Endocrinology.  3:798-799. 2007
  • Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction.  Journal of the American Medical Association (JAMA).  298:2399-2399. 2007
  • A Family-based Intervention to Promote Healthy Lifestyles in an Aboriginal Community in Canada.  Canadian Journal of Public Health.  98:447-452. 2007
  • Incidence and Predictors of Hyperkalemia in Patients With Heart Failure.  Journal of the American College of Cardiology.  50:1959-1966. 2007
  • Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy.  Journal of the American College of Cardiology.  50:2156-2161. 2007
  • Resequencing Genomic DNA of Patients With Severe Hypertriglyceridemia (MIM 144650).  Arteriosclerosis, Thrombosis and Vascular Biology.  27:2450-2455. 2007
  • Venous thromboembolism in association with features of the metabolic syndrome.  QJM - Monthly Journal of the Association of Physicians.  100:679-684. 2007
  • Appropriate medical management and close follow-up for adherence and efficacy.  New England Journal of Medicine.  357:1763. 2007
  • Clinical decisions. Management of stable coronary disease..  New England Journal of Medicine.  357:1762-1766. 2007
  • Management of Stable Coronary Disease.  New England Journal of Medicine.  357:1762-1766. 2007
  • Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.  Journal of the American College of Cardiology.  50:1742-1751. 2007
  • Global burden of cardiovascular disease.  Heart.  93:1175-1175. 2007
  • Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy.  American Heart Journal.  154:743-750. 2007
  • Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure.  Circulation.  116:1482-1487. 2007
  • Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non–ST-Segment Elevation Acute Coronary Syndromes.  ACP journal club.  147:304-304. 2007
  • Coronary artery disease - Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study.  American Heart Journal.  154:448-453. 2007
  • Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study.  American Heart Journal.  154:448-453. 2007
  • The Editor's Roundtable: Arterial Thrombosis and Acute Coronary Syndromes.  American Journal of Cardiology.  100:974-980. 2007
  • Body Mass Index and Prognosis in Patients With Chronic Heart Failure.  Circulation.  116:627-636. 2007
  • Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation.  Circulation.  116:449-455. 2007
  • Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease.  New England Journal of Medicine.  357:217-227. 2007
  • Quantitating loss of life by smoking a single cigarette.  Clinical Research in Cardiology.  96:522-523. 2007
  • Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure.  Journal of the American College of Cardiology.  50:40-47. 2007
  • Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).  American Heart Journal.  154:94-101. 2007
  • Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure.  Circulation.  115:3111-3120. 2007
  • Acute coronary syndromes without ST segment elevation.  The BMJ.  334:1265-1269. 2007
  • Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods.  American Journal of Cardiology.  99:S21-S33. 2007
  • Capacity planning for cardiac catheterization: A case study.  Health Policy.  82:1-11. 2007
  • Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.  European Heart Journal.  28:1382-1388. 2007
  • Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.  Clinical Trials.  4:218-234. 2007
  • Response to Letter Regarding Article, “The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets?”.  Circulation.  115:E476-E476. 2007
  • Risk Factors for Early Myocardial Infarction in South Asians—Reply.  Journal of the American Medical Association (JAMA).  297:1880-1880. 2007
  • Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system.  Journal of Hypertension.  25:951-958. 2007
  • Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme.  European Journal of Heart Failure.  9:510-517. 2007
  • Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure.  Epidemiology and Infection.  135:574-582. 2007
  • Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure.  Epidemiology and Infection.  135:574-582. 2007
  • Stroke and Cardiovascular Diseases: The Need for a Global Approach for Prevention and Drug Development.  International Journal of Stroke.  2:104-108. 2007
  • Defining Obesity Cut Points in a Multiethnic Population.  Circulation.  115:2111-2118. 2007
  • Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.  European Journal of Preventive Cardiology (EJPC).  14:312-318. 2007
  • Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk.  Circulation.  115:1371-1375. 2007
  • Risk Factors for Acute Myocardial Infarction in Latin America.  Circulation.  115:1067-1074. 2007
  • Effect of ramipril on the incidence of diabetes - Reply.  New England Journal of Medicine.  356:523-524. 2007
  • The authors reply [6].  New England Journal of Medicine.  356:523-524. 2007
  • Risk Factors for Early Myocardial Infarction in South Asians Compared With Individuals in Other Countries.  Journal of the American Medical Association (JAMA).  297:286-286. 2007
  • Carbohydrate intake and HDL in a multiethnic population.  American Journal of Clinical Nutrition.  85:225-230. 2007
  • Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.  European Journal of Heart Failure.  9:83-91. 2007
  • Monitoring the randomized trials of the Women's Health Initiative the experience of the data and safety monitoring board.  Clinical Trials.  4:218-234. 2007
  • Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.  Heart.  93:59-64. 2007
  • Prevalence of traditional cardiovascular risk factors among Nigerians with stroke..  SAMJ - South African Medical Journal.  18:290-294. 2007
  • Prevention of vascular events in atrial fibrillation – Authors' reply.  The Lancet.  369:106-106. 2007
  • Rationale, Design and Baseline Data of a Randomized, Double-Blind, Controlled Trial Comparing Two Antithrombotic Regimens (a Fixed-Dose Combination of Extended-Release Dipyridamole plus ASA with Clopidogrel) and Telmisartan versus Placebo in Patients with Strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).  Cerebrovascular Diseases.  23:368-380. 2007
  • Rosiglitazone delays the development of diabetes mellitus (DREAM trial).  Cleveland Clinic Journal of Medicine.  74:64-64. 2007
  • Independent design and conduct of clinical trials.  Clinical Trials.  3:503-507. 2006
  • Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study.  American Journal of Kidney Diseases.  48:889-896. 2006
  • Reply.  Journal of the American College of Cardiology.  48:2357-2357. 2006
  • The DREAM trial – Authors' reply.  The Lancet.  368:2050-2051. 2006
  • Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction—Reply.  Journal of the American Medical Association (JAMA).  296:2087-2087. 2006
  • In reply [4].  Journal of the American Medical Association (JAMA).  296:2088-2089. 2006
  • Effect of Ramipril on the Incidence of Diabetes.  New England Journal of Medicine.  355:1551-1562. 2006
  • The Inflammatory Hypothesis.  Circulation.  114:1557-1560. 2006
  • Social disadvantage and cardiovascular disease: development of an index and analysis of age, sex, and ethnicity effects.  International Journal of Epidemiology.  35:1239-1245. 2006
  • Unmasking of the Brugada Syndrome Phenotype During the Acute Phase of Amiodarone Infusion.  Circulation.  114:e489-e491. 2006
  • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.  The Lancet.  368:1096-1105. 2006
  • Impact of Ramipril on the Circadian Periodicity of Acute Myocardial Infarction.  American Journal of Cardiology.  98:758-760. 2006
  • Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?.  European Heart Journal.  27:2154-2157. 2006
  • The burden of cardiovascular disease in the Indian subcontinent..  Indian Journal of Medical Research.  124:235-244. 2006
  • Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes.  Circulation.  114:774-782. 2006
  • Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.  Circulation.  114:774-782. 2006
  • Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.  The Lancet.  368:581-588. 2006
  • Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) Trial: A randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery.  American Heart Journal.  152:223-230. 2006
  • Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study.  The Lancet.  368:647-658. 2006
  • Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study.  Circulation.  114:201-208. 2006
  • Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing.  Circulation.  114:11-17. 2006
  • A cardiologist's guide to waist management.  Heart.  92:865-866. 2006
  • Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.  American Heart Journal.  152:86-92. 2006
  • The decline of academic medicine.  The Lancet.  368:284-284. 2006
  • Enoxaparin versus Unfractionated Heparin in ST-Elevation Myocardial Infarction.  New England Journal of Medicine.  354:2830-2832. 2006
  • Fondaparinux versus enoxaparin in acute coronary syndromes - Reply.  New England Journal of Medicine.  354:2830-2830. 2006
  • Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.  The Lancet.  367:1903-1912. 2006
  • Endovascular repair of abdominal aortic aneurysms in patients with severe angulation of the proximal neck using a flexible stent-graft: European Multicenter Experience..  Journal of Cardiovascular Surgery.  47:245-250. 2006
  • Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.  American Heart Journal.  151:1187-1193. 2006
  • Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.  European Heart Journal.  27:1447-1458. 2006
  • What Is the Economic Value of Digoxin Therapy in Congestive Heart Failure Patients? Results From the DIG Trial.  Journal of Cardiac Failure.  12:336-342. 2006
  • Preventing Vascular Events Due to Elevated Blood Pressure.  Circulation.  113:2166-2168. 2006
  • Preventing vascular events due to elevated blood pressure.  Circulation.  113:2166-2168. 2006
  • Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction.  Journal of the American College of Cardiology.  47:1997-2004. 2006
  • Early Versus Delayed Enalapril in Patients With Left Ventricular Systolic Dysfunction: Impact on Morbidity and Mortality 15 Years After the SOLVD Trial.  Journal of the American College of Cardiology.  47:1904-1905. 2006
  • Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program..  American Heart Journal.  151:985-991. 2006
  • Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial.  American Heart Journal.  151:985-991. 2006
  • [Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries in a case-control study based on the INTERHEART study]..  Orvosi Hetilap.  147:675-686. 2006
  • Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease.  New England Journal of Medicine.  354:1567-1577. 2006
  • Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes.  New England Journal of Medicine.  354:1464-1476. 2006
  • Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial.  Journal of the American Medical Association (JAMA).  295:1519-1530. 2006
  • An evaluation of door to needle time (DNT) of thrombolytic therapy following acute myocardial infarction in three large tertiary referral hospitals in Dhaka City..  Bangladesh Medical Research Council Bulletin.  32:29-34. 2006
  • Obesity and risk of myocardial infarction: the INTERHEART study – Author's reply.  The Lancet.  367:1054-1054. 2006
  • Corrigendum to “Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta‐analysis” [Eur J Heart Fail 7 (2005) 1133—1144].  European Journal of Heart Failure.  8:223-224. 2006
  • Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure.  Circulation.  113:986-994. 2006
  • Effect of Crude Methanol Extract ofTerminalia avicennioidesin Normal Gastric/Histamine-Induced HCl Secretions in Rats.  Journal of Herbs, Spices and Medicinal Plants.  12:29-37. 2006
  • Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure.  Circulation.  113:671-678. 2006
  • Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials.  American Heart Journal.  151:282-287. 2006
  • Effect of angiotensin‐converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction—a meta‐analysis.  European Journal of Heart Failure.  8:90-96. 2006
  • Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.  American Heart Journal.  151:219-227. 2006
  • Predictors of mortality and morbidity in patients with chronic heart failure.  European Heart Journal.  27:65-75. 2006
  • Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial.  Canadian Journal of Cardiology.  22:47-53. 2006
  • The effects of oral anticoagulants in patients with peripheral arterial disease: Rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials.  American Heart Journal.  151:1-9. 2006
  • Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction.  Circulation.  112:3855-3867. 2005
  • Routine vs Selective Invasive Strategies in Acute Coronary Syndromes.  Journal of the American Medical Association (JAMA).  294:2844-2844. 2005
  • Routine vs Selective Invasive Strategies in Acute Coronary Syndromes—Reply.  Journal of the American Medical Association (JAMA).  294:2844-2844. 2005
  • Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients.  Circulation.  112:3738-3744. 2005
  • Aspirin improves the outcome of intra-arterial thrombolysis with tissue plasminogen activator.  British Journal of Surgery.  82:1357-1358. 2005
  • Risk Factors Associated With Myocardial Infarction in Africa.  Circulation.  112:3554-3561. 2005
  • Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.  The Lancet.  366:2005-2011. 2005
  • Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.  American Heart Journal.  150:1177-1184. 2005
  • Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes.  American Heart Journal.  150:1107.e1-1107.e10. 2005
  • Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta‐analysis.  European Journal of Heart Failure.  7:1133-1144. 2005
  • Differences in the Management and Prognosis of Women and Men Who Suffer From Acute Coronary Syndromes.  Journal of the American College of Cardiology.  46:1845-1851. 2005
  • Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention.  European Heart Journal.  26:2396-2403. 2005
  • Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study.  The Lancet.  366:1640-1649. 2005
  • Racial differences in outcome and treatment effect in congestive heart failure.  American Heart Journal.  150:968-976. 2005
  • WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE)..  Bulletin of the World Health Organization.  83:820-829. 2005
  • Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure.  Journal of the American Medical Association (JAMA).  294:1794-1794. 2005
  • Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.  The Lancet.  366:1267-1278. 2005
  • Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  173:779-788. 2005
  • Deciphering the sinus tachycardias - Reply.  Clinical Cardiology.  28:401-401. 2005
  • Intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI.  ACP journal club.  143:43-43. 2005
  • The nutrition transition in India.  South African Journal of Clinical Nutrition.  18:198-201. 2005
  • The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.  Diabetologia.  48:1749-1755. 2005
  • Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both.  American Journal of Cardiology.  96:698-704. 2005
  • Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes.  Circulation.  112:1339-1346. 2005
  • How strong is the evidence for the use of perioperative β blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials.  The BMJ.  331:313-321. 2005
  • Determining optimal population rates of cardiac catheterization: A phantom alternative?.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  173:49-52. 2005
  • Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure.  Circulation.  112:48-53. 2005
  • Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes.  Journal of the American Medical Association (JAMA).  293:2908-2908. 2005
  • Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study.  International Journal of Obesity.  29:656-667. 2005
  • Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial—Reply.  Journal of the American Medical Association (JAMA).  293:2596-2596. 2005
  • Glucose-insulin-potassium infusion and mortality in the CREATE-ECLA trial..  Journal of the American Medical Association (JAMA).  293:2596-2597. 2005
  • Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.  European Journal of Heart Failure.  7:650-656. 2005
  • Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.  Journal of the American College of Cardiology.  45:1832-1839. 2005
  • Reviparin in Acute Myocardial Infarction—Reply.  Journal of the American Medical Association (JAMA).  293:2595-2595. 2005
  • Reviparin in acute myocardial infarction..  Journal of the American Medical Association (JAMA).  293:2595. 2005
  • Protein Intake Is Inversely Associated with Abdominal Obesity in a Multi-Ethnic Population.  Journal of Nutrition.  135:1196-1201. 2005
  • Commentary: Insights from cross-population studies: Rose revisited.  International Journal of Epidemiology.  34:244-246. 2005
  • Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention.  Circulation.  111:1390-1397. 2005
  • Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer.  Journal of the American Medical Association (JAMA).  293:1338-1338. 2005
  • Effects of long-term supplementation on and cancer vitamin E cardiovascular events - A randomized controlled trial.  Journal of the American Medical Association (JAMA).  293:1338-1347. 2005
  • ACE Inhibition in Stable Coronary Artery Disease.  New England Journal of Medicine.  352:937-939. 2005
  • Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.  Journal of the American College of Cardiology.  45:838-845. 2005
  • Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE Study.  Clinical Nephrology.  63:181-187. 2005
  • Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.  Journal of the American College of Cardiology.  45:391-399. 2005
  • Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.  European Journal of Preventive Cardiology (EJPC).  12:75-81. 2005
  • Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction.  Journal of the American Medical Association (JAMA).  293:437-437. 2005
  • Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation.  Journal of the American Medical Association (JAMA).  293:427-427. 2005
  • Need for expertise based randomised controlled trials.  The BMJ.  330:88-88. 2005
  • Risks and benefits of  -blockade.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  172:14-14. 2005
  • Risks and benefits of  -blockade.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  172:14-15. 2005
  • Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes.  Canadian Journal of Physiology and Pharmacology.  83:98-103. 2005
  • INTERHEART.  The Lancet.  365:117-117. 2005
  • INTERHEART.  The Lancet.  365:119-120. 2005
  • INTERHEART.  The Lancet.  365:118-118. 2005
  • Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease.  American Heart Journal.  149:54-60. 2005
  • The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences.  Scandinavian Journal of Clinical and Laboratory Investigation.  65:143-156. 2005
  • Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2..  Indian Heart Journal.  57:217-225. 2005
  • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (vol 364, pg 937m 2004).  The Lancet.  364:2020-2020. 2004
  • Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: The CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction.  American Heart Journal.  148:1068-1078. 2004
  • Department of Error.  The Lancet.  364:2020-2020. 2004
  • The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study..  European Journal of Preventive Cardiology (EJPC).  11:460-465. 2004
  • Effect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.  European Heart Journal.  25:1920-1926. 2004
  • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (vol 364, pg 937, 2004).  The Lancet.  364:1938-1938. 2004
  • Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction.  Circulation.  110:2618-2626. 2004
  • Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.  Cochrane Database of Systematic Reviews.  CD003611. 2004
  • Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients.  Circulation.  110:2180-2183. 2004
  • Randomized clinical trials: Slow death by a thousand unnecessary policies?.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  171:889-892. 2004
  • Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians.  Atherosclerosis.  176:361-370. 2004
  • Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians.  Atherosclerosis.  176:361-370. 2004
  • Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction.  Circulation.  110:1413-1417. 2004
  • Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome.  Circulation.  110:1202-1208. 2004
  • Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study.  The Lancet.  364:953-962. 2004
  • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.  The Lancet.  364:937-952. 2004
  • Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.  Diabetologia.  47:1519-1527. 2004
  • Are the recommendations to use perioperative beta-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence?.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  171:245-247. 2004
  • Are the recommendations to use perioperative  -blocker therapy in patients undergoing noncardiac surgery based on reliable evidence?.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  171:245-247. 2004
  • C-Reactive Protein as a Screening Test for Cardiovascular Risk in a Multiethnic Population.  Arteriosclerosis, Thrombosis and Vascular Biology.  24:1509-1515. 2004
  • Transforming the scientific, health care, and sociopolitical culture of an entire country through clinical research: The story of GISSI.  American Heart Journal.  148:193-195. 2004
  • Newspaper Articles as a Tool for Cardiovascular Prevention Programs in a Developing Country.  Journal of Health Communication.  9:355-369. 2004
  • Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.  American Heart Journal.  148:52-61. 2004
  • Tackling the challenge of cardiovascular disease burden in developing countries.  American Heart Journal.  148:1-4. 2004
  • The McMaster- Lancet health and peace conferences.  The Lancet.  364:311-312. 2004
  • Principles for National and Regional Guidelines on Cardiovascular Disease Prevention.  Circulation.  109:3112-3121. 2004
  • Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction.  Journal of the American College of Cardiology.  43:2200-2206. 2004
  • Quantification of mitochondrial sublimons in human fibrillating atria.  Clinical Science.  106:653-659. 2004
  • Cost‐effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long‐term model based on the cure trial.  Journal of Internal Medicine.  255:562-570. 2004
  • Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study.  Kidney International.  65:1375-1380. 2004
  • Prevalence of mitral valve prolapse in ethnic groups..  Canadian Journal of Cardiology.  20:511-515. 2004
  • A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction.  American Journal of Medicine.  116:300-304. 2004
  • Candesartan reduced mortality and hospital admissions in chronic heart failure.  BMJ Evidence-Based Medicine.  9:44-45. 2004
  • Canadian Trial of Physiological Pacing.  Circulation.  109:357-362. 2004
  • Effect of combined high pressure and mild heat on carrot pectinmethylesterase activity..  Communications in agricultural and applied biological sciences.  69:195-198. 2004
  • Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease.  European Heart Journal.  25:17-24. 2004
  • ACE inhibitors reduce all-cause mortality in people with asymptomatic or symptomatic left ventricular dysfunction.  Evidence-based Cardiovascular Medicine.  7:186-188. 2003
  • Lessons learned from the DIG trial.  Contemporary Clinical Trials.  24:S316-S326. 2003
  • Overview of the DIG trial.  Contemporary Clinical Trials.  24:S269-S276. 2003
  • Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.  European Journal of Preventive Cardiology (EJPC).  10:420-428. 2003
  • The role of the data coordinating center in the DIG trial.  Contemporary Clinical Trials.  24:S277-S288. 2003
  • The role of the pharmacy coordinating center in the DIG trial.  Contemporary Clinical Trials.  24:S289-S297. 2003
  • Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina.  Circulation.  108:2439-2445. 2003
  • Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.  The Lancet.  362:1527-1535. 2003
  • Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity..  Canadian Journal of Cardiology.  19:1387-1391. 2003
  • Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: Results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.  American Journal of Kidney Diseases.  42:936-942. 2003
  • Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.  American Journal of Kidney Diseases.  42:936-942. 2003
  • The CHARM programme.  The Lancet.  362:1678-1679. 2003
  • The CHARM programme.  The Lancet.  362:1675-1676. 2003
  • Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes.  Circulation.  108:1682-1687. 2003
  • Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure.  European Heart Journal.  24:1727-1734. 2003
  • Conundrum of the HOPE study: Authors' reply.  The BMJ.  327:682-682. 2003
  • Clopidogrel reduces ischemic events in the short and long term after acute coronary syndromes.  Evidence-based Cardiovascular Medicine.  7:122-123. 2003
  • Development and evaluation of cultural food frequency questionnaires for South Asians, Chinese, and Europeans in North America.  Journal of the Academy of Nutrition and Dietetics.  103:1178-1184. 2003
  • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.  The Lancet.  362:777-781. 2003
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.  The Lancet.  362:772-776. 2003
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.  The Lancet.  362:767-771. 2003
  • Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.  The Lancet.  362:759-766. 2003
  • New evidence on the importance of the renin???angiotensin system in the treatment of higher-risk patients with hypertension.  Journal of Hypertension.  21:1599-1608. 2003
  • Methodologic Issues in Randomized Controlled Trials of Surgical Interventions.  Clinical Orthopaedics and Related Research.  413:25-32. 2003
  • Tackling the growing global burden of atherosclerotic cardiovascular diseases.  European Journal of Preventive Cardiology (EJPC).  10:236-239. 2003
  • The evolution of the randomized controlled trial and its role in evidence‐based decision making.  Journal of Internal Medicine.  254:105-113. 2003
  • Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease.  Circulation.  108:420-425. 2003
  • Primary angioplasty for ST-segment elevation myocardial infarction: ready for prime time?.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  169:32-35. 2003
  • More than just hype [4] (multiple letters).  CANADIAN MEDICAL ASSOCIATION JOURNAL.  168:1646-1648. 2003
  • More than just hype..  CANADIAN MEDICAL ASSOCIATION JOURNAL.  168:1646. 2003
  • Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin.  Circulation.  107:2884-2888. 2003
  • Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme.  European Journal of Heart Failure.  5:261-270. 2003
  • Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.  The Lancet.  361:1843-1848. 2003
  • The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure..  Canadian Journal of Cardiology.  19:347-356. 2003
  • Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.  Circulation.  107:1284-1290. 2003
  • Development of Renal Disease in People at High Cardiovascular Risk.  Journal of the American Society of Nephrology.  14:641-647. 2003
  • Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.  The Lancet.  361:1077-1083. 2003
  • Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study.  Circulation.  107:960-965. 2003
  • Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes.  Circulation.  107:966-972. 2003
  • The evolving role of direct thrombin inhibitors in acute coronary syndromes..  Journal of the American College of Cardiology.  41:70S-78S. 2003
  • Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic Population.  Diabetes Care.  26:290-296. 2003
  • Heart Protection Study.  The Lancet.  361:530-530. 2003
  • Heart Protection Study.  The Lancet.  361:528-528. 2003
  • Oral anticoagulants in patients with coronary artery disease.  Journal of the American College of Cardiology.  41:S62-S69. 2003
  • Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.  Journal of the American College of Cardiology.  41:S79-S88. 2003
  • The evolving role of direct thrombin inhibitors in acute coronary syndromes.  Journal of the American College of Cardiology.  41:S70-S78. 2003
  • Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study.  Circulation.  107:251-257. 2003
  • Preventing stroke with ramipril---authors' reply.  The BMJ.  326:52-52. 2003
  • Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies.  European Heart Journal, Supplement.  5:A43-A48. 2003
  • Oral Anticoagulant Therapy in Patients with Coronary Artery Disease.  Seminars in Thrombosis and Hemostasis.  03:323-332. 2003
  • Singapore and coronary heart disease: a population laboratory to explore ethnic variations in the epidemiologic transition.  European Heart Journal.  24:127-129. 2003
  • Singapore and coronary heart disease: a population laboratory to explore ethnic variations in the epidemiologic transition.  European Heart Journal.  24:127-129. 2003
  • The Relationship Between Dysglycemia and Atherosclerosis in South Asian, Chinese, and European Individuals in Canada.  Diabetes Care.  26:144-149. 2003
  • A Lifetime of Prevention.  Circulation.  106:2997-2998. 2002
  • Role of infarct size in explaining the higher mortality in older patients with acute myocardial infarction.  American Journal of Cardiology.  90:1370-1374. 2002
  • The relevance of subgroup-specific treatment effects: The Studies Of Left Ventricular Dysfunction (SOLVD) revisited.  American Heart Journal.  144:941-947. 2002
  • A letter from CMAJ's editorial board to the CMA..  CANADIAN MEDICAL ASSOCIATION JOURNAL.  167:1230. 2002
  • Reasons for Resistance to Aspirin in Cardiovascular Disease.  Circulation.  106:1-2. 2002
  • Reasons for resistance to aspirin in cardiovascular disease..  Circulation.  106:e181-e182. 2002
  • Relationship of Anti-60 kDa Heat Shock Protein and Anti-Cholesterol Antibodies to Cardiovascular Events.  Circulation.  106:2775-2780. 2002
  • The risks of waiting for cardiac catheterization: a prospective study..  CANADIAN MEDICAL ASSOCIATION JOURNAL.  167:1233-1240. 2002
  • Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes.  European Heart Journal.  23:1771-1779. 2002
  • Reserving judgement on HRT - Response.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  167:1105-1105. 2002
  • Reserving judgement on HRT..  CANADIAN MEDICAL ASSOCIATION JOURNAL.  167:1104-1105. 2002
  • Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes.  Diabetes Care.  25:1919-1927. 2002
  • Reserving judgement on HRT.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  167:1105-1105. 2002
  • Clinical research and trials in developing countries.  Statistics in Medicine.  21:2859-2867. 2002
  • Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.  The Lancet.  360:1037-1043. 2002
  • Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups.  Circulation.  106:1622-1626. 2002
  • Myocardial infarction in South Asians - Four of the authors respond.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  167:454-455. 2002
  • Myocardial infarction in South Asians..  CANADIAN MEDICAL ASSOCIATION JOURNAL.  167:454. 2002
  • Myocardial infarction in South Asians.  CANADIAN MEDICAL ASSOCIATION JOURNAL.  167:454-455. 2002
  • Who is fooling us?.  The Lancet.  360:873-874. 2002
  • Hormone replacement therapy: a time for pause..  CANADIAN MEDICAL ASSOCIATION JOURNAL.  167:357-359. 2002
  • Direct thrombin inhibitors in acute coronary syndromes.  The Lancet.  360:491-492. 2002
  • Direct thrombin inhibitors in acute coronary syndromes.  The Lancet.  360:492-492. 2002
  • Effect of long-term therapy with ramipril in high-risk women.  Journal of the American College of Cardiology.  40:693-702. 2002
  • Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis..  Cochrane Database of Systematic Reviews.  106:75-80. 2002
  • Effects of exercise training in patients with heart failure: The Exercise Rehabilitation Trial (EXERT).  American Heart Journal.  144:23-30. 2002
  • Two decades of progress in preventing vascular disease.  The Lancet.  360:2-3. 2002
  • Ramipril and cardiovascular risk reduction - Response.  Circulation.  105:A194-A195. 2002
  • Blood pressure and cardiovascular risk in the HOPE study.  The Lancet.  359:2118-2118. 2002
  • Blood pressure and cardiovascular risk in the HOPE study.  The Lancet.  359:2117-2118. 2002
  • Urate levels as a predictor of cardiac deaths: causal relation or mere association?.  European Heart Journal.  23:760-761. 2002
  • Cardiovascular Outcomes and Renal Disease.  ACP journal club.  136:634-634. 2002
  • Cardiovascular Outcomes and Renal Disease.  ACP journal club.  136:633-633. 2002
  • A pill for every ill - Response.  Circulation.  105:E82-E82. 2002
  • Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events.  Circulation.  105:1650-1655. 2002
  • Use of ramipril in preventing stroke: double blind randomised trial.  The BMJ.  324:699-699. 2002
  • Risk factors, hospital management and outcomes after acute myocardial infarction in South Asian Canadians and matched control subjects..  CANADIAN MEDICAL ASSOCIATION JOURNAL.  166:717-722. 2002
  • Notes.  Biomedicine and Pharmacotherapy.  56:60-61. 2002
  • A symposium: New frontiers in cardiovascular clinical trials: The ontarget study in high-risk patients - Introduction.  American Journal of Cardiology.  89:1A-2A. 2002
  • Angiotensin II and trials of cardiovascular outcomes - Discussion.  American Journal of Cardiology.  89:16A-17A. 2002
  • From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis - Discussion.  American Journal of Cardiology.  89:25A-26A. 2002
  • Treatment of Acute Coronary Syndromes.  New England Journal of Medicine.  346:206-208. 2002
  • Treatment of acute coronary syndromes - Reply.  New England Journal of Medicine.  346:207-208. 2002
  • Effect of ramipril and vitamin E on atherosclerosis - Response.  Circulation.  105:E5-E6. 2002
  • Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention.  European Heart Journal.  23:117-123. 2002
  • Ramipril and Risk of Diabetes—Reply.  Journal of the American Medical Association (JAMA).  287:186-186. 2002
  • Cardiovascular Risk in Patients with Early Renal Insufficiency.  American Journal of Cardiovascular Drugs.  2:157-162. 2002
  • Choice of clinical outcomes in randomized trials of heart failure therapies: Disease-specific or overall outcomes?.  American Heart Journal.  143:22-28. 2002
  • Clopidogrel and percutaneous coronary intervention.  The Lancet.  359:169-169. 2002
  • Clopidogrel and percutaneous coronary intervention.  The Lancet.  359:169-169. 2002
  • Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.  The Lancet.  359:294-302. 2002
  • From the hope to the ontarget and the transcend studies: challenges in improving prognosis.  American Journal of Cardiology.  89:18-25. 2002
  • The Global Epidemic of Atherosclerotic Cardiovascular Disease.  Medical Principles and Practice.  11:3-8. 2002
  • The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis.  Journal of the American College of Cardiology.  39:30-36. 2002
  • The value of large, robust trials: the HOPE study.  Practical Diabetes.  19:29-30. 2002
  • Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.  Cochrane Database of Systematic Reviews.  CD003463. 2002
  • Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation.  New England Journal of Medicine.  345:1716-1716. 2001
  • Global Burden of Cardiovascular Diseases.  Circulation.  104:2855-2864. 2001
  • Blood-pressure reduction and cardiovascular risk in HOPE study.  The Lancet.  358:2130-2131. 2001
  • Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures.  Hypertension.  38:E28-E32. 2001
  • Comparative effects of Ramipril on ambulatory and office blood pressures - A HOPE substudy.  Hypertension.  38:1480-1480. 2001
  • The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure..  Canadian Journal of Cardiology.  17 Suppl E:5E-25E. 2001
  • Global Burden of Cardiovascular Diseases.  Circulation.  104:2746-2753. 2001
  • Acute Precipitants of Congestive Heart Failure Exacerbations.  JAMA Internal Medicine.  161:2337-2337. 2001
  • Ramipril and the Development of Diabetes.  Journal of the American Medical Association (JAMA).  286:1882-1882. 2001
  • Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril.  Circulation.  104:1615-1621. 2001
  • Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure.  American Heart Journal.  142:698-703. 2001
  • Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP).  The Lancet.  358:1147-1153. 2001
  • Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation.  New England Journal of Medicine.  345:837-839. 2001
  • Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study.  Journal of the American College of Cardiology.  38:806-813. 2001
  • Tackling the growing epidemic of cardiovascular disease in South Asia∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology..  Journal of the American College of Cardiology.  38:688-689. 2001
  • Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation.  New England Journal of Medicine.  345:494-502. 2001
  • Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.  The Lancet.  358:527-533. 2001
  • Effects of Ramipril on Coronary Events in High-Risk Persons.  Circulation.  104:522-526. 2001
  • Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals.  Journal of the American Medical Association (JAMA).  286:421-421. 2001
  • Stroke in Relation to Cardiac Procedures in Patients With Non–ST-Elevation Acute Coronary Syndrome.  Circulation.  104:269-274. 2001
  • Relationship Between Pacemaker Dependency and the Effect of Pacing Mode on Cardiovascular Outcomes.  Circulation.  103:3081-3085. 2001
  • EDITORIAL.  Evidence-based Cardiovascular Medicine.  5:31-31. 2001
  • Electrical cardioversion preceded by TEE was no more effective than a conventional strategy of cardioversion but did prevent hemorrhagic events.  Evidence-based Cardiovascular Medicine.  5:65-67. 2001
  • Health and peace: time for a new discipline.  The Lancet.  357:1460-1461. 2001
  • INTER-HEART: A global study of risk factors for acute myocardial infarction.  American Heart Journal.  141:711-721. 2001
  • Overutilization and underutilization of thrombolysis in routine clinical practice∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology..  Journal of the American College of Cardiology.  37:1588-1589. 2001
  • Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction.  Journal of the American College of Cardiology.  37:1677-1682. 2001
  • Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial.  ACP journal club.  134:629-629. 2001
  • The Data and Safety Monitoring Committee: Some final thoughts.  American Heart Journal.  141:548-549. 2001
  • Previous exposure to Chlamydia pneumoniae, Helicobacter pylori and other infections in Canadian patients with ischemic heart disease..  Canadian Journal of Cardiology.  17:270-276. 2001
  • Effects of Ramipril and Vitamin E on Atherosclerosis.  Circulation.  103:919-925. 2001
  • Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation.  Circulation.  103:643-650. 2001
  • Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina.  Journal of the American College of Cardiology.  37:475-484. 2001
  • Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials.  Journal of the American Medical Association (JAMA).  285:444-444. 2001
  • Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study.  European Heart Journal.  22:103-104. 2001
  • Angiotensin-converting enzyme inhibitors as a new frontier in cardiovascular prevention: Results of the HOPE trial.  International Journal of Clinical Practice, Supplement.  7-7. 2001
  • Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction11Drs. Mehta and Eikelboom were recipients of Heart and Stroke Foundation of Canada Research Fellowship Awards. Professor Yusuf is the recipient of a Medical Research Council of Canada Senior Scientist Award and holds a Heart and Stroke Foundation of Ontario Research Chair..  Journal of the American College of Cardiology.  37:37-43. 2001
  • Increased risk of acute myocardial infarction associated with beedi and cigarette smoking in Indians: final report on tobacco risks from a case-control study..  Indian Heart Journal.  53:731-735. 2001
  • Validity of the US Behavioral Risk Factor Surveillance System's health related quality of life survey tool in a group of older Canadians..  Chronic Diseases and Injuries in Canada.  22:93-101. 2001
  • Vitamin E supplementation in coronary artery disease and atherosclerosis.  Surgeon.  30:90-93. 2001
  • The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.  European Heart Journal.  21:2033-2041. 2000
  • ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations.  Indian Journal of Thoracic and Cardiovascular Surgery.  16:110-128. 2000
  • Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials.  The Lancet.  356:1955-1964. 2000
  • HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction - Pharmacological approaches.  Prevention and Management of Congestive Heart Failure.  6. 2000
  • [After the HOPE Study. ACE inhibitor now for every diabetic patient?. Interview by Dr. Dirk Einecke]..  MMW Fortschritte der Medizin.  142:10. 2000
  • Intracranial haemorrhage with bolus thrombolytic agents.  The Lancet.  356:1850-1850. 2000
  • Intracranial haemorrhage with bolus thrombolytic agents.  The Lancet.  356:1848-1848. 2000
  • Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: A critical analysis based on 100 studies.  Progress in Cardiovascular Diseases.  43:171-196. 2000
  • Incidence, Predictive Factors, and Prognostic Significance of Supraventricular Tachyarrhythmias in Congestive Heart Failure.  Chest.  118:914-922. 2000
  • Recommendations for national and local regulatory authorities concerning research in genetic markers of disease.  American Heart Journal.  140:S3-S5. 2000
  • Functional capacity in patients with congestive heart failure.  Journal of Cardiac Failure.  6:214-219. 2000
  • Management of unstable angina and myocardial infarction.  The Lancet.  356:1193-1194. 2000
  • Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial.  European Heart Journal.  21:1473-1481. 2000
  • Vitamin E did not reduce myocardial infarction, death, or stroke in adults at high risk for cardiovascular events.  BMJ Evidence-Based Medicine.  5:137-137. 2000
  • Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction.  Circulation.  102:1014-1019. 2000
  • Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.  European Heart Journal.  21:1368-1375. 2000
  • Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis.  The Lancet.  356:449-454. 2000
  • The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction.  Heart.  84:142-148. 2000
  • Effect of Ramipril on Cardiovascular Events in High-Risk Patients.  New England Journal of Medicine.  343:64-66. 2000
  • Effect of ramipril on cardiovascular events in high-risk patients. Reply.  New England Journal of Medicine.  343:66-66. 2000
  • Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases.  Current Cardiology Reports.  2:293-299. 2000
  • Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE).  The Lancet.  356:279-284. 2000
  • Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients.  New England Journal of Medicine.  342:1917-1918. 2000
  • Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin.  Journal of the American College of Cardiology.  35:1801-1807. 2000
  • The impending global epidemic of cardiovascular diseases.  European Heart Journal.  21:880-883. 2000
  • Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.  The Lancet.  355:1936-1942. 2000
  • Effects of Physiologic Pacing versus Ventricular Pacing on the Risk of Stroke and Death Due to Cardiovascular Causes.  New England Journal of Medicine.  342:1385-1391. 2000
  • HEART FAILURE SOCIETY OF AMERICA (HFSA) PRACTICE GUIDELINES.  Pharmacotherapy.  20:495-522. 2000
  • Implications of the Heart Outcomes Prevention Evaluation (HOPE) for the treatment of patients at high cardiovascular risk; systolic versus diastolic pressure predictive value.  Heart.  83. 2000
  • Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients.  The Lancet.  355:1575-1581. 2000
  • Homocyst(e)ine and Cardiovascular Disease.  ACP journal club.  132:676-676. 2000
  • Homocyst(e)ine and Cardiovascular Disease.  ACP journal club.  132:676-676. 2000
  • Challenges in the conduct and interpretation of phase II (pilot) randomized trials.  American Heart Journal.  139:S136-S142. 2000
  • Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators..  Diabetes Care.  23 Suppl 2:B35-B39. 2000
  • Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.  American Heart Journal.  139:609-617. 2000
  • The HOPE study and diabetes.  The Lancet.  355:1183-1184. 2000
  • The HOPE study and diabetes.  The Lancet.  355:1181-1181. 2000
  • Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction..  Diabetes Care.  23:377-380. 2000
  • Ramipril reduced mortality and cardiovascular morbidity in high risk adults.  BMJ Evidence-Based Medicine.  5:47-47. 2000
  • Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy.  Circulation.  101:378-384. 2000
  • Management of myocardial infarction: looking beyond efficacy∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology..  Journal of the American College of Cardiology.  35:380-381. 2000
  • Management of unstable coronary-artery disease.  The Lancet.  355:572-572. 2000
  • Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients.  New England Journal of Medicine.  342:145-153. 2000
  • Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients.  New England Journal of Medicine.  342:154-160. 2000
  • Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme.  Blood Pressure.  9:60-60. 2000
  • Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE)..  Indian Heart Journal.  52:S35-S43. 2000
  • Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.  The Lancet.  355:253-259. 2000
  • Cardiovascular diseases in ethnic groups..  Canadian Journal of Cardiology.  15 Suppl G:47G-50G. 1999
  • Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study.  Prevention and Management of Congestive Heart Failure.  5:286-287. 1999
  • HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches.  Journal of Cardiac Failure.  5:357-382. 1999
  • Oral Anticoagulant Therapy in Patients With Coronary Artery Disease: A Meta-analysis.  Journal of the American Medical Association (JAMA).  282:2058-2058. 1999
  • Low rates of preventive practices in patients with peripheral vascular disease..  Canadian Journal of Cardiology.  15:1259-1263. 1999
  • ACC/AHA guidelines for coronary artery bypass graft surgery.  Journal of the American College of Cardiology.  34:1262-1347. 1999
  • Clinical Evidence: Emerging approaches in preventing cardiovascular disease..  Western Journal of Medicine.  171:247-252. 1999
  • Emerging approaches in preventing cardiovascular disease.  Western Journal of Medicine.  171:247-252. 1999
  • ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: Executive Summary and Recommendations.  Circulation.  100:1464-1480. 1999
  • Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths (vol 161, pg 132, 1999).  CANADIAN MEDICAL ASSOCIATION JOURNAL.  161:489-489. 1999
  • Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure.  Circulation.  100:1056-1064. 1999
  • Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence.  ACP journal club.  131:363-363. 1999
  • Lifeline - Salim Yusuf.  The Lancet.  354:876-876. 1999
  • Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design.  Journal of Cardiac Failure.  5:276-282. 1999
  • Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes–2 (OASIS–2) trial.  American Journal of Cardiology.  84:20-25. 1999
  • Homocysteine and cardiovascular risk: is it time to treat?.  Evidence-based Cardiovascular Medicine.  3:59-60. 1999
  • The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina.  American Journal of Cardiology.  84:7-12. 1999
  • Randomised controlled trials in cardiovascular medicine: past achievements, future challenges.  The BMJ.  319:564-568. 1999
  • Role of antioxidant vitamins in prevention of cardiovascular diseases.  The BMJ.  319:577-577. 1999
  • Role of antioxidant vitamins in prevention of cardiovascular diseases - Meta-analysis seems to exclude benefit of vitamin C supplementation - Reply.  The BMJ.  319:577-577. 1999
  • Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.  European Heart Journal.  20:1182-1190. 1999
  • Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths..  CANADIAN MEDICAL ASSOCIATION JOURNAL.  161:132-138. 1999
  • Review: Glucose levels are associated with cardiovascular risk in persons without diabetes mellitus.  Evidence-Based Medicine.  4:127. 1999
  • Increased winter mortality from acute myocardial infarction and stroke: the effect of age.  Journal of the American College of Cardiology.  33:1916-1919. 1999
  • Recurrent events in meta-analysis of multiple clinical trials..  Acta Pharmacologica Sinica.  20:495-499. 1999
  • Evidence based cardiology: Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction.  The BMJ.  318:1400-1402. 1999
  • Emerging approaches in preventing cardiovascular disease.  The BMJ.  318:1337-1341. 1999
  • The gap between reliable evidence and adoption of therapies..  European Heart Journal.  20:637-638. 1999
  • Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study.  Journal of the American College of Cardiology.  33:612-619. 1999
  • Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial.  The Lancet.  353:429-438. 1999
  • The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years..  Diabetes Care.  22:233-240. 1999
  • Study on propionyl-?-carnitine in chronic heart failure.  European Heart Journal.  20:70-76. 1999
  • Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors.  Clinical and Experimental Hypertension.  21:835-845. 1999
  • The role of digitalis in the treatment of heart failure.  Coronary Artery Disease.  10:353-360. 1999
  • Third Meeting of the International Working Group on Coronary Artery Disease in South Asians. 29 March 1998, Atlanta, USA..  Indian Heart Journal.  51:99-103. 1999
  • Can medicine prevent war?.  The BMJ.  317:1669-1670. 1998
  • Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials.  European Heart Journal.  19:1742-1742. 1998
  • Blood product requirements in patients undergoing elective endovascular abdominal aortic aneurysm repair.  European Journal of Vascular and Endovascular Surgery.  16:390-394. 1998
  • The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators..  Canadian Journal of Cardiology.  14:1349-1357. 1998
  • The study of health assessment and risk in ethnic groups (SHARE): Rationale and design.  Canadian Journal of Cardiology.  14:1349-1357. 1998
  • Variations between countries in invasive cardiac procedures.  The Lancet.  352:1470-1471. 1998
  • Variations between countries in invasive cardiac procedures.  The Lancet.  352:1469-1469. 1998
  • Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non–Q-Wave Myocardial Infarction.  Circulation.  98:1064-1070. 1998
  • Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials..  European Heart Journal.  19 Suppl J:J36-J44. 1998
  • Factors influencing exercise performance in patients with left ventricular dysfunction.  Journal of Cardiac Failure.  4:159-167. 1998
  • Primary coronary angioplasty is superior to thrombolytic therapy for acute MI.  Evidence-based Cardiovascular Medicine.  2:81-81. 1998
  • Strategies for patient recruitment into clinical trials.  Journal of Cardiac Failure.  4:235-236. 1998
  • Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials..  Canadian Journal of Cardiology.  14:1045-1053. 1998
  • Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation.  The Lancet.  352:507-514. 1998
  • Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial Infarction.  Circulation.  97:2202-2212. 1998
  • Meta-analysis.  The Lancet.  351:1960-1960. 1998
  • Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction.  New England Journal of Medicine.  338:1488-1497. 1998
  • Emerging approaches in the prevention of atherosclerotic cardiovascular diseases..  International Journal of Clinical Practice, Supplement.  94:7-19. 1998
  • The global problem of cardiovascular disease..  International Journal of Clinical Practice, Supplement.  94:3-6. 1998
  • Digoxin in heart failure: results of the recent digoxin investigation group trial in the context of other treatments for heart failure (vol 18, pg 1685, 1998).  European Heart Journal.  19:675-675. 1998
  • Erratum.  European Heart Journal.  19:675-675. 1998
  • Predicting mortality and hospitalization in 5025 patients with heart failure utilizing baseline quality of life.  Prevention and Management of Congestive Heart Failure.  4:31-37. 1998
  • Emerging Epidemic of Cardiovascular Disease in Developing Countries.  Circulation.  97:596-601. 1998
  • Elevated lipoprotein(a) levels in South Asians in North America.  Metabolism: Clinical and Experimental.  47:182-184. 1998
  • Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration..  Journal of Hypertension.  16:127-137. 1998
  • Coronary artery disease in South Asians. Second meeting of the International Working Group. 16 March 1997, Anaheim, California..  Indian Heart Journal.  50:105-113. 1998
  • Overcoming the limitations of current meta-analysis of randomised controlled trials.  The Lancet.  351:47-52. 1998
  • Primary Angioplasty Compared With Thrombolytic Therapy for Acute Myocardial Infarction.  Journal of the American Medical Association (JAMA).  278:2110-2110. 1997
  • Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction.  Journal of the American Medical Association (JAMA).  278:2110-2111. 1997
  • Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study..  Canadian Journal of Cardiology.  13:1166-1174. 1997
  • Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis.  Contemporary Clinical Trials.  18:580-593. 1997
  • From journal to bedside: obtaining medically useful answers from a meta-analysis.  Evidence-based Cardiovascular Medicine.  1:85-86. 1997
  • Introduction.  Contemporary Clinical Trials.  18:477-477. 1997
  • Meta-analysis of randomized trials: Looking back and looking ahead.  Contemporary Clinical Trials.  18:594-601. 1997
  • Strengths and limitations of meta-analysis: Larger studies may be more reliable.  Contemporary Clinical Trials.  18:568-579. 1997
  • A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias.  New England Journal of Medicine.  337:1576-1584. 1997
  • Classifying ethnicity utilizing the Canadian mortality data base.  Ethnicity and Health.  2:287-295. 1997
  • Digoxin in heart failure: results of the recent digoxin investigation group trial in the context of other treatments for heart failure.  European Heart Journal.  18:1685-1688. 1997
  • Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials.  The Lancet.  350:1417-1424. 1997
  • Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data..  Canadian Journal of Cardiology.  13:957-965. 1997
  • From journal to bedside: quantifying the benefits of treatment.  Evidence-based Cardiovascular Medicine.  1:57-58. 1997
  • Comparison of the Effects of Two Doses of Recombinant Hirudin Compared With Heparin in Patients With Acute Myocardial Ischemia Without ST Elevation.  Circulation.  96:769-777. 1997
  • Risk factors for cardiovascular disease in Canadians of South Asian and European origin: a pilot study of the Study of Heart Assessment and Risk in Ethnic Groups (SHARE)..  Clinical and Investigative Medicine.  20:204-210. 1997
  • Digoxin in Patients with Heart Failure.  New England Journal of Medicine.  337:129-131. 1997
  • Digoxin in patients with heart failure - Reply.  New England Journal of Medicine.  337:130-131. 1997
  • Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction.  American Heart Journal.  134:37-43. 1997
  • Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Collaborative Organization for RheothRx Evaluation (CORE)..  Circulation.  96:192-201. 1997
  • The Ten Most Commonly Asked Questions about the Calcium Channel Blocker Controversy.  Cardiology in Review.  5:196-198. 1997
  • Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding.  Journal of Human Hypertension.  11:331-342. 1997
  • From journal to bedside: application of clinical trial results to individual patients.  Evidence-based Cardiovascular Medicine.  1:29-31. 1997
  • Selection of patients for angiography following myocardial infarction was not based on risk but on young age and availability of angiographic facilities.  Evidence-based Cardiovascular Medicine.  1:52-52. 1997
  • Evidence-based cardiovascular medicine: Why another journal?.  Evidence-based Cardiovascular Medicine.  1:1-1. 1997
  • The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure.  New England Journal of Medicine.  336:525-533. 1997
  • Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension..  Journal of Hypertension.  15:105-115. 1997
  • A comparison of practice patterns for acute myocardial infarction between hospitals in Canada and India..  Indian Heart Journal.  49:35-41. 1997
  • The effect of RheothRx Injection on the hemorheological parameters in patients with acute myocardial infarction..  Clinical Hemorheology and Microcirculation.  17:117-125. 1997
  • The rationale for exercise training patients with congestive heart failure.  Prevention and Management of Congestive Heart Failure.  3:26-34. 1997
  • Treatment for acute myocardial infarction: Overview of randomized clinical trials.  European Heart Journal.  17:16-29. 1996
  • Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study.  Diabetes Care.  19:1225-1228. 1996
  • Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation..  Diabetes Care.  19:1225-1228. 1996
  • Risk factors for coronary heart disease in Asian Indians.  The Lancet.  348:1242-1242. 1996
  • Baseline Quality of Life as a Predictor of Mortality and Hospitalization in 5,025 Patients With Congestive Heart Failure.  American Journal of Cardiology.  78:890-895. 1996
  • Study Design and Baseline Characteristics of the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E: SECURE**This study was supported by Research Grant Ul-12363 from the Medicine Research Council of Canada, Ottawa; and by Hoechst Marion Roussel, Laval, Canada, Inc..  American Journal of Cardiology.  78:914-919. 1996
  • Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.  The BMJ.  313:652-659. 1996
  • Calcium antagonists in coronary disease and hypertension - Response.  Circulation.  94:1143-1143. 1996
  • Calcium antagonists in coronary disease and hypertension..  Circulation.  94:1142-1143. 1996
  • Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction.  Circulation.  94:690-697. 1996
  • Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure..  Heart.  76:137-143. 1996
  • Dual-Chamber Versus Ventricular Pacing.  Circulation.  94:578-583. 1996
  • Risk factors for acute myocardial infarction in Indians: a case-control study.  The Lancet.  348:358-363. 1996
  • Dysglycaemia and risk of cardiovascular disease - Reply.  The Lancet.  347:1834-1835. 1996
  • Dysglycaemia and risk of cardiovascular disease.  The Lancet.  347:1833-1835. 1996
  • Cost of Prevention.  Circulation.  93:1774-1776. 1996
  • The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data (vol 123, pg 860, 1995).  Annals of Internal Medicine.  124:934-934. 1996
  • Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry.  American Journal of Cardiology.  77:1017-1020. 1996
  • Dysglycaemia and risk of cardiovascular disease.  The Lancet.  347:949-950. 1996
  • Chronic coronary artery disease: Drugs, angioplasty, or surgery? Tailor the treatment to the patient.  The BMJ.  312:265-266. 1996
  • Chronic coronary artery disease: drugs, angioplasty, or surgery?.  The BMJ.  312:265-266. 1996
  • Rationale, design, implementation, and baseline characteristics of patients in the dig trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure.  Contemporary Clinical Trials.  17:77-97. 1996
  • Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks atter acute myocardial infarction: The GISSI-3 trial.  Journal of the American College of Cardiology.  27:337-344. 1996
  • The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators..  Canadian Journal of Cardiology.  12:127-137. 1996
  • Verapamil following uncomplicated myocardial infarction: Promising, but not proven.  American Journal of Cardiology.  77:421-422. 1996
  • Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America..  Indian Heart Journal.  48:343-353. 1996
  • Meeting of the International Working Group on Coronary Artery Disease in South Asians. 24 March 1996, Orlando, Florida, USA..  Indian Heart Journal.  48:727-732. 1996
  • Using exercise endpoints in heart failure trials: design considerations.  European Heart Journal.  17:4-6. 1996
  • The Antioxidant Vitamins and Cardiovascular Disease: A Critical Review of Epidemiologic and Clinical Trial Data.  ACP journal club.  123:860-860. 1995
  • Effects of ACE Inhibitors on Mortality When Started in the Early Phase of Myocardial Infarction: Evidence from the Larger Randomized Controlled Trials.  European Journal of Preventive Cardiology (EJPC).  2:423-428. 1995
  • Calcium Antagonists in Coronary Artery Disease and Hypertension.  Circulation.  92:1079-1082. 1995
  • Collaborative cardiovascular clinical trials in Canada. The Canadian Cardiovascular Collaboration..  Canadian Journal of Cardiology.  11:649-657. 1995
  • OVERVIEW OF RANDOMIZED TRIALS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS ON MORTALITY AND MORBIDITY IN PATIENTS WITH HEART-FAILURE (VOL 273, PG 1450, 1995).  Journal of the American Medical Association (JAMA).  274:462-462. 1995
  • Advances in antithrombotic drug therapy for coronary artery disease.  European Heart Journal.  16:10-21. 1995
  • Adjunctive therapy for myocardial infarction..  Arquivos Brasileiros de Cardiologia.  65:97-110. 1995
  • Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction.  American Journal of Cardiology.  75:1151-1157. 1995
  • Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure.  American Journal of Cardiology.  75:1244-1249. 1995
  • Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens.  American Journal of Cardiology.  75:1130-1134. 1995
  • Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure.  Journal of the American Medical Association (JAMA).  273:1450-1450. 1995
  • Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.  Journal of the American Medical Association (JAMA).  273:1450-1456. 1995
  • Patterns of Medication Use in Patients With Heart Failure.  Southern Medical Journal.  88:514-523. 1995
  • COST-EFFECTIVENESS STUDIES - CAN BENEFIT BE SHOWN ONLY IN HIGH-RISK POPULATIONS.  British Journal of Clinical Practice.  22-25. 1995
  • Magnesium in acute myocardial infarction.  The BMJ.  310:751-752. 1995
  • Effects of exercise training in patients with congestive heart failure: A critical review.  Journal of the American College of Cardiology.  25:789-796. 1995
  • ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction.  The Lancet.  345:669-685. 1995
  • Neurohumoral variability in left ventricular dysfunction.  American Journal of Cardiology.  75:354-359. 1995
  • Does PTCA in Acute Myocardial Infarction Affect Mortality and Reinfarction Rates?.  Circulation.  91:476-485. 1995
  • Issues regarding the use of heparin following streptokinase therapy.  Journal of Thrombosis and Thrombolysis.  2:5-10. 1995
  • Pharmacological treatment for myocardial infarction Part 2: Implications of clinical trials of other adjunctive therapies..  Indian Heart Journal.  47:95-105. 1995
  • Pharmacological treatment for myocardial infarction. Part 1: Implications of clinical trials of thrombolytic and antithrombotic therapies.  Indian Heart Journal.  47:3-11. 1995
  • EFFECT OF CORONARY-ARTERY BYPASS GRAFT-SURGERY ON SURVIVAL - REPLY.  The Lancet.  344:1224-1224. 1994
  • Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 2 of 2..  The Online journal of current clinical trials.  Doc No 144:[3987-words. 1994
  • Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2..  The Online journal of current clinical trials.  Doc No 145:[3987-words. 1994
  • Effect of coronary artery bypass graft surgery on survival.  The Lancet.  344:1222-1224. 1994
  • Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection..  Circulation.  90:2056-2069. 1994
  • Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.  The Lancet.  344:563-570. 1994
  • Tolerability of enalapril initiation by patients with left ventricular dysfunction: Results of the medication challenge phase of the studies of left ventricular dysfunction.  American Heart Journal.  128:358-364. 1994
  • GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico..  The Lancet.  343:1115-1122. 1994
  • Panel discussion.  European Heart Journal.  15:26-30. 1994
  • Role of Angiotensin Converting Enzyme Inhibitors in Patients with Left Ventricular Dysfunction and Congestive Heart Failure.  European Heart Journal.  15:9-13. 1994
  • Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunction.  Journal of the American College of Cardiology.  23:1410-1420. 1994
  • The impact of left ventricular dysfunction on outcomes with the implantable defibrillator.  American Heart Journal.  127:1159-1163. 1994
  • Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients.  The Lancet.  343:311-322. 1994
  • Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunction.  Journal of the American College of Cardiology.  23:393-400. 1994
  • Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  The BMJ.  308:81-106. 1994
  • Calcium antagonists in the treatment of ischemic heart disease.  Coronary Artery Disease.  5:21-26. 1994
  • Diagnosis and management of heart failure. Canadian Cardiovascular Society..  Canadian Journal of Cardiology.  10:613-654. 1994
  • Panel discussion.  European Heart Journal.  15:26-30. 1994
  • Recent Advances and Future Directions in Myocardial Infarction.  Cardiology.  84:391-407. 1994
  • Effect of Angiotensin-Converting Enzyme Inhibitors in Left Ventricular Dysfunction.  Journal of Cardiovascular Pharmacology.  22:S28-35. 1993
  • Maximizing benefits of therapies in acute myocardial infarction.  American Journal of Cardiology.  72:G145-G155. 1993
  • Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure..  Herz.  18 Suppl 1:444-448. 1993
  • Critical review of the approaches to the prevention of sudden death.  American Journal of Cardiology.  72:F51-F58. 1993
  • Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators..  Circulation.  88:2277-2283. 1993
  • PREDICTION OF MORTALITY AND MORBIDITY WITH A 6-MINUTE WALK TEST IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION.  Journal of the American Medical Association (JAMA).  270:1702-1707. 1993
  • Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators.  Journal of the American Medical Association (JAMA).  270:1702-1707. 1993
  • EFFECTS OF PROPHYLACTIC ANTIARRHYTHMIC DRUG-THERAPY IN ACUTE MYOCARDIAL-INFARCTION - AN OVERVIEW OF RESULTS FROM RANDOMIZED CONTROLLED TRIALS.  Journal of the American Medical Association (JAMA).  270:1589-1595. 1993
  • Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials.  Journal of the American Medical Association (JAMA).  270:1589-1595. 1993
  • Effects of  -blockers and calcium channel blockers in acute myocardial infarction.  European Heart Journal.  14:18-25. 1993
  • Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry.  Journal of the American College of Cardiology.  22:A146-A153. 1993
  • Current and ongoing randomized trials in heart failure and left ventricular dysfunction.  Journal of the American College of Cardiology.  22:A194-A197. 1993
  • Discussion I.  Journal of the American College of Cardiology.  22:A20-A21. 1993
  • Discussion IX.  Journal of the American College of Cardiology.  22:A192-A193. 1993
  • Discussion V.  Journal of the American College of Cardiology.  22:A127-A128. 1993
  • Discussion VII.  Journal of the American College of Cardiology.  22:A162-A164. 1993
  • HEART-FAILURE IN THE 1990S - EVOLUTION OF A MAJOR PUBLIC-HEALTH PROBLEM IN CARDIOVASCULAR MEDICINE.  Journal of the American College of Cardiology.  22:A3-A5. 1993
  • Heart failure in the 1990s: Evolutions of a major public health problem in cardiovascular medicine.  Journal of the American College of Cardiology.  22:A3-A5. 1993
  • Natural history and patterns of current practice in heart failure.  Journal of the American College of Cardiology.  22:A14-A19. 1993
  • Panel discussion I: Evaluation and management of chronic heart failure.  Journal of the American College of Cardiology.  22:A201-A203. 1993
  • Role of Magnesium in Reducing Mortality in Acute Myocardial Infarction.  Drugs.  46:347-359. 1993
  • Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators..  Circulation.  88:481-491. 1993
  • DESIGN, RESULTS, AND INTERPRETATION OF RANDOMIZED, CONTROLLED TRIALS IN CONGESTIVE-HEART-FAILURE AND LEFT-VENTRICULAR DYSFUNCTION.  Circulation.  87:115-121. 1993
  • Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention..  Circulation.  87:2043-2046. 1993
  • Primary and secondary prevention of myocardial infarction and strokes.  Journal of Hypertension.  11:S61???S74-S61???S74. 1993
  • CARDIAC MECHANICS DURING DEVELOPMENT OF HEART-FAILURE.  Circulation.  87:14-20. 1993
  • Cardiac mechanics during development of heart failure. SOLVD Investigators..  Circulation.  87:IV14-IV20. 1993
  • Clinical experience in protecting the failing heart..  Clinical Cardiology.  16:II25-II29. 1993
  • A SURVEY OF MONITORING PRACTICES IN CANCER CLINICAL-TRIALS - DATA MONITORING COMMITTEES FOR SOUTHWEST ONCOLOGY GROUP CLINICAL-TRIALS - DISCUSSION.  Statistics in Medicine.  12:457-459. 1993
  • ACE inhibitors for myocardial infarction and unstable angina.  The Lancet.  341:829-829. 1993
  • PRACTICAL ISSUES IN DATA MONITORING OF CLINICAL-TRIALS - SUMMARY OF RESPONSES TO A QUESTIONNAIRE AT NIH - DISCUSSION.  Statistics in Medicine.  12:553-553. 1993
  • Preface.  Statistics in Medicine.  12:415-415. 1993
  • Coronary Artery Disease in Asian Indians: Prevalence and Risk Factors..  Asian American and Pacific Islander journal of health.  1:163-175. 1993
  • Design, results, and interpretation of randomized, controlled trials in congestive heart failure and left ventricular dysfunction.  Circulation.  87. 1993
  • Discussion I.  Journal of the American College of Cardiology.  22. 1993
  • Discussion IX.  Journal of the American College of Cardiology.  22. 1993
  • Discussion V.  Journal of the American College of Cardiology.  22. 1993
  • Discussion VII.  Journal of the American College of Cardiology.  22. 1993
  • Enalapril for asymptomatic reduced left ventricular ejection fraction.  Annals of Internal Medicine.  118:3. 1992
  • Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study.  Journal of the American College of Cardiology.  20:1056-1062. 1992
  • Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.  The Lancet.  340:1173-1178. 1992
  • Clinical characteristics of patients in Studies of Left Ventricular Dysfunction (SOLVD).  American Journal of Cardiology.  70:894-900. 1992
  • Prevalence of coronary artery disease in Asian Indians.  American Journal of Cardiology.  70:945-949. 1992
  • Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions.  New England Journal of Medicine.  327:685-691. 1992
  • Report of the Conference on Low Blood Cholesterol: Mortality Associations..  Circulation.  86:1046-1060. 1992
  • Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators..  Circulation.  86:431-438. 1992
  • Studies of left ventricular dysfunction (SOLVD) registry: Rationale, design, methods and description of baseline characteristics.  American Journal of Cardiology.  70:347-353. 1992
  • Cholesterol and total mortality: need for larger trials..  The BMJ.  304:1689-1689. 1992
  • Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland..  Circulation.  85:2337-2344. 1992
  • Effectiveness of preload reserve as a determinant of clinical status in patients with left ventricular systolic dysfunction.  American Journal of Cardiology.  69:1591-1595. 1992
  • Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure.  American Journal of Cardiology.  69:64-70. 1992
  • The effect of treatment on survival in congestive heart failure.  Clinical Cardiology.  15:323-329. 1992
  • Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: The need for randomized trials.  American Journal of Cardiology.  69:959-962. 1992
  • ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction.  The Lancet.  339:753-770. 1992
  • Preserved left ventricular function during supine exercise in patients after orthotopic cardiac transplantation.  European Heart Journal.  13:321-329. 1992
  • Reply.  American Journal of Cardiology.  69:837-837. 1992
  • Enalapril may prevent cardiovascular failure.  American Family Physician.  45:823. 1992
  • Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials..  The BMJ.  303:1499-1503. 1991
  • Analyses by the Intention‐to‐Treat Principle in Randomized Trials and Databases.  PACE - Pacing and Clinical Electrophysiology.  14:2078-2082. 1991
  • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.  Annals of Internal Medicine.  115:67. 1991
  • Are we biased in our approach to treating elderly patients with heart disease?.  American Journal of Cardiology.  68:954-956. 1991
  • Implantable Cardioverter Defibrillators in Cardiovascular Practice: Report of the Policy Conference of the North American Society of Pacing and Electrophysiology.  Journal of Interventional Cardiology.  4:211-220. 1991
  • Antiarrhythmics and VPD suppression..  Circulation.  84:928-930. 1991
  • Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure.  New England Journal of Medicine.  325:293-302. 1991
  • Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical Trials.  Journal of the American Medical Association (JAMA).  266:93-93. 1991
  • Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.  Journal of the American Medical Association (JAMA).  266:93-98. 1991
  • Update of effects of calcium antagonists in myocardial infarction or angina in light of the second danish verapamil infarction trial (DAVIT-II) and other recent studies.  American Journal of Cardiology.  67:1295-1297. 1991
  • Randomized Trials to Assess the Long-term Effects of Therapies on Angiographic End Points.  Chest.  99:1243-1247. 1991
  • Exposing Patients With Chronic, Stable, Exertional Angina to Placebo Periods in Drug Trials.  Journal of the American Medical Association (JAMA).  265:1550-1550. 1991
  • Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials.  Journal of the American Medical Association (JAMA).  265:1550-1554. 1991
  • Reply.  American Journal of Cardiology.  67:331-332. 1991
  • Enalapril for increased survival in congestive heart failure.  Annals of Internal Medicine.  115:67. 1991
  • Risk-Benefit Assessment of Antiarrhythmic Drugs.  Drug Safety.  6:323-331. 1991
  • t-PA and APSAC for acute myocardial infarction: A meta-analysis.  Annals of Internal Medicine.  114:36. 1991
  • Selecting adjunctive treatments for use with thrombolysis in acute myocardial infarction.  Primary cardiology.  16. 1990
  • Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)..  Circulation.  82:1724-1729. 1990
  • Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction..  Circulation.  82:1668-1674. 1990
  • CORRECTION.  American Journal of Cardiology.  66:1026-1026. 1990
  • ROUTINE MEDICAL-MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION - LESSONS FROM OVERVIEWS OF RECENT RANDOMIZED CONTROLLED TRIALS.  Circulation.  82:117-134. 1990
  • Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials..  Circulation.  82:II117-II134. 1990
  • Studies of Left Ventricular Dysfunction (SOLVD)—Rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction.  American Journal of Cardiology.  66:315-322. 1990
  • Evaluating effects of treatment in subgroups of patients within a clinical trial: The case of non-Q-wave myocardial infarction and beta blockers.  American Journal of Cardiology.  66:220-222. 1990
  • MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction.  The Lancet.  336:65-71. 1990
  • ANISTREPLASE (APSAC) - A CLINICAL INVESTIGATORS UPDATE - A SYMPOSIUM - DISCUSSION .1..  Clinical Cardiology.  13:V27-V32. 1990
  • ANISTREPLASE (APSAC) - A CLINICAL INVESTIGATORS UPDATE - A SYMPOSIUM - DISCUSSION .2..  Clinical Cardiology.  13:V67-V72. 1990
  • Expanding indications for the use of thrombolytic agents in acute myocardial infarction.  Clinical Cardiology.  13:53-61. 1990
  • Effect of acute angiotensin converting enzyme inhibition on left ventricular filling in patients with congestive heart failure. Relation to right ventricular volumes..  Circulation.  81:III115-III122. 1990
  • Calcium channel blockers in myocardial infarction: Authors' reply.  The BMJ.  300:260-260. 1990
  • Cost and efficiency in clinical trials: Preface.  Statistics in Medicine.  9:1. 1990
  • Preface.  Statistics in Medicine.  9:1-1. 1990
  • Prognostic value of prolonged ventricular repolarization following myocardial infarction: The BHAT experience.  Journal of Clinical Epidemiology.  43:167-172. 1990
  • Selection of patients for randomized controlled trials: Implications of wide or narrow eligibility criteria.  Statistics in Medicine.  9:73-86. 1990
  • Calcium channel blockers in acute myocardial infarction and unstable angina: an overview..  The BMJ.  299:1187-1192. 1989
  • AHA Conference Report on Cholesterol. Intervention studies..  Circulation.  80:739-743. 1989
  • Influence of beta blockade on exercise capacity and heart rate response after human orthotopic and heterotopic cardiac transplantation.  American Journal of Cardiology.  64:636-641. 1989
  • WORKSHOP .5. INTERVENTION STUDIES.  Circulation.  80:739-743. 1989
  • An overview of randomized trials of rehabilitation with exercise after myocardial infarction..  Circulation.  80:234-244. 1989
  • The likelihood ratio versus the p value in meta-analysis: Where is the evidence?.  Contemporary Clinical Trials.  10:205-208. 1989
  • Randomized Clinical Trials in Heart Disease-Reply.  Journal of the American Medical Association (JAMA).  261:2953-2953. 1989
  • Changes in hypertension treatment and in congestive heart failure mortality in the United States..  Hypertension.  13:I74-I79. 1989
  • Renin response to sympathetic stimulation in cyclosporin-treated heart-transplant patients.  American Journal of Cardiology.  63:1142-1144. 1989
  • Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction..  Circulation.  79:610-619. 1989
  • Early Intravenous Beta-Blockade in Acute Myocardial Infarction.  Cardiology.  76:132-143. 1989
  • OVERVIEW OF RESULTS OF RANDOMIZED CLINICAL-TRIALS IN HEART-DISEASE .2. UNSTABLE ANGINA, HEART-FAILURE, PRIMARY PREVENTION WITH ASPIRIN, AND RISK FACTOR MODIFICATION.  Journal of the American Medical Association (JAMA).  260:2259-2263. 1988
  • Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification.  Journal of the American Medical Association (JAMA).  260:2259-2263. 1988
  • OVERVIEW OF RESULTS OF RANDOMIZED CLINICAL-TRIALS IN HEART-DISEASE .1. TREATMENTS FOLLOWING MYOCARDIAL-INFARCTION.  Journal of the American Medical Association (JAMA).  260:2088-2093. 1988
  • Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction.  Journal of the American Medical Association (JAMA).  260:2088-2093. 1988
  • EFFECTS OF PROPHYLACTIC LIDOCAINE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - AN OVERVIEW OF RESULTS FROM THE RANDOMIZED, CONTROLLED TRIALS.  Journal of the American Medical Association (JAMA).  260:1910-1916. 1988
  • Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials.  Journal of the American Medical Association (JAMA).  260:1910-1916. 1988
  • Ventricular arrhythmias in long term survivors of orthotopic and heterotopic cardiac transplantation..  Heart.  59:648-652. 1988
  • EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL-INFARCTION - AN OVERVIEW OF THE RANDOMIZED TRIALS.  The Lancet.  1:1088-1092. 1988
  • Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous Heparin.  New England Journal of Medicine.  318:1162-1173. 1988
  • EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL INFARCTION: AN OVERVIEW OF THE RANDOMISED TRIALS.  The Lancet.  331:1088-1092. 1988
  • The 24-hour heart rate behavior in long-term survivors of cardiac transplantation.  American Journal of Cardiology.  61:880-884. 1988
  • Early intravenous beta blockade in acute myocardial infarction..  Postgraduate Medicine.  Spec No:90-95. 1988
  • Diurnal variations of QT interval after cardiac transplantation.  American Journal of Cardiology.  61:482-485. 1988
  • An Overview of the Clinical Trials of Agents (Other than β-Blockers) That Potentially Limit Myocardial Infarct Size.  Journal of Cardiovascular Pharmacology.  12:S48-55. 1988
  • Effect of drug therapy on survival in chronic congestive heart failure.  American Journal of Cardiology.  62:41A-45A. 1988
  • THE USE OF BETA-ADRENERGIC BLOCKING-AGENTS, IV NITRATES AND CALCIUM-CHANNEL BLOCKING-AGENTS FOLLOWING ACUTE MYOCARDIAL-INFARCTION.  Chest.  93:S25-S28. 1988
  • The Use of Beta-adrenergic Blocking Agents, IV Nitrates and Calcium Channel Blocking Agents following Acute Myocardial Infarction.  Chest.  93:25S-28S. 1988
  • [Effect of atenolol on the QT interval in the acute phase of myocardial infarction]..  Kardiologia Polska.  31:505-509. 1988
  • Effects of calcium channel blockers on survival after myocardial infarction.  Cardiovascular Drugs and Therapy.  1:343-344. 1987
  • Interventions that potentially limit myocardial infarct size: Overview of clinical trials.  American Journal of Cardiology.  60:11-17. 1987
  • Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta-adrenergic blockade..  Circulation.  75:696-704. 1987
  • Obtaining medically meaningful answers from an overview of randomized clinical trials.  Statistics in Medicine.  6:281-286. 1987
  • Preface.  Statistics in Medicine.  6:217-218. 1987
  • Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction.  American Journal of Cardiology.  59:245-250. 1987
  • DOES THERAPY DIRECTED BY PROGRAMMED ELECTRICAL-STIMULATION PROVIDE A SATISFACTORY CLINICAL-RESPONSE.  Circulation.  73:59-66. 1986
  • Does therapy directed by programmed electrical stimulation provide a satisfactory clinical response?.  Circulation.  73:II59-II66. 1986
  • Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods..  Circulation.  73:14-18. 1986
  • Effect of Drug Therapy on Survival in Chronic Heart Failure.  Advances in Cardiology.  34:124-130. 1986
  • Interrelation between donor and recipient heart rates during exercise after heterotopic cardiac transplantation..  Heart.  54:173-178. 1985
  • Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials.  European Heart Journal.  6:556-585. 1985
  • Effect of betablockade on dynamic exercise in human heart transplant recipients..  The Journal of Heart and Lung Transplantation.  4:312-314. 1985
  • Effect of vasodilators on survival in chronic congestive heart failure.  American Journal of Cardiology.  55:1110-1113. 1985
  • Beta blockade during and after myocardial infarction: An overview of the randomized trials.  Progress in Cardiovascular Diseases.  27:335-371. 1985
  • Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial.  European Heart Journal.  6:199-226. 1985
  • Overview of randomised trials of diuretics in pregnancy..  The BMJ.  290:17-23. 1985
  • Potential for altering the natural history of congestive heart failure: Need for large clinical trials.  American Journal of Cardiology.  55:A45-A47. 1985
  • Why do we need some large, simple randomized trials?.  Statistics in Medicine.  3:409-420. 1984
  • The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction.  European Heart Journal.  5:690-696. 1984
  • Perioperative Myocardial Reinfarction.  Anesthesiology.  59:493-494. 1983
  • Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction..  Circulation.  67:I32-I41. 1983
  • Glucose-insulin-potassium infusion in acute myocardial infarction.  American Journal of Cardiology.  51:1566-1566. 1983
  • Limitation of Myocardial Infarct Size Present Status.  Drugs.  25:441-450. 1983
  • Intravenous Streptokinase for Acute Myocardial Infarction.  New England Journal of Medicine.  308:592-594. 1983
  • Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction..  The BMJ.  286:506-510. 1983
  • INTRAVENOUS STREPTOKINASE FOR ACUTE MYOCARDIAL-INFARCTION - REPLY.  New England Journal of Medicine.  308:593-594. 1983
  • Limitation of myocardial infarct size: Present status.  Current Therapeutics.  24:9-21. 1983
  • REDUCTION IN INFARCT SIZE, ARRHYTHMIAS AND CHEST PAIN BY EARLY INTRAVENOUS BETA-BLOCKADE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION.  Circulation.  67:32-41. 1983
  • Reduction in Infarct Size, Arrhythmias, Chest Pain and Morbidity by Early Intravenous β-Blockade in Suspected Acute Myocardial Infarction.  Drugs.  25:303-307. 1983
  • Effect of Intravenous Streptokinase on Acute Myocardial Infarction.  New England Journal of Medicine.  307:1180-1182. 1982
  • Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol.  American Heart Journal.  103:459-467. 1982
  • Early intravenous beta‐blockade in myocardial infarction..  British Journal of Clinical Pharmacology.  14:37S-43S. 1982
  • Factors of Importance for QRS Complex Recovery after Acute Myocardial Infarction.  Journal of Internal Medicine.  211:157-162. 1982
  • Regional Ischemic Ventricular Dysfunction in Myocardium Supplied by a Narrowed Coronary Artery with Increasing Halothane Concentration in the Dog.  Anesthesiology.  55:349-359. 1981
  • ATENOLOL, HEPARIN AND THE INTERMEDIATE CORONARY SYNDROME.  The Lancet.  318:46-46. 1981
  • Variability of electrocardiographic and enzyme evolution of myocardial infarction in man..  Heart.  45:271-280. 1981
  • EARLY INTRAVENOUS ATENOLOL TREATMENT IN SUSPECTED ACUTE MYOCARDIAL INFARCTION.  Journal of Internal Medicine, Supplement.  210:185-192. 1981
  • Heart rate and ectopic prematurity in relation to sustained ventricular arrhythmias..  Heart.  44:233-239. 1980
  • The role of serum myoglobin in the detection and measurement of myocardial infarction.  Clinica Chimica Acta.  106:17-28. 1980
  • EARLY INTRAVENOUS ATENOLOL TREATMENT IN SUSPECTED ACUTE MYOCARDIAL INFARCTION.  The Lancet.  316:273-276. 1980
  • Beta-blockers in immediate treatment of myocardial infarction.  The BMJ.  280:1619-1620. 1980
  • Beta-blockers in immediate treatment of myocardial infarction.  British medical journal.  280:1619-1620. 1980
  • Effect of beta-blockers on arrhythmias..  The BMJ.  2:864-864. 1979
  • EFFECT OF ATENOLOL ON RECOVERY OF THE ELECTROCARDIOGRAPHIC SIGNS OF MYOCARDIAL INFARCTION.  The Lancet.  314:868-869. 1979
  • Value of electrocardiogram in predicting and estimating infarct size in man..  Heart.  42:286-293. 1979
  • PRELIMINARY NOTE ON CARBONATITE IN WAH-SUNG VALLEY OF JAINTIA-HILLS DISTRICT, MEGHALAYA.  Current Science.  46:703-704. 1977

• preprints

  • Proteome-wide Mendelian randomization study implicates inflammaging biomarkers in retinal vasculature, cardiometabolic diseases and longevity 2024
  • The Burden of Cardiovascular Events According to Cardiovascular Risk Profile in Adults from High-, Middle- and Low-Income Countries 2024
  • Visceral Adiposity and Subclinical Left Ventricular Remodeling 2023
  • The circulating proteome and brain health: Mendelian randomisation and cross-sectional analyses 2023
  • The circulating proteome and brain health: Mendelian randomisation and cross-sectional analyses 2023
  • Multi-ancestry genome-wide study in >2.5 million individuals reveals heterogeneity in mechanistic pathways of type 2 diabetes and complications 2023
  • Trans-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation 2020
  • Association of Dairy Consumption with Metabolic Syndrome, Hypertension and Diabetes in 147,812 Individuals from 21 Countries 2019